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Diese Arbeit enthält Studien zweier bekannter, aber noch wenig untersuchter mikrobieller 
Naturstoffklassen hinsichtlich ihres Wirk- und Resistenzmechanismus, sowie ihrer Struktur-
Aktivitäts-Beziehungen. 
 
Chelocardin und sein amidiertes Derivat wurden als bakterizide Substanzen mit 
Wirksamkeit gegen ein weites Spektrum von Bakterienspezies und Resistenz-brechenden 
(„resistance-breaking“) Eigenschaften charakterisiert. Es wurde gezeigt, dass Chelocardine 
einen Einfluss auf bakterielle Membranen ausüben und dass der Resistenzmechanismus 
gegenüber Chelocardin auf Efflux-Mechanismen beruht, die durch Mutationen im 
Repressorprotein RamR vermittelt werden. 
 
Das Antibiotikum Telomycin wurde als stark bakterizid und Calcium-abhängig mit 
Wirksamkeit gegen Gram-positive Bakterien charakterisiert. Zwei semisynthetische 
Derivate  zeigten eine verbesserte und Calcium-unabhängige antibakterielle Aktivität. 
Weiter wurde gezeigt, dass die Verbindungen in erster Linie mit der Zellmembran 
interagieren und dass Cardiolipin insbesondere für Telomycin einen wichtigen Bindepartner 
darstellt. Die Aktivität beider Derivate beruht nicht ausschließlich auf einer Bindung an 
Cardiolipin, was auf eine Interaktion mit weiteren Targetmolekülen hindeutet und einen 
Wirkmechanismus jenseits der Membranaktivität – auch für Telomycin –  denkbar macht. 
Zudem wurden potentielle Proteintargets untersucht, jedoch konnte keine eindeutige 











Within this thesis, two known but rather underexploited microbial natural product classes 
were characterized in terms of their mechanisms of action, their resistance mechanisms and 
their structure-activity-relationships. 
Chelocardin and its amidated analogue were shown to act bactericidal on a broad-spectrum 
of bacterial species including resistant isolates. Both molecules were shown to exert a cell 
membrane-based mechanism and the resistance mechanism of chelocardin was identified 
and characterized to rely on efflux mediated by mutations of the repressor protein RamR. 
Telomycin was characterised to act strongly bactericidal on Gram-positive bacteria in a 
calcium-dependent manner. Two acylated derivatives were shown to exhibit an improved 
and calcium-independent activity pattern compared to the parent molecule. Studies as part 
of this thesis led to the assumption that the compounds interfere mainly with the cellular 
membrane and cardiolipin was characterised as main interaction partner, particularly for 
telomycin. However, the antibacterial activity of both acylated derivatives does not 
exclusively rely on a binding to this phospholipid. This hints towards interaction with 
additional target molecules and a mechanism of action beyond membrane activity, which 
might also hold true for telomycin itself. Potential protein targets were studied but the 
mechanism of action of telomycins could not be elucidated in detail. 
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1.1 EMERGENCE OF ANTIMICROBIAL RESISTANCE 
The introduction of antibacterial agents to treat bacterial infections goes back to the early 
1900s. A milestone was the discovery of penicillin from the fungus Penicillium notatum by 
Alexander Fleming in 1929.1,2 The introduction of penicillin in the clinics is an integral part 
of the “Golden Era” of antibiotic discovery (1930s-1960s), which resulted in the 
development of more than 150 different types of antibiotic compounds1. However, the vast 
advent of new antibiotics implicated a concurrent emergence of antibiotic resistance (Figure 
1-1).1 Soon after the introduction of penicillin as antibiotic drug in the 1940s, first cases of 
antibiotic resistance were observed1,3,4 – still until today a severe problem that accompanies 
not only the use of antibacterial agents but antimicrobial drugs in general.5 In this context it 
is worth mentioning that already in 1945, Alexander Fleming declared a warning that 
resistant bacteria will appear if antibiotics are misused in terms of incorrect dosage.6 
 
Figure 1-1: Timeline of the deployment of antibiotic agent and the development of resistance towards it. Adapted from 
Dantas and Sommer1 
 
The development of antibiotic resistance has been described among all clinically important 
compound classes (e.g.: tetracyclines, glycopeptides)1,7–9 and is spread among Gram-
positive and Gram-negative bacteria. The most severe and hard-to-treat pathogens are 
grouped as so-called ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, 
Enterobacter spp.).10–12 They depict a tremendous threat for the human population, since 
1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010
Golden era of antibiotic discovery Innovation gap
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they cause serious nosocomial infections and their treatment is hampered due to their ability 
of “escaping” the effects of clinical used antibiotics.13–15 Moreover, an ongoing decline in 
the development of effective drugs contributes severely to the failure in the treatment of 
resistant pathogens.16 This drop was already loomed in the mid-sixties by the “innovation 
gap” in the development of new effective drugs, a gap which lasted until the start of the new 
millennium (Figure 1-1) and we are now facing a “pre-antibiotic” era.17–19 Until today, the 
development and approval of new antibacterial agents is only slowly progressing and it is 
accompanied by a permanent increase of the number and types of resistant bacteria (Figure 
1-2)5,8,20. This problem is accompanied by the prevalence of multidrug-resistant (MDR) 
pathogens, which are described among Gram-positive and Gram-negative bacteria belonging 
to the ESAKPE panel. The most severe pathogens are methicillin-resistant Staphyloccocus 
aureus (MRSA), vancomycin-resistant Enterococci (VRE), Enterobacteriaceae (e.g. 
Klebsiella pneumoniae) and Pseudomonas aeruginosa.8,21 
 
Figure 1-2: Representation of the permanent decrease in the development of new antibiotics (black arrow) and concurrent 
increase of resistant bacteria (red arrow; vancomycin-resistant bacteria as example). Adapted from Schäberle et al.20 
 
The development of antibacterial resistance relies on several factors that emanate from 
humans, the bacteria and the antibiotic itself.22–24 The rise of new MDR pathogens and the 
spread within health care units and into the community depicts a global problem and needs 
to be kept down by better hygiene standards and safety precautions for caretakers and 
patients.5,25–27 Additionally, the overuse and incongruous prescription of antibiotics is a 
serious problem that contributes to the development of resistance.28–30 Numerous studies 
point towards a direct connection of the application of antibiotics and the emergence of 
resistant pathogens in hospitals.30,31 Moreover, the outstanding misuse of antibiotics in 
Introduction 
3 
agriculture (preventative or to promote growth) is as alarming. Resistant bacteria can be 
spread via direct contact of humans and animals (via farmers) or through the food chain 
during food preparation.32 In general, antibiotic resistance refers to different protection 
mechanisms which are carried out by bacteria to adapt towards external stress.33 It can rely 
on intrinsic factors such as the presence of resistance genes34 within the bacteria’s genome 
or resistance can be acquired. For instance, the spread of resistance determinants by 
horizontal gene transfer (HGT; e.g. transformation, conjugation or transduction) between 
different bacterial species contributes to acquired resistance properties.29,33 This way of 
resistance spread is particularly problematic since it also occurs between unrelated bacteria 
genera like for instance between Gram-positive and Gram-negative bacteria.35 One example 
is the appearance of ermC in Enterobacteriaceae (e.g. E. coli), a gene involved in resistance 
to macrolide, lincosamide and streptogramin (MLS) antibiotics (e.g. erythromycin) which 
was originally described in Staphylococcus species.35,36 Moreover, bacteria can produce 
detoxifying enzymes that lead to an inactivation of the molecule and thus, loss of its 
antibacterial function. Those enzymes include β-lactamases or extended-spectrum β-
lactamases (ESBL), which are mostly produced by Gram-negative bacteria and which 
mediate the hydrolysis of the β-lactam ring of β-lactam antibiotics, such as penicillins or 
carbapenemes.37,38 Moreover, transferases are able to modify the molecule’s structure (e.g. 
addition of acyl groups) to prevent its binding to the target molecule.39,40 These enzymes 
include for instance phosphotransferases or acetyltransferases which are involved in 
modifying aminoglycosides such as streptomycin.39 Another way of bacteria to protect 
themselves against antibacterial agents relies on modifications of the target molecule. 
Structural alterations contribute to resistance in a way, that the antibiotic is unable to bind to 
its target and to perform its antibacterial mechanism.33,41 For instance, changes of the cell 
wall composition such as alterations of the peptidoglycan or mutations within penicillin-
binding proteins (PBPs) lead to resistance of cell wall targeting compounds 
(e.g. glycopeptides).33,40 Since target mutations involve modifications of important cellular 
processes, which often introduces a fitness cost for the bacterium, sometimes additional 
cellular changes are required to compensate for the acquired modifications and thereof 
relying altered functions.40 For instance, the β-lactam antibiotic methicillin inhibits cell wall 
synthesis by binding to PBPs and thus, inhibiting their function. To compensate the loss in 
functional PBPs, MRSA bears the resistant determinant mecA which encode PBP2a, an 
alternative PBP which has only low affinity to β-lactams.42–44 Due to additional alterations, 
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PBP2a is able to maintain the cell wall synthesis and resist the antibacterial effect of 
methicillin.40,42,45 
The most frequently occurring resistance mechanisms are mediated by efflux of the 
compounds or by alterations of the composition of the outer membrane (OM) of Gram-
negative bacteria.22,23 Resistance through efflux relies on the (over-)expression of efflux 
systems, which are distributed among all clinically relevant bacteria including for instance 
S. aureus (e.g. MepA), P. aeruginosa:(e.g. MexAB-OprM) and E. coli: (e.g. AcrAB-
TolC).33,46,47 On the one hand, efflux pumps may act drug-specific (e.g. tetracycline 
resistance through pumps encoded by tet genes48,49). However, on the other hand classes of 
efflux pumps exist [e.g. major facilitator superfamily (MFS), family, multidrug and toxic 
compound extrusion (MATE) family, resistance-nodulation-division (RND) family] which 
are able to export a broad variety of structurally unrelated antimicrobial compounds, which 
contributes severely to an MDR phenotype.40,46,50,51 Additionally, the OM of Gram-negative 
bacteria acts as an additional barrier to many commonly used antibacterial drugs 
(e.g. hydrophobic antibiotics) and contributes to impaired effectiveness due to hindered 
uptake.52–54 However, small molecules (molecular weight < 600 Da55) are able to enter the 
cell through porins, by diffusing through the lipid bilayer or by binding to lipopolysaccharide 
(LPS; self-mediated uptake). Nonetheless, a change or re-arrangement of structural 
components of the OM hampers the uptake of these compounds.22,56 In addition, even if a 
molecule is able to traverse the OM (e.g. through porins), efflux pumps counteract this 
process by pumping out the compounds before it is able to proceed its antibacterial action in 
many cases 40; a process that severely adds to an MDR phenotype as well. Moreover, 
different resistance mechanisms are often mediated simultaneously56 (e.g. increased efflux 
and altered OM) which complicates the treatment and underlines the urgent need of new 
antibacterial agents with new mechanisms of action an even new target molecules.21 In 
general, the treatment of Gram-negative bacteria is per se more challenging due to the 
presence of the OM. In contrast, the OM is absent in Gram-positive bacteria what implicates 
a somewhat easier treatment approach for this type of bacteria. Nevertheless, the appearance 
of MDR Gram-positive bacteria is as alarming, especially since S. aureus (incl. MRSA) 
depicts on of the most threating pathogens among those causing hospital- and community-
acquired infections.15,57 Vancomycin (VAN) is used as first-line treatment against infections 
caused by MRSA and also against other Gram-positive bacteria including Enterococcus spp.. 
However, the emergence of reduced susceptibility towards vancomycin in staphylococcal 
and enterococcal pathogens [VRE, vancomycin-resistant S. aureus (VRSA) and vancomycin 
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intermediate S. aureus (VISA)]8,57,58 depicts a major threat in the treatment of nosocomial 
infections. Resistance of VISA and VRSA relies mainly on the presence of the resistance 
gene vanA, a gene that was originally described in VRE.59–62 This furthermore underlines 
the ongoing risk of HGT and its severe contribution to MDR. Over the last years, only limited 
alternatives have been provided, among which the lipopeptide antibiotic daptomycin (DAP) 
depicts the last-resort treatment against MDR Gram-positive pathogens.63 However, as 
suspected, the appearance of DAP-resistant bacteria was described shortly after its 
introduction into the clinics (Figure 1-1) and resistance is spread among different species of 
Gram-positive bacteria (S. aureus, Enterococcus spp.).64,65 Regarding infections caused by 
MDR Gram-negative bacteria, effective drugs are likewise limited, especially due to the 
appearance of resistance against last-resort antibiotics which are characterized by them 
causing severe side-effects (e.g. colistin). Nevertheless, the treatment of infections caused 
by carbapenemase-producing MDR Gram-negative species relies mainly on the application 
of the polypeptide antibiotic colistin.66 However, colistin-resistance has already been 
described and the risk of a spread among different species is worrisome due to recent studies 
describing plasmid-mediated colistin-resistance (mcr-1 gene).67,68 
These facts, with a special consideration of the severe increase of antimicrobial resistance 
(AMR), emphasize on the urgent need of alternative treatment schemes.5 Only recently, the 
World Health Organization (WHO) published a priority list of pathogens, to guide the 
research and development (R&D) of new effective antibacterial compounds.69 The list 
comprises 12 pathogens for which new antibacterial agents are urgently needed and aims to 
globally prioritize R&D of new treatments against those pathogens. Based on the species 
and type of resistance, the pathogens are grouped into critical, high and medium priority, 
and comprise all clinical relevant pathogens. The primarily focus (critical prioritized 
pathogens, Table 1-1) lies on Gram-negative pathogens (e.g. carbapenem-resistant 
Enterobacteriaceae), followed by MDR Gram-positive bacteria (highly prioritized; 
e.g. MRSA) and less severe Gram-negative species such as Helicobacter spp. or Salmonella 
spp.69 In conclusion, due to the wide spread of AMR among all bacterial species, 





Table 1-1: Extract of the global priority list of pathogens published by the WHO.69 
Priority 1: Critical Type of resistance 
Acinetobacter baumannii Carbapenem-resistant 
Pseudomonas aeruginosa Carbapenem-resistant 
Enterobacteriaceae* Carbapenem-resistant, 3rd generation cephalosporin-resistant 
*K. pneumonia, E. coli, Enterobacter spp., Serratia spp., Proteus spp., Providencia spp., Morganella spp. 
 
1.2 SOURCES OF NEW ANTIBIOTICS 
Not only since the “Golden Era” of antibiotic discovery, but already since centuries, major 
sources for the discovery and development of new pharmaceuticals are natural products 
(NPs). They comprise compounds exhibiting various biological activities derived from 
natural sources such as plants and microorganisms, including bacteria and fungi.70–72 Ancient 
records of the medical use of herbal extracts demonstrate the importance of NPs as sources 
for active compounds since the advent of medicine.70,73,74 The multiplicity of today’s drugs 
derived from NPs and their use in a wide range of medical applications, such as anticancer, 
antitumor or antidiabetic therapy, underpins the importance of NPs in disease control.72 
Accounting not only NP and NP-derived drugs (26 %), but also NP-inspired drugs (synthetic 
compounds mimicking NPs or with NP-pharmacophore), more than 50 % of all new 
chemical entities (NCEs; 1562) approved by the Food and Drug Administration (FDA) 
between 1981 to 2014 are NP-like.72 Additionally, one of the most important properties of 
NPs is their antibacterial effect. Until today, the percentage of antibacterial effective small 
molecules derived from nature constitute around 74 % of all approved antibacterial small 
molecules.72 Interestingly, those compounds are mostly derived from soil living bacteria.70,72 
The beneficial effects of these secondary metabolites produced by bacteria have already been 
discovered long before the existence of the actual active metabolites has been proven. One 
example depicts ancient reports of using red soil from the Hashemite Kingdom of Jordan to 
treat skin infections.75 Those applications already pointed towards the importance of soil-
dwelling bacteria producing potent antibacterial compounds. Indeed, recent studies 
confirmed the effectiveness of red soil samples against S. aureus and Micrococcus luteus 
and identified several known antibiotic producer strains within the soil samples.75 They 
comprise Lysobacter spp., Bacillus spp. and actinomycetes, with the latter one being the 
most studied and successful order of bacteria producing potent biologically active NPs.76,77 
Actinomycetes are Gram-positive bacteria and the order comprises - amongst others - 
species of the genera Amycolatopsis and Streptomyces, whereas Streptomyces is the most 
important genus with regards to antibiotic production.78,79 Already 70 years ago, the first 
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antibiotic from Streptomyces (streptothricin) was described and the breakthrough of this 
genus as important source for new antibiotics was impelled by the isolation of streptomycin 
from Streptomyces griseus in 1944.78,80 The aminoglycoside streptomycin was the first 
antibiotic effective against tuberculosis and is still used as second-line anti-tuberculosis 
drug.81 Up to 80 % of contemporary used clinically relevant drugs are derived from 
Streptomyces.77,78 Not only this, but also the wide diversity of structural and mechanistic 
features77 - including all typical antibiotic mechanisms (inhibition of RNA, DNA, protein or 
cell wall synthesis; Figure 1-3) - illustrates the importance of this genus in the development 
of antibiotics. Examples for clinically used NPs and NP-derived drugs are DAP produced by 
S. roseosporus82, VAN produced by S. orientalis83 or tetracycline (TET) produced by 
S. rimosus and S. aureofacines.49  
 
Figure 1-3: Schematic representation of the mechanism of action and target-site of several antibiotic compounds derived 
from actinobacteria. Adapted from Procopio et al.77 
 
Nevertheless, the isolation of new compounds with potent antibacterial activity from former 
promising sources (e.g. Streptomyces) declines.78 At first glance, this seems to rely on the 
complete exploitation of the microbial sources as producer of antimicrobial compounds, but 
studies estimate that there are still many unknown compounds to be discovered.84 
Nevertheless, the frequency of identifying novel antibiotics is dropping. This is due to the 
fact, that a further exploitation of promising sources is hampered since already known 
antibiotics appear in much higher frequencies what clouds the identification of so far 








































screening of natural product libraries on new potential targets or total chemical synthesis 
were rather unsuccessful in developing new potential lead structures.86 Even though total 
synthesis seems to be a viable alternative to provide larger amounts of compounds, this route 
is accompanied by drawbacks. The structurally complex NPs often require a multiplicity of 
synthetic steps to finally yield the desired molecule.87,88 Thus, new innovative strategies and 
novel sources for the development of new antimicrobial drugs are needed. One promising 
approach is the examination of so far unexplored or under-exploited genera (found for 
instance among rare actinobacteria, myxobacteria, marine sponges) and under-explored 
habitats (e.g. deep seas).89–93 This approach is however often accompanied by major 
drawbacks such as difficulties regarding the cultivation of bacteria in laboratory 
environments and low yields of produced NPs.94,95 Metagenomic studies estimated that of 
all microbial species, approximately 99 % are uncultured (no growth conditions reported 
under laboratory conditions), but at the same time they are promising sources to produce 
novel and potent compounds.96,97 Thus, alternative and innovative strategies to increase 
biodiversity of strain collection and at the same time chemical diversity of isolated NPs are 
needed.79,98,99 For instance, the development of an isolation chip100 (iChip) led to the 
discovery of potent new antibiotics from previously uncultured bacteria, such as the cell wall 
inhibitor teixobactin.101 Nonetheless, microbial fermentations, production optimization and 
the development of an efficient downstream process are highly challenging as well.102,103 
This implies to limitations in the biological and chemical characterization of potential new 
agents.  
Considering these issues in NP discovery, an alternative way for drug development is the re-
assessment of already known and effective, but neglected NP scaffolds. Such antibiotics 
might have shown suboptimal pharmacological properties, which could not be addressed at 
the time upon their discovery due to minor chemical or genetic engineering knowledge or 
other antibiotics with similar activity profile entered the market at the time of their discovery 
and development into a drug was not further pursued (e.g. octapeptins104). Already known 
NP scaffolds can serve as basis for further structural modifications to generate new 
derivatives through different chemical approaches (e.g. semi-synthesis). Moreover, 
biosynthetic studies such as the investigations of biosynthesis gene clusters and genetic 
engineering paves the way towards the development of new NP derivatives with improved 
pharmaceutical properties. Improvements of existing compound classes, based on these 
techniques, have already been shown to be successful for e.g. ceftaroline a cephalosporin 
class derivative.105 In summary, this so-called rekindling of old antibiotics can provide 
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potent drug candidates, which can be forwarded into (pre-)clinical development106 In 
antibiotic discovery and hit to lead programs the overall aim is to provide derivatives with 
optimized pharmaceutical properties (ADMET: absorption, distribution, metabolism, 
excretion, toxicity), improved activity, and resistance-breaking properties and without toxic 
liabilities. 
Chelocardins and telomycins depict two examples of such under-exploited compound 
classes derived from actinobacteria, which will be further described in the following 
paragraphs (1.3 and 1.4). 
 
1.3 CHELOCARDINS 
Chelocardin (CHD; formerly known as M-319 or cetocycline; Figure 1-4) belongs to the 
family of tetracyclines (TCs; Figure 1-4) and is produced by the actinomycete Amycolatopsis 
sulphurea.107 It was already described in the early 1960s and CHD exhibits – like other 
members of tetracycline family – broad-spectrum antibacterial activity.107–109 TCs inhibit the 
protein biosynthesis by binding to 30S subunit of the ribosome and are used as first-line 
treatment against infectious diseases such as respiratory (e.g. atypical pneumonia) or genital 
infection (e.g. cervicitis) and additionally applied as alternative therapy for syphilis or 
community-acquired pneumonia.48,110 Moreover, several non-antibacterial properties are 
described, such as anti-inflammatory or anti-apoptotic effects or the inhibition of matrix 
metalloproteinases.110,111 Nevertheless, the main area of application of TCs comprises the 
treatment of bacterial infections. Their era as antibacterial agents began in 1948 with the 
isolation of chlortetracycline (aureomycin) from S. aureofaciens, followed by the discovery 
of oxytetracycline (OTC, terramycin) from S. rimosus.112,113 Chemical modifications of 
chlortetracycline (catalytic hydrogenation) led to a C-7-deschloro derivative which was 
named tetracycline (TET), the structurally simplest member of the first generation of TCs. 
Shortly after, TET was also found to be naturally produced by S. aureofaciens and S. rimosus 
as it serves as precursor molecule in the generation of chlortetracycline.114–116 Importantly, 
TET depicts one of the first semi-synthetically generated and FDA approved antibiotics used 
in the clinics.49,117 Between the 1960s and the end of the 20th century Pfizer and Lederle 
Laboratories developed a second generation of tetracyclines. The overall aim was to improve 
pharmaceutical properties, to enhance TCs antibiotic activity and decrease toxic effects. The 
most potent TC derivative of that time was minocycline (Figure 1-4), which exhibits 
improved pharmacokinetic properties compared to previously applied TCs.112,118 However, 
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due to increasing reports of resistance against TCs, a third generation – also known as 
glycylcyclines – was developed by using minocycline as precursor molecule.119,120 The most 
prominent molecule among this series is tigecycline, which was the first member of the 
family of glycylcyclines and it was approved by the FDA in 2005.121–123 Even though 
tigecycline shares the common mechanism of action of TCs through inhibiting the bacterial 
protein synthesis, this molecule is able to inhibit bacteria which carry TET-resistance genes 
(e.g. tetB coding for an efflux pump).48,124–126 TCs act by binding to the 30S subunit of the 
ribosome, and block the binding site of aminoacyl-tRNA, which hinders the transfer of 
amino acid residues to peptide chains and consequently the elongation of the growing 






Figure 1-4: Structures of typical and atypical (light-grey box) tetracyclines and derivatives. 
 
Importantly, CHD belongs to a group of TCs for which a different mechanism of action was 
described. This group includes anhydrotetracycline, anhydrochlortetracycline, 4-epi- 
anhydrochlortetracycline, 6-thiatetracycline, and CHD, all of which do not seem to interact 
with the ribosome, but rather interfere with the cytoplasmic bacterial membrane.127–129 
Moreover, this group of molecules act bactericidal, whereas all other TCs exhibit a 
bacteriostatic effect.48,127 Based on these observations, the family of tetracycline antibiotics 
was divided into two classes: typical and atypical TCs.128 Typical TCs act by inhibiting 
protein biosynthesis, whereas atypical TCs, such as CHD, seem to act on bacterial 
membranes. Previous studies indicated that the differences regarding the target site rely on 
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different structural features. All TCs (typical and atypical) share a common basic structure: 
a DCBA naphthacene core (Figure 1-5). However, the main difference of the two classes of 
TCs relies on a different aromatic pattern of the C ring. This seems to leads to a more planar 
structure in the case of atypical TCs (aromatic C ring), and an increased lipophilicity in 
comparison to typical TCs. The more lipophilic form of this TC sub-class of TC is thought 
to be the main reason why atypical TCs interfere with the membrane and do not primarily 
interact with the ribosome.127,128 In the case of CHD, additional structural differences are the 
primary amine at C-4 (tertiary amine in typical TCs) and CHD bears an additional methyl-
group at C-9. Moreover, typical TCs carry a carboxamido group at C-2, which is replaced 
by an acetyl group in CHD. Importantly, this structural feature at C-2 is found among all 
typical tetracyclines and is crucial for these molecules to perform their antibacterial action 
as observed in extensive SAR studies.130–133 
  
Figure 1-5: Structural differences of typical and atypical tetracyclines. 
 
Besides the differences in the mechanism of action, the most important characteristic of 
CHD is its ability to inhibit tetracycline-resistant bacteria.129,134,135 Resistance against TCs 
can rely on innate mechanisms, such as export by small molecule transporters (drug export) 
or a decreased permeability (OM). However, TET-specific resistance determinants 
contribute to acquired resistance mechanisms (Table 1-2). These mechanisms mainly rely 
on efflux mediated through 28 individual classes of pumps. Moreover, 12 resistance 
determinants are involved in ribosomal protection, two in compound degradation and five 
mutations are related to an impaired binding affinity to the ribosome.112 Resistance through 
ribosomal protection is mediated by specific proteins (ribosomal protection proteins), which 
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hinder the compound to perform its action on the ribosome.48 The frequent occurrence of 
resistance against TCs is primarily caused by resistance determinants on mobile genetic 
elements, such as plasmids or conjugative chromosomal elements. Those facilitate the 
horizontal gene transfer among different bacterial species.136,137 Based on this, it is important 
to find alternative antibacterial agents, which are able to inhibit the multiplicity of bacteria 
bearing TC resistance determinants within their genome.  





tetA tetY tetAB(46) tetM tetX G1058C 
tetB tetZ tcr3 tetO tet37 A926T 
tetC tet30 otrC tetQ  G927T 
tetD tet31 otrB tetS  A928C 
tetE tet33  tetT  ∆G942 
tetG tet35  tetW   
tetH tet38  tetB(P)   
tetJ tet39  tet32   
tetK tet40  tetB36   
tetL tet41  tet44   
tetA(P) tet42  ortA   
tetV tet45  tet   
tet: tetracycline resistance gene; ort: oxytetracycline resistance gene; ∆: deletion 
 
Due to its broad-spectrum activity and putative lack of cross-resistance with TCs, CHD 
depicts a promising candidate to be used as alternative to typical TCs. Moreover, in the late 
1970s, it was already shown that CHD displays potent in vivo efficacy. In a small phase II 
clinical study, twelve patients suffering from urinary tract infections (pyelonephritis) caused 
by Gram-negative bacteria were treated with CHD and infection was cured in all cases.138  
Even though the effectiveness of CHD comprises the inhibition of a wide range of bacteria, 
one bacterial species belonging to the ESKAPE group of pathogens is not susceptible. 
Natural CHD is not able to inhibit the growth of P. aeruginosa, a species that is also found 
among TC-resistant pathogens.48 To improve CHD’s pharmaceutical properties and to widen 
its antibacterial spectrum, structural modifications were introduced. Based on the knowledge 
that the carboxamido group onC-2 of typical TCs is crucial for their activity, this moiety was 
installed on CHD through biosynthetic engineering. 2-carboxamindo-2-deacetyl-CHD 
(amidochelocardin, CDCHD, Figure 1-4) depicts a CHD derivative, which comprises all 
structural important features from typical and atypical TCs.139 Activity studies revealed 
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CDCHD to exhibit an improved antibacterial activity in comparison to the parent molecule 
CHD, including significant inhibitory effects against clinical isolates of Pseudomonas 
species.139  
Despite the fact that chelocardins depict potent molecules with resistance-breaking 
properties, their mechanism of action is still far from understood and it is only 
controversially discussed. On the one hand, reports describe CHD as inhibitor of protein 
synthesis140 and on the other hand, CHD was shown to induce cell lysis by interfering with 
the cell membrane and no interaction with the ribosome was found.127–129,135 Interestingly, a 
recent study, which was based on a global proteome analysis, predicated a dual mechanism 
of action of CHD through inhibition of the protein biosynthesis and interference with the 
cell membrane in a concentration-dependent manner (low concentrations: protein 
biosynthesis; higher concentrations: membrane).141 However, no specific hint towards the 
main target molecule exists and it still remains elusive.  
To further optimize the compound class of chelocardins and to develop a potent antibiotic 
drug, which is able to overcome AMR, is important to identify the target molecule and to 
fully characterize the mechanism of action. 
 
1.4 TELOMYCINS 
Telomycin (TM; Figure 1-6) belongs to the family of cyclic depsipeptide antibiotic 
molecules and is composed of 11 amino acids, five of which are non-proteinogenic amino 
acids.142–144 The natural product TM is already known since the 1950s and is produced by 
the actinomycete Streptomyces canus.145–147 Besides reports of TM’s effectiveness against 
Gram-positive bacteria144,146,148 and its complete structural elucidation more than 20 years 
after the first description of TM142–144, no extensive investigation on the natural product was 
documented until the characterisation of the biosynthesis gene cluster in 2015.148 Within the 
latter study, natural lipopeptides were identified to serve as precursors for TM and 
intriguingly, these derivatives showed improved activity compared to TM itself.148 Overall, 
lipopeptides are a promising class of NPs with potent antibacterial activity. Natural sources 
for lipopeptide antibiotics are mainly actinobacteria, but also other species such as Bacillus 
spp., Enterobacter spp. or Citrobacter spp. were described to produce potent 
lipopeptides.149,150 Lipopeptides are structurally related as they are composed of a fatty acyl 
chain which is covalently bound to the N-terminus of a linear or cyclic peptide core.19,151,152 
However, due to variations in the composition of the lipid tail and the peptide chain, diverse 
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classes of lipopeptides exist (e.g. surfactin, fengycin, polymyxins).149,153 Their lipid tails can 
differ in length (C6-C18) and composition (type of fatty acid moiety) and amino acids can 
vary in their type (e.g. acidic, basic, aromatic), in the number (2-25) or in their configuration 
(D, L).154 Moreover, due to the fact that lipopeptides are generated via a non-ribosomal 
biosynthetic pathway, they are often composed of non-proteinogenic or unusually 
configured or modified proteinogenic amino acids.19,154 Lipopeptides are active against 
MDR bacteria, but most do not exhibit broad-spectrum activity and rather act one type of 
bacteria (Gram-positive or Gram-negative).19,151,155 In contrast to anionic lipopeptides 
– which solely act on Gram-positive bacteria (e.g. DAP, surfactin) – cationic lipopeptides 
are able to travers the OM (self-mediated uptake) and inhibit Gram-negative bacteria 
(e.g. polymyxin B).19,155 The characterization of the first lipopeptides is already more than 
60 years ago. Among the anionic lipopeptide class amphomycin was the first characterized 
member and isolated in the early 1950s156, followed by the discovery of structurally related 
classes such as friulimicins and glycinocins.154 Regarding cationic lipopeptides, polymyxins 
depict one of the oldest family among this type of lipopeptide antibiotics.153,157 Over the past 
decades, only few new antibiotics were approved by the FDA, among which the cyclic 
lipopeptide DAP was successfully approved for the treatment of complicated skin and soft 
tissue infections caused by Gram-positive bacteria including MRSA.63,158 Nevertheless, the 
exact mechanism of action of DAP and of most lipopeptides is not complete understood, but 
they seem interact with the bacterial membrane.59,155 Moreover – regardless of their net 
charge – all lipopeptides are able to interact with the bacterial membrane via their lipid side 
chain. Certainly, a class of calcium-dependent-antibiotics (CDA) exists among lipopeptides 
comprising for instance DAP or tsushimycin, both of which require the presence of divalent 
ions (Ca2+) to fulfil their complete activity.151 Only recently, a novel class of CDA cyclic 
lipopeptides, the malacidins, were described. Malacidins were discovery within on a culture-
independent screening approach and characterized to exhibit promising resistance-breaking 
properties including activities against MDR Gram-positive bacteria.159 This supports not 
only the potency of lipopeptides, but also the importance of applying novel approaches to 
identify new compound classes. Regarding the class of telomycins (TMs) Fu et al. identified 
new natural telomycin derivatives, and described the semi-synthesis of several lipopeptide 
TM analogues with improved effectiveness. One semi-synthetic compound depicts TM-
Dodec (Figure 1-6), an acyl-derivative bearing an additional dodecanoic acid side chain at 






Figure 1-6: Structure of the natural product telomycin (TM) and semi-synthetic generated derivatives TM-Dodec and TM-
N-Oct. 
 
TM is described to act bactericidal against Gram-positive bacteria including MRSA, VISA 
and VRE.146,148,160 Since the prevalence of MDR among Gram-positive bacteria is still 
increasing and alternative treatments are missing, TMs seems to be a viable alternative for 
the treatment of infections caused by such pathogens. This area of application might be 
especially favourable since TM is effective against DAP-resistant pathogens and the acylated 
derivative TM-Dodec exerts an even stronger bactericidal effect on S. aureus compared to 
the gold-standard antibiotic DAP.148  
Only recently, Magarvey and co-workers described the identification of TM’s putative target 
molecule. Within their study, a large collection of NPs (1908) was profiled by applying a 
retro-biosynthetic algorithm, aiming to identify antibiotic classes with unknown mechanisms 
of action or mechanisms of resistance. Thereby, TM was identified as promising candidate 
and a further investigation led to the characterization of the phospholipid cardiolipin as 
binding partner for TMs.161 Besides this report and a study on a truncated version of TM, 
named LL-AO341β1 (Figure 1-7), no reports on the mechanism of action exist. LL-AO341β1 
was described not to be involved in classical antibacterial mechanisms such as the inhibition 
of RNA, DNA, protein and peptidoglycan synthesis. However, this molecule was postulated 
to interact with the cytoplasmic membrane by a “de-energization” effect.160 Nevertheless, 
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even though CL was identified as target molecule, solely the binding of TMs to CL is 
unlikely to cause the bactericidal effects, especially since a depletion of CL is not lethal.162 
Therefor it still needs to be further investigated if TMs act on a specific target protein and 
how exactly this compound class performs the bactericidal mechanism of action. 
Additionally, the impact of the addition of acyl chains to TM (TM-Dodec, TM-N-Oct; Figure 
1-6) should be considered as well.  
 
 
Figure 1-7: Structure of truncated TM analogue LL-AO341β1. 
 
1.5 OUTLINE OF THE DISSERTATION 
The aim of the present work was the elucidation of the mechanism of action and resistance 
mechanism of chelocardins and telomycins and the identification of (additional) target 
molecules for both compound classes. 
The first part of this study deals with the biological characterisation of chelocardin and its 
amidated analogue 2-carboxamindo-2-deacetyl-CHD (CDCHD). For both derivatives a 
comprehensive in vitro activity-based screen was performed and antibacterial as well as 
cytotoxic effects were investigated. Moreover, derivatives derived from semi-synthesis and 
genetic engineering were used to establish structure-activity relationships and to compare 
the in vitro potency of these compounds to both parent molecules, CHD and CDCHD, 
aiming to identify a derivative with improved overall profile.  
Several in vitro studies were applied to reveal further insight into the mechanism of action 
of both compounds with a focus on cell viability and cellular processes such as the synthesis 
of macromolecules. Additionally, Gram-positive and Gram-negative wildtype species 
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served to generate CHD- and CDCHD-resistant mutants aiming to characterise the 
mechanism underlying resistance and preferably to identify the target molecule. 
 
In the second part, telomycin and two semi-synthetic derived analogues, TM-Dodec and 
TM-N-Oct were biologically characterized, and screened for their antibacterial effectiveness 
against laboratory pathogens and clinical isolates. The in vitro generation of TM- and TM-
Dodec-resistant bacteria and analysis of their genomes in comparison to the wildtype 
genome was performed to elucidate the resistance mechanism and to gain further hints 
towards the target molecule. Those results served as basis for the investigation of the 
mechanism of action of TM and both acyl derivatives. Studies included the characterization 
of the interaction of the compounds with potential binding partners and target fishing 
experiments with biotinylated tool compounds. 
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 MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 COMPOUNDS 
Chelocardin is produced by Amycolatopsis sulphurea NRRL2822 and derivatives were 
synthesized or isolated from the genetically engineered producer strain. Compounds were 
kindly provided by several co-workers from HZI and HIPS: Dr. Antoine Abou Fayad, 
Dr. Tadeja Lukežič, Chantal Bader, Dr. Rolf Jansen, Kerstin Schober, Dr. Suryanarayana 
Birudukota and Dr. Charlotte Grandclaudon. 
Telomycin is produced by Streptomyces canus ATCC 12646 and derivatives were 
synthesized from the isolated natural product. All compounds were kindly provided by 
Dr. Armin Bauer (Sanofi) and Dr. Antoine Abou Fayad (HIPS-MINS). 
2.1.2 CHEMICALS 
All chemicals were of reagent grade quality and were obtained from commercial sources. 
2.1.3 BACTERIAL GROWTH MEDIUM 
All media were prepared in Milli-Q-water (MQ) and sterilized by autoclaving. Agar-based 
media were prepared by the addition of 1.6 % agar (Sigma Aldrich) to the medium. 
Table 2-1: Bacterial growth medium. 
Medium Ingredients Concentration 
CASO agar (Carl Roth); pH 7.3 
casein peptone 1.5 % 
soya peptone 5 % 
NaCl 5 %  
Agar 1.5 %  
EBS; pH 7 
peptone from casein 0.5 % 
peptone from beef 0.1 % 
peptone from protease 0.5 % 
yeast extract 0.1 % 
Middlebrook 7H9 medium (M7H9) 




Glycerol 2 mL/L 
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Müller Hinton broth (MHB, BD 
Difco); pH 7.4 
casein hydrolysate 1.75 % 
beef infusion solids 0.2 % 
Starch 0.15 % 
Müller Hinton broth II (MHBII, 
BD Difco); cation adjusted; pH 7.3 
casein acid hydrolysate 1.75 % 
beef extract 0.3 % 
starch 0.15 % 
CaCl2 1.25 mM 
MgCl2 0.8 mM 
LB; pH 8.0 
NaCl 1 %  
tryptone 1 % 
yeast extract 0.5 % 
LBlow-Hyg; pH 8.0 
NaCl 0.5 %  
tryptone 1 % 
yeast extract 0.5 % 
Hygromycin B 100 µg/mL 
LB-Apr; pH 8.0 
NaCl 1 %  
tryptone 1 % 
yeast extract 0.5 % 
Apramycin 50 µg/mL 
SOC  
NaCl 0.05 % 
tryptone 2 % 
yeast extract 0.5 % 
KCl 2.5 mM 
MgCl2 10 mM 
MgSO4 10 mM 
glucose 20 mM 
Tryptic Soy Broth (TSB); pH 7.3 
peptone from casein  1.7 % 
peptone from soya 0.3 % 
NaCl 0.5 % 
K2HPO4 0.25 % 
glucose 0.15 % 
yeast extract 0.25 % 
TSB-G, pH 7.3 
 
peptone from casein  1.7 % 
peptone from soya 0.3 % 
NaCl 0.5 % 
K2HPO4 0.25 % 
glucose 0.9 % 
yeast extract 0.25 % 
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2.1.4 MICROORGANISMS 
Table 2-2: Microorganisms. 
Classification Strain  Source 
Gram-negative 
Acinetobacter baumannii DSM-30008 DSMZ 
Burkholderia cenocepacia DSM-16553 DSMZ 
Citrobacter freundii DSM-30039 DSMZ 
Enterobacter aerogenes DSM-30053 DSMZ 
Escherichia coli DSM-1116 DSMZ 
Escherichia coli ATCC-25922 ATCC 
Escherichia coli TolC internal strain collection 
Escherichia coli WT Prof. Dr. Peter Heisig[a] 
Escherichia coli WT-III Prof. Dr. Peter Heisig[a] 
Escherichia coli WT-3 Prof. Dr. Peter Heisig[a] 
Haemophilus influenzae DSM-11970 DSMZ 
Klebsiella pneumoniae DSM-30104 DSMZ 
Pseudomonas aeruginosa DSM-11128 DSMZ 
Pseudomonas aeruginosa PA14 internal strain collection 
Pseudomonas aeruginosa PA14 ∆mexAB Prof. Dr. Susanne Häußle[b] 
Pseudomonas aeruginosa PA14 ∆mexCD Prof. Dr. Susanne Häußle[b] 
Pseudomonas aeruginosa PA14 ∆mexEF Prof. Dr. Susanne Häußle[b] 
Pseudomonas aeruginosa PA14 ∆mexXY Prof. Dr. Susanne Häußle[b] 
Pseudomonas aeruginosa DSM-24599 DSMZ 
Proteus vulgaris DSM-2140 DSMZ 
Proteus mirabilis DSM-4479 DSMZ 
Serratia marcescens DSM-30121 DSMZ 
Gram-positive 
Bacillus subtilis DSM-10 DSMZ 
Bacillus megaterium DSM-32 DSMZ 
Corynebacterium glutamicum DSM-20300 DSMZ 
Enterococcus faecalis DSM-20478 DSMZ 
Enterococcus faecium DSM-20477 ATCC 
Streptococcus pneumoniae DSM-11865 DSMZ 
Micrococcus luteus DSM-1790 DSMZ 
Micrococcus luteus DSM-20030 DSMZ 
Mycobacterium smegmatis mc2155 ATCC 
Mycobacterium bovis BCG DSM-43990 DSMZ 
Nocardia asteroides DSM-43757 DSMZ 
Staphylococcus epidermidis DSM-28765 DSMZ 
Staphylococcus carnosus DSM-20501 DSMZ 
Staphylococcus aureus DSM-346 DSMZ 
Staphylococcus aureus DSM-11822 DSMZ 
Staphylococcus aureus ATCC-29213 ATCC 
Staphylococcus aureus Cowan1 Prof. Dr. Markus Bischoff[c] 
Staphylococcus aureus Newman Prof. Dr. Markus Bischoff[c] 
Staphylococcus aureus N315 Prof. Dr. Markus Bischoff[c] 
Staphylococcus aureus Mu50 Prof. Dr. Markus Bischoff[c]  
[a] University Hamburg, Department Biochemistry and Molecular Biology, Hamburg, Germany ; [b] Helmholtz Centre for 
Infection Research, Braunschweig/Twincore, Hannover, Germany; [c] Saarland University Hospital, Homburg, Germany 
Materials and Methods 
22 
2.1.5 CELL LINES 
Table 2-3: Cell lines. 
Cell line Species Type Medium Supplements 
HCT-116 human colon carcinoma McCoy’s 5A 10 % FBS 
HepG2 human hepatocellular carcinoma DMEM 10 % FBS 
L929 murine  connective tissue fibroblast RPMI-1640 10 % FBS 
RAW 264.7 murine 
macrophage-like (leukemia virus-
induced tumour) 
DMEM 10 % FBS 
THP-1 human acute monocytic leukemia RPMI-1640 10 % FBS 
U-2 OS human bone osteosarcoma McCoy’s 5A 10 % FBS 
 
2.1.6 CELL CULTURE MEDIUM AND REAGENTS 
Table 2-4: Cell culture reagents. 
Reagent Description Manufacturer 
Dulbecco’s modified Eagle’s 
Medium (DMEM) 





McCoy’s 5A  
L-glutamine 
NaHCO3 
Invitrogen, Karlsruhe, Germany 







Foetal bovine serum (FBS) 
heat inactivated, FBS 
Good 




HBS-P (pH 7.4)  
HEPES   0.01 M 
NaCl   0.15 M 
Tween-20   0.005 % (v/v) 
 
HBS-EP (pH 7.4)  
HEPES   0.01 M 
NaCl    0.15 M 
EDTA   3 mM 
Tween-20   0.005 % (v/v) 
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HEPES buffer (pH 7.2, adjusted with NaCl) 
HEPES  5 mM  
 
NAE buffer 
Na-acetate (3M, pH 5.1)  50 mM 
EDTA    10 mM 
 
NAES buffer 
NAE buffer + 1 % (w/v) SDS 
 
NAE-phenol 
50 mL NAE buffer per 500 mL aqua-phenol 
 
PBS (pH 7.45) 
sodium phosphates  10 mM 
KCl   2.68 mM 
NaCl   140 nM 




PBS + 0.05 % (v/v) Tween-20 
 
SPR coupling buffer   
Acetic acid  1 mM 
pH was adjusted to 4, 4.5, 5 or 5.5 with sodium hydroxide 
 
Maleic acid   1 mM 
pH was adjusted to 6, 6.5 or 7 with sodium hydroxide  
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TBS-T (pH 7.0, adjusted with HCl) 
Tris   0.1 M   
NaCl   0.15 M  
Tween-20  0.1 % (v/v) 
 
TCA (10 %) 
Trichloroacetic acid 10 % (w/v)   
NaCl   1 M  
 
TCA (2.5 %) 
Trichloroacetic acid 2.5 % (w/v)   
NaCl   1 M  
 
TMRM assay buffer (pH 7.35, adjusted with 10 N NaOH) 
NaCl    135 mM 
KCl    5.4 mM 
MgCl2   2 mM 
Glucose   10 mM 
CaCl2    2 mM 
HEPES   10 mM 
 
SDS-PAGE 
SDS-PAGE loading buffer (4 x) 
Tris/HCl (1 M, pH 6.8)  500 mM 
Glycerol (87 %)   30% (v/v) 
Bromophenol blue   0.01% (w/v) 
SDS     10% (w/v) 
DTT    4 mM 
 
SDS-PAGE running buffer (4x; pH 8.6, adjusted with HCl) 
Tris    250 mM  
Glycine  2 M 
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SDS-PAGE separating buffer (4x; pH 8.8, adjusted with HCl) 
Tris    1.5 M 
10 % SDS  4 % (w/v) 
 
SDS-PAGE stacking buffer (4x; pH 6.7, adjusted with HCl) 
Tris    0.5 M  
10 % SDS  4 % (w/v) 
 
Separating gel (12.5 %) 
Bis-Acrylamide (30 % v/v)   5 mL  
4x separating buffer (pH 8.8)  2.5 mL 
dH20     2.5 mL  
TEMED    10 µL 
APS (10 %)     100 µL 
 
Stacking gel (5 %) 
Bis-Acrylamide (30 % v/v)   830 µL 
4x stacking buffer (pH 6.8)   1275 µL 
dH20     3 mL 
TEMED    5 µL 
APS (10 % w/v)   50 µL 
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2.1.8 OTHER REAGENTS 
Table 2-5: Reagents. 
Reagent Description Manufacturer 
Aqua-Phenol Water saturated phenol 
Carl Roth GmbH, 
Karlsruhe, Germany 
Bis-acrylamide 30 % (v/v) 
Carl Roth GmbH, 
Karlsruhe, Germany 
DECP water 
Ambion® DEPC-treated water 
nuclease-free 






DNase I  RNase-free, 2 U/mL 
New England Biolabs 





Lysozyme  20,000 U/mg 
Carl Roth GmbH, 
Karlsruhe, Germany 
















Ribonuclease A ~ 90 U/mg 





Carl Roth GmbH, 
Karlsruhe, Germany 
Polymerase GoTag Green Mastermix 
Promega, Madison, WI, 
USA 
Proteinase K from 
Tritirachium album 




Proteinase inhibitor  





Random Primer 3 ug/µL 





Thermo Fisher Scientific, 
Schwerte, Germany 
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RiboLock RNase Inhibitor 40 U/µL 
Thermo Fisher Scientific, 
Schwerte, Germany 
Restriction enzymes  
Thermo Fisher Scientific, 
Schwerte, Germany 
Tetramethyl rhodamine 







Carl Roth GmbH, 
Karlsruhe, Germany 
 
2.1.9 CONSUMABLES AND TECHNICAL EQUIPMENT 
Table 2-6: Consumables. 
Description Type Manufacturer 
6-well plates 
Costar® 6 well, sterile, clear, flat 
bottom 
Coring Life Sciences, 
Amsterdam, Netherlands 
24-well plates 
Corning® CellBIND® 24 well, 
sterile, clear, flat bottom 
Coring Life Sciences, 
Amsterdam, Netherlands 
96-well plates 
Corning® CellBIND® 96 well, 
sterile, clear, flat bottom 
Coring Life Sciences, 
Amsterdam, Netherlands 




96 well, sterile, clear, flat bottom 
Sarstedt AG & Co., 
Nümbrecht, Germany 
96 well, white, flat bottom 
Coring Life Sciences, 
Amsterdam, Netherlands 




25 cm2 (T-25), filter cap 
Sarstedt AG & Co., 
Nümbrecht, Germany 
75 cm2 (T-75), filter cap 
Cyro beads 
Chemically treated beads covered 
with special cryogenetic 
preservative 
solution within a cryovial 
Mast Diagnostica GmbH, 
Reinfeld, Germany 
Filter 
Glass microfiber binder free filter, 
25 mm diameter Whatman™, GE 
Healthcare, Germany 
Whatman™ cellulose filter grade 1 
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Kits 
miRNAse mini Kit 
Qiagen GmbH, Hilden, 
Germany 
BacLight™ Bacterial Membrane 









SPR amine coupling kit 
Biacore, GE Healthcare, 
Germany 










Corning®Costar® Stripette (2 mL, 
5 mL, 10 mL, 25 mL, 50 mL) 
Coring Life Sciences, 
Amsterdam, Netherlands 
SPR vials 
Plastic Vials and Caps, Ø 11 mm 
Plastic Vials, Ø 15 mm 
Biacore, GE Healthcare, 
Germany 
SPR chips CM5 
Biacore, GE Healthcare, 
Germany 
TLC plates 









Table 2-7: Technical equipment. 












CT15RE VWR, Leuven, Belgium 
Ultracentrifuge, Avanti J-26 S 
Beckman Coulter, Krefeld, 
Germany 
Concentrator SpeedVac Concentrator Plus 
Eppendorf, Hamburg, 
Germany 
Freeze dryer Vacuum freeze dryer 
Christ, Osterode am Harz, 
Germany 
French press Fresh press 






CO2, Innova CO-170 
New Brunswick Scientific, 
Edison, USA 
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Microscope (automated)  Pathway 855 
BD, Biosciences, 
Heidelberg, Germany 
Microscope (optical) ECLIPSE TS100 Niko, Düsseldorf, Germany 




NanoDrop 2000c (spectral) 





Pipettors Accu-jet pro Brand, Wertheim, Germany 
Pipettes 
Transferpette® S, (0.1-2.5 µL, 0.5-
10 µL, 2-20 µL, 20-200 µL, 100- 
1000 µL) 
Brand, Wertheim, Germany 
Transferpette® S-8 (20-200 µL) 
Transferpette® S-12 (20-200 µL) 
Plate reader Infinite 200 M Pro  
Tecan Group Ltd., 
Männedorf, Switzerland 
qPCR cycler Peqstar 96Q 
Peqlab Biotechnology 
GmbH, Erlangen, Germany 





MicroBeta TriLux 1450 LSC & 
Luminescence 
Perkin Elmer, Waltham, 
MA, USA 
Shaker Infors HT Minitron Shaker 
Infors HAT, Basel, 
Switzerland 
Surface Plasmon resonance 
(SPR) 
X100 




Table 2-8: Plasmids. 
Plasmid Description Selection marker Source 
pIJ773 
template for apramycin resistance 
cassette 
apramycin Huang et al.163 
pACBSR-Hyg 
p15A replicon plasmid; arabinose-
inducible λ-Red recombinase 
hygromycin Huang et al.163 
pFLP-Hyg 
heat-shock inducible FLP 
recombinase 
hygromycin Huang et al.163 
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2.1.11 PRIMER 
Table 2-9: Primer for in vitro translation, heterologous expression and gene knockout. 
Primer Sequence (5’  3’ direction) 
In vitro translation  
Fluc_fwd  CGAGATCTCGATCCCGC 


























Table 2-10: Primer for qPCR 




AcrA_fwd ACCAAAGTCACCTCGCCG acrA 
AcrA_rev CCTGCTGGTACCGCAACA 
AcrB_fwd GGACGGTTCCCAGGTTCG acrB 
AcrB_rev TTTTCCTCACCCGGACGC 
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2.1.12 ISOTOPES 
Table 2-11: Isotopes. 
Isotope Manufacturer 
Deoxythymidine 5’-Triphosphate, [Methyl-3H], 
Tetrasodium Salt 
Perkin Elmer, Waltham, MA, USA 
Uridine 5’Triphosphate, Tetrasodium Salt [5,6-3H] Perkin Elmer, Waltham, MA, USA 
L-[Methyl-3H]-Methionine Perkin Elmer, Waltham, MA, USA 
Glucosamine D-[1-3H] hydrochloride 
American Radiolabeled Chemicals, 
Saint Louis, MO, USA 
 
2.2 METHODS 
Methods marked with an asterisk (*) were applied by collaborators and are described in 
brief. Methods marked with a double asterisk (**) were partly applied by collaborators and 
partly by the author. 
2.2.1 BACTERIAL CULTIVATION 
Bacterial strains were either conserved as glycerol stocks (50 % (v/v) glycerol) or in 
cryovials, containing ‘cryo beads’ (MAST CRYOBANK™) and stored at -80°C. To obtain 
a liquid culture one ‘cryo bead’ or a few microliters of the glycerol stock were inoculated in 
the appropriate growth medium and incubated overnight at 30°C or 37°C at 210 rpm or at 
37°C/5% CO2. Cultures at a specific growth phase were obtained by re-inoculation of the 
overnight cultures followed by cultivation under appropriate conditions up to a respective 
optical density of 600 nm (OD600). Bacterial cultures on agar-based growth medium were 
prepared by streaking a few microliters of a liquid culture on an agar plate followed by an 
overnight incubation at the appropriate growth conditions.  
2.2.2 MIC DETERMINATION 
** All microorganisms were handled according to standard procedures and were obtained 
from the German Collection of Microorganisms and Cell Cultures (Deutsche Sammlung für 
Mikroorganismen und Zellkulturen, DSMZ) and the American Type Culture Collection 
(ATCC) or were part of our internal strain collection. Minimal inhibitory concentrations 
(MIC) for M. bovis were determined in 5 mL cultures (three to four weeks incubation) and 
all other values were determined by micro-dilution assays.164 Overnight cultures were 
diluted in modified tryptic soy broth (TSB, Enterococcus spp.), in Middlebrook 7H9 (M7H9; 
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Sigma-Aldrich®; mycobacteria), Mueller-Hinton broth (MHB, or all other listed bacteria for 
chelocardin-related studies) or cation-adjusted Mueller-Hinton broth II (MHBII, for all other 
listed bacteria for telomycin-related studies) to achieve a final inoculum of approximately 
1 x 106 CFU/mL. Serial dilutions of compounds were prepared in sterile clear 96-well plates 
(Sarstedt AG & Co). The cell suspension was added and microorganisms were grown for 
16-18 h at either 30°C or 37°C (Enterococcus spp. were grown under microaerophilic 
conditions). Growth inhibition was assessed by visual inspection and MIC values were 
determined as the lowest concentration of antibiotic at which no visible growth was 
observed.  
MIC determination for M. tuberculosis 
* MIC determination for M. tuberculosis (strain H37Rv) was performed by Alamar Blue 
assay165 as described previously.166,167 In brief, 2-fold serial dilutions of compounds were 
prepared in M7H9 broth (Sigma-Aldrich) in round-bottom 96-well plates and 100 µL 
M. tuberculosis suspension (105 CFU/mL in M7H9 broth) was added per well. Plates were 
stored in plastic bags and incubated at 37°C for seven days. At day seven, 10 µL Alamar 
Blue solution (Invitrogen) was added per well and incubated for additional 24 h at 37°C. 
Fluorescence was measured (excitation: 544 nm; emission: 590 nm) by using a microplate 
reader (FLUOstar OPTIMA, MG LABTECH). MIC was defined based on relative 
fluorescence as lowest drug concentration leading to an inhibition of ≥ 90 % compared to 
the control. MICvis values were determined visually by determination of a colour change 
from blue to pink (MICvis: lowest drug concentration preventing colour change).  
MIC/MBC determination of clinical uropathogens 
* MIC determinations of clinical bacterial uropathogens were performed by micro-dilution 
assays according to guidelines of the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST; DIN EN ISO 20776-1).168 MIC values were determined as lowest 
concentration leading to no visible growth. Minimum bactericidal concentrations (MBC) 
were determined by inoculation of 3 µL/well of the 96-well plates (used for MIC 
determination) to rectangular blood-agar plates (Iso-Sensitest + 5 % sheep blood) and 
incubated overnight at 37°C. MBC values were determined as the lowest concentration 
which leads to killing of 99.9 % (> log3) of each inoculum.  
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2.2.3 CELL VIABILITY BASED ON ATP QUANTIFICATION 
To determine cell viability based on the amount of ATP present in bacterial cells, the 
luminescence-based BacTiter-Glo™ Microbial Cell Viability Kit (Promega) was used. 1 mL 
overnight culture of S. aureus Newman wildtype and cls2 disrupted mutant was washed with 
MHB medium and 100 µL cell solution was added per well to a white, flat bottom 96-well 
plate (Corning). Cells were treated with 2-fold MIC per compound for 1 h at 37°C and 800 
rpm. 100 µL of the BacTiter-Glo reagent was added per well and mixed briefly (900 rpm). 
Luminescence was recorded by using a microplate reader (Tecan Infinite M200 Pro).  
2.2.4 BIOFILM FORMATION  
Overnight cultures of S. aureus Newman and TM-Dodec-resistant mutants were adjusted to 
a final cell concentration of 106 CFU/mL in TSB-G. 200 µL cells were added per well to 96-
well plates and incubated at 37°C for 24 and 48 h. To determine biofilm formation, cells 
were washed twice with 200 µL MQ and 50 µL of 0.5 % (w/v) crystal violet was added. 
After 10 min of staining at room temperature, cells were washed twice with MQ and 200 µL 
EtOH were added per well. Optical density at 590 nm was measured using a microplate 
reader plate (Tecan Infinite M200 Pro).  
2.2.5 TIME-KILL CURVES 
Overnight cultures of S. carnosus DSM-20501 or K. pneumoniae DSM-30104 were diluted 
in MHB medium to achieve a start inoculum of 106 CFU/mL. Compounds were added at the 
assigned concentrations and cell viability was assessed at several time points (S. aureus: 0, 
0.5, 1, 2, 4, 6, 9, 12, 24 h; K. pneumoniae: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24 h) by CFU counts 
of samples (in 0.9 % (w/v) NaCl) in serial dilution after overnight incubation at 37°C on 
solid medium (CASO agar). Time-kill curves were obtained by plotting CFU counts (log10 
scale) versus time. 
2.2.6 LIVE DEAD ASSAY 
Bactericidal effects were determined by using the BacLight™ LIVE/DEAD Bacterial 
Viability Kit (Invitrogen) following the manufacturer protocol with minor modifications. An 
overnight culture of E. coli DSM-1116 was sub-cultivated in MHB medium to reach a start 
inoculum of approximately 2.5 x 108 CFU/mL (OD600: 0.5). Untreated control cells were 
centrifuged for 20 min at 4,000 rpm (5180R Eppendorf), the supernatant was discarded and 
the pellets were re-suspended in 2 mL 0.85 % (w/v) NaCl. Live and dead cells were prepared 
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by adding 1 mL cells to either 7 mL 0.85 % (w/v) NaCl (live, negative control) or to 7 mL 
70 % (v/v) isopropyl (dead, positive control) and incubated for 1 h at room temperature. 
Antibacterial activities were examined by exposing cells for 4 h to compounds at 5-fold 
MIC. All samples were centrifuged for 20 min at 4,000 rpm (5180R Eppendorf), washed 
with 5 mL 0.85 % (w/v) NaCl and centrifuged again. The pellets were re-suspended in 10 
mL 0.85 % (w/v) NaCl and the OD600 values were measured (BioPhotometer Plus, 
Eppendorf). All samples were adjusted to the lowest OD600 and a standard curve was prepared 
by mixing five different portions of live:dead control cells (0, 10, 50, 90, 100 % live cells). 
A 2-fold staining solution was prepared (6 μL SYTO9, 6 μL propidium iodide (PI) added to 
2 mL MQ) and all samples were stained (1:1) for 15 min at room temperature, protected 
from light. Fluorescence was measured using a microplate reader (Tecan Infinite M200 Pro) 
at excitation was recorded at a fixed wavelength (485 nm) and emission at 530 nm (green) 
or 630 nm (red). The ratio of green and red fluorescence was calculated and the percentage 
of live cells was determined. 
2.2.7 NPN UPTAKE 
Uptake of 1-N-phenylnaphtylamine (NPN) was performed as described by Masschelein et 
al.169. In brief, an overnight culture of E. coli DSM-1116 was sub-cultivated (1:100) in fresh 
MHB medium at 37°C and 210 rpm to obtain cells in exponential growth phase (OD600 of 
0.6). Cells were centrifuged for 20 min at 4,000 rpm (5180R Eppendorf) and washed with 5 
mM HEPES (pH 7.2). Compounds were diluted in 50 μL 5 mM HEPES (pH 7.2) at 
concentrations 3-fold higher than the intended final concentration. 100 μL cells were added 
per well and mixed with the previously diluted compounds (50 μL). Control samples were 
prepared as listed in Table 2-12 and all samples were incubation for 2 h at 37°C. 50 μL NPN 
staining solution (40 μM NPN in 5mM HEPES, pH 7.2) were added and fluorescence was 
measured within 3 min using a microplate reader plate (Tecan Infinite M200 Pro). After 
excitation at 355 nm fluorescence was detected at an emission wavelength of 405 nm, 
followed by measuring optical densities of each sample at 600 nm (BioPhotometer Plus, 
Eppendorf). The relative NPN uptake factor was calculated in the following way: 
realtive NPN uptake factor =  
x
fluorescene value of control E
  
with  x =  
fluorescence value sample with NPN
OD 600 of sample with NPN
−  
fluorescence value sample without NPN
OD 600 of sample without NPN
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Table 2-12: Control samples used for NPN uptake assay 
Control Bacterial suspension [µL] 5 mM HEPES [µL] Compound [µL] NPN [µL] 
A 100 50 - 50 
B 100 50 50 - 
C 100 100 - - 
D - 150 - 50 
E - 200 - - 
 
2.2.8 MEMBRANE POTENTIAL 
Membrane potential was determined using the BacLight Membrane Potential Kit 
(Invitrogen) according to manufacturer’s instructions with minor modifications. An 
overnight culture of S. aureus Newman was sub-cultivated in fresh MHB medium to obtain 
a start inoculum of 108 CFU/mL. Compounds were added to 1 mL cells at the assigned 
concentration. Cells exposed to 15 µM carbonyl cyanide 3- chlorophenylhydrazone (CCCP) 
served as positive control [exposure during staining with DiOC2(3)]. After 0.5 and 2 h 
incubation, samples were washed once with PBS (pH 7.4) and re-suspended in 100 µL PBS 
(pH 7.4). 30 µM 3,3‘-diethyloxacarbocyanin iodide (DiOC2(3) was added per sample and 
after 30 min staining at room temperature, samples were transferred to black 96-well plates 
(Greiner Bio One) and fluorescence was measured using a microplate reader (Tecan Infinite 
M200 Pro). After excitation at 488 nm, red fluorescence was detected at an emission 
wavelength of 675 nm and green fluorescence at 525 nm. To determine changes of the 
membrane potential, the ratio of red and green fluorescence was calculated relative to 
untreated control cells.  
2.2.9 MACROMOLECULE BIOSYNTHESIS 
To examine the inhibition of macromolecule biosynthesis, an overnight culture of 
S. carnosus DSM-20501 was sub-cultivated (1:100) in TSB medium at 37°C to obtain a start 
inoculum of approximately 108 CFU/mL (OD600: 0.2-0.4). The respective isotope [RNA: 
3H-
uridine (Perkin Elmer); protein: 3H-thymidine (Perkin Elmer); DNA: 3H-methionine (Perkin 
Elmer); cell wall: 3H-glucosamine (American Radiolabeled Chemicals)] was added at a final 
concentration of 1 µCi/µL and compounds were added at 0.5-fold MIC. Samples were 
incubated for 180 min at 37°C under permanent shaking (approx. 200 rpm) and sampling 
took place at several time points (0, 10, 20, 30, 45, 60, 90, 120, 180 min). 200 µL per sample 
was added to scintillation tubes (Perkin Elmer) containing 2 mL pre-cooled 10 % 
(w/v) TCA/1M NaCl, precipitated on ice for at least 45 min and filtered through 25 mm glass 
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microfiber (PALL Corporation). Filters were washed with 4 mL 2.5 % (w/v) TCA/1M NaCl 
and transferred into new scintillation tubes. 4 mL scintillation liquid (Perkin Elmer) was 
added per tube and radioactivity was measured by a scintillation counter (MicroBeta TriLux 
1450 LSC & Luminescence; Perkin Elmer) for 5 min per sample. Radioactivity was plotted 
in counts per minute (cpm) against time.  
2.2.10 IN VITRO TRANSLATION ASSAY 
* In vitro translation assays were performed using the RTS 100 E. coli HY Kit (5PRIME) 
according to manufacturer’s instructions. T7-bacteriophage DNA dependent RNA 
polymerase was cloned in front of a 130 pmol DNA product of Firefly luciferase [generated 
in a previous step by PCR using primers Fluc_fwd and Fluc_rev (listed in Table 2-9); 
reduction of reaction size to 5 µL)]. 1 µL per compound per test condition was added at the 
assigned concentration and samples were incubated for 1 h at 30°C and 750 rpm. 0.5 µL of 
each sample was added per well to a 96-well plate containing 7.5 µL kanamycin (50 mg/mL) 
and 40 µL Fluc Substrate (PROMEGA, Cat. No. E655207). Luminescence was recorded 
using a microplate reader (Tecan Infinite M1000). 
2.2.11 GENERATION OF CHELOCARDIN-RESISTANT MUTANTS 
** Resistant chelocardin mutants were generated by exposing wildtype strains E. coli DSM-
1116 and K. pneumoniae DSM-30104 to stepwise increasing CHD concentrations (E. coli: 
2.5, 5, 7.7, 12.5, 15, 20, 30 µg/mL; K. pneumoniae: 2, 4, 8 µg/mL) in a repetitive process of 
inoculation of single resistant colonies from agar plates into liquid medium with a concurrent 
increase of CHD concentration. To gain CDCHD resistant mutants, the above described 
approach was likewise used by exposing wildtype strain K. pneumoniae DSM-30104 and 
S. aureus N315 to stepwise increasing CDCHD concentrations (K. pneumoniae: 2, 4, 
8 µg/mL; S. aureus: 4, 8, 12 µg/mL). 
2.2.12 GENERATION OF TELOMYCIN-RESISTANT MUTANTS 
** Resistant telomycin mutants were generated by exposing wildtype strain S. aureus 
Newman to stepwise increasing concentrations of either TM (8, 30, 50, 100 µg/mL + 10 mM 
CaCl2) or TM-Dodec (10, 20, 50, 100 µg/mL+ 1.25 mM CaCl2) in a repetitive process of 
inoculation of single resistant colonies from agar plates into liquid medium with a concurrent 
increase of telomycin concentration. The frequency of spontaneous generated resistant 
telomycin mutants was determined as described by Butler et al.170 and Evans et al.171. 
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S. aureus Newman was incubated at a final concentration of 107 (TM) or 108 (TM-Dodec) 
CFU/plate overnight at 37°C on agar plates containing compounds at 4-fold MIC. In 
addition, control plates with no antibiotic were incubated with S. aureus Newman in several 
dilutions. The frequency of resistance was determined by dividing CFUs counted on 
antibiotic containing plate by the total CFU number of control plate. 
2.2.13 ISOLATION OF BACTERIAL GENENOMIC DNA 
DNA isolation was performed by standard phenol-chloroform extraction. Bacteria were 
cultivated overnight in 5 mL of their respective growth medium and centrifuged for 10 min 
at 4°C and 3,500 rpm (5180R Eppendorf) After washing with Milli-Q-water (MQ) cell 
pellets were re-suspended in 1.8 mL10 mM Tris-HCl (pH 8.0), incubated for 3.5 h at 37°C 
and inverted every 30 min. 200 µL proteinase K (20 mg/mL) and 20 µL 20 % (w/v) SDS 
were added and incubated for 2 h at 55°C. Subsequently, 100 µL RNase A (20 mg/mL) was 
added and incubated for additional 30 min. 2 mL phenol:chloroform:isoamyl alcohol 
(25:24:1) was added and after 1 h incubation at 5 rpm and room temperature, samples were 
centrifuged for 10 min at 3,500 rpm (5180R Eppendorf). The upper, aqueous phase was 
added to 2 mL phenol:chloroform:isoamyl alcohol (25:24:1) and incubated again at room 
temperature for 1 h at 5 rpm. After centrifuging for 10 min at 3,500 rpm (5180R Eppendorf), 
1/10 volumes 3 M NaOAc (pH 4.8) and 2.5 volumes ice cold 100 % EtOH were added to 
the aqueous phase and precipitated DNA was transferred to 1 mL ice cold 70 % (v/v) EtOH. 
After centrifugation for 5 min at 4°C and 4,000 rpm (5180R Eppendorf), DNA was dried 
overnight at room temperature and dissolved in 100 µL MQ at 55°C and 300 rpm for 1 h. 
DNA concentration and purity was measured by using a spectrometer (NanoDrop 2000c 
Thermo Fisher Scientific). 
2.2.14 WHOLE GENOMCE SEQUENCING AND ANALYSIS 
* Whole genome sequencing of strains obtained by in vitro resistance development, as 
described in section 2.2.11 and 2.2.12 were sequenced by using Illumina sequencing 
technology on a MiSeq platform at the Helmholtz Centre for Infection Research 
(Braunschweig, Germany). Sequencing was performed in paired-end fashion. Raw data were 
analysed by an alignment against the reference genome sequences of E. coli DSM-1116 
(NCBI GenBank accession code: NC_017635), S. aureus Newman (NCBI GenBank 
accession code: NC_009641) and K. pneumoniae DSM-30104. The genome sequence of 
K. pneumoniae DSM-30104 was not readily available from the public databases, therefore, 
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to obtain its complete reference sequence, high-molecular-weight DNA was submitted for 
sequencing with PacBio technology at the German Collection of Microorganisms and Cell 
Cultures (Deutsche Sammlung für Mikroorganismen und Zellkulturen, DSMZ). After de 
novo sequence assembly of raw data with SMRT portal provided by Pacific Biosciences 
(Menlo Park, CA, USA), a single contig for each chromosome and three extrachromosomal 
replicating elements were obtained (chromosome: 5,295,933 bp; pKPD1: 105,910 bp; 
pKPD2: 96,086 bp; pKPD3: 44,026 bp). The reference-guided whole genome assembly of 
Illumina raw sequencing data for all mutant samples was carried out in Geneious software172 
(Biomatters Ltd., Auckland, New Zealand) with “low sensitivity” parameters, otherwise the 
parameters were left default. The consensus calling for mutant and control strains was 
performed in Geneious software by executing the “generate consensus sequence” command 
and using “highest quality” as consensus calling algorithm, while other parameters were left 
default. Comparison of consensus sequences generated in the previous step was performed 
in Geneious software with the help of “MAUVE” whole-genome alignment plugin. Apart 
from using default settings, the “assume collinear genomes” option was selected to be on. 
The final step of the analysis comprised of manual verification of consensus inconsistencies 
between samples and comparing those to the reference and control sample sequences. 
2.2.15 GENE KNOCKOUT IN KLEBSIELLA PNEUMONIAE 
The generation of knockout mutants was performed as described by Huang et al.163 with 
minor modifications. For preparing electrocompetent K. pneumoniae (wildtype: DSM-
30104) cells, an overnight culture was sub-cultivated in 5 mL LB medium at 37°C and 
210 rpm to obtain an OD600 of 0.4-0.6. Cells were centrifuged at 15,000 rpm and 4°C 
(CT15RE VWR) for 15 min. The supernatant was discarded and the cells were washed with 
2 mL ice-cold MQ water, followed by centrifugations as indicated above. The washing-
centrifugation-step was repeated for additional two times and cells were finally diluted in 
100 µL ice-cold MQ. 400 ng pACBSR-Hyg was added to 50 µL cells, transferred to ice cold 
electroporation cuvettes (0.2 cm gap) and electroporated at 2,500 V. Subsequently 250 µL 
pre-warmed SOC medium was added and cells were incubated for 60 min at 30 °C. 100 µL 
culture was spread onto LBlow-Hyg agar plates and incubated overnight at 30°C. A single 
colony (K. pneumoniae + pACBSR-Hyg) was inoculated in LBlow-Hyg medium overnight 
at 30° and 210 rpm. 50 µL overnight culture were added to medium containing 4.5 mL LBlow-
Hyg medium, 450 µL 1 M L-arabinose and incubated until an OD600 of 0.4-0.6 was reached. 
Electrocompetent cells were prepared as described above and cells were finally diluted in 
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100 µL ice-cold MQ. Approximately 1µg FRT-flanked AprR knockout cassette [AprR; 
prepared by PCR: pIJ773 served as template to gain apramycin resistance gene (aac(3)IV) 
and flanking FRT sites; primers RamRKO_fwd and RamRKO_rev were used (listed in Table 
2-9)] was added to 100 µL cells, transferred to ice cold electroporation cuvettes (0.2 cm gap) 
and electroporated at 2,500 V. Subsequently 500 µL pre-warmed SOC medium was added 
and cells were incubated for 90 min at 37 °C. The culture was spread onto two LB-Apr agar 
plates and incubated overnight at 37°C. Colonies were screened for the insertion of the 
knockout by PCR and correct transformants were spread on LB-Apr agar plates and 
incubated overnight at 37°C. Single colonies of the confirmed mutants were streaked on LB-
Apr agar plates, incubated at 37°C overnight and this procedure was repeated for three days. 
Mutants that lost pACBSR-Hyg were detected by streaking colonies on LB-Apr and LBlow-
Hyg agar plates following incubation at 37°C overnight. Hygromycin sensitive mutants were 
inoculated in 5 mL LB-Apr medium and incubated overnight at 37°C at 210 rpm. To remove 
the knockout cassette, 50 µL overnight culture was sub-cultivated at 37°C in 5 mL LB-Apr 
medium to reach an OD600 of 0.4-0.6. Electrocompetent cells were prepared as described 
above and cells were finally diluted in 100 µL ice-cold MQ. 300 ng pFLP-Hyg was added 
to 50 µL cells, transferred to ice cold electroporation cuvettes (0.2 cm gap) and 
electroporated at 2,500 V. Subsequently 250 µL pre-warmed SOC medium was added and 
cells were incubated for 60 min at 30 °C. 100 µL culture was spread onto LBlow-Hyg agar 
plates and incubated overnight at 30°C. Mutants were heat-shocked by incubation at 43°C 
overnight and single colonies were streaked onto LB and LB-Apr agar plates and incubated 
overnight at 37°C. Apramycin-sensitive mutants were passed three times on LB agar plates 
and incubated each time overnight at 37°C. The loss of pFLP-Hyg was determined by 
streaking single colonies on LBlow-Hyg and LB agar plates. Hygromycin-sensitive mutants 
were prepared for sequencing by performing PCR (using primers RamRconf_fwd and 
RamRconf_rev; Table 2-9) and DNA was subsequently purified by using NucleoSpin® Gel 
and PCR Clean-up Kit (Macherey-Nagel). 
2.2.16 GENE KNOCKOUT IN STAPHYLOCOCCUS AUREUS 
* Gene knockout with S. aureus Newman was performed by using the TargeTron®-Gene-
Knockout-System Kit (Sigma Aldrich) with minor modifications. In brief, a PCR was 
performed to re-target the intron by primer-mediated mutations at several position within the 
target site. This reaction was followed by the purification of the PCR product by using the 
NucleoSpin® Gel and PCR Clean-up Kit (Macherey-Nagel). Afterwards, a restriction 
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digestion with the purified DNA and pNL9164 was performed. The reaction mixtures (Table 
2-13) were incubated for 40 min at 37°C, following 20 min at 60°C and 10 min at 80°C. The 
digested templates were ligated and transformed into E.coli DH10b cells. After plasmid 
isolation, it was first transformed into S. aureus RN4220 following the transformation into 
S. aureus Newman (21 kV/cm, 100 Ω, and 25 µF). To induce gene disruption, S. aureus 
Newman cells (+ pNL9164) were incubated overnight at 32°C on BHI (Brain Heart Infusion) 
agar plates containing 10 µg/mL erythromycin. To confirm intron insertions, a colony PCR 
was performed by using primers designed with the TargeTron algorithm tool. The curing of 
the plasmid was performed by a heat shock reaction at 43°C overnight, followed by 
screening for erythromycin-sensitive colonies. 
Table 2-13: Restriction digest reagent composition. 
Reagent 
Template 
pNL9164 Purified DNA 
Vector or PCR product (~200 ng) 2 µL 9.7 µL 
10X restriction enzyme buffer 2 µL (Tango) 2 µL 
Hind III (20U/µL) 1 µL 1 µL 
BsrG I (10U/µL) 1 µL 1 µL 
Dpn I (20U/µL) / 1 µL 
Water 14 µL 5.3 µL 
 
2.2.17 GENE EXPRESSION ANALYSIS 
RNA isolation 
150 mL of bacteria in mid-log phase was centrifuged for 10 min and 8,000 rpm (5180R 
Eppendorf) at 37°C. 4 mL pre-heated (60°C) NAE-Phenol was added to the pellet and 
incubated for 5 min at 60°C. 4 mL pre-heated (60°C) NAES buffer was added and incubated 
for additional 5 min at 60°C, followed by 5 min incubation on ice. Samples were centrifuged 
for 8 min at 8,000 rpm and 4°C (Avanti J-26 S Beckman) and the water phase was transferred 
to a PhaseLockGel-tube (Eppendorf). 4 mL phenol:chloroform (6:1) was added and mixed 
for 2 min, followed by centrifugation for 8 min at 8,000 rpm and 4°C (Avanti J-26 S 
Beckman). The above described transfer of the water phase and following centrifugation 
step was repeated two more times. The upper phase was mixed with 4 mL ice-cold 
isopropanol and 400 µL 3 M sodium acetate (pH 5.1). RNA was precipitated overnight at -
20°C and samples were centrifuged for 40 min at 8,000 rpm and 4°C (Avanti J-26 S 
Beckman). Pellets were washed with 70 % (v/v) EtOH and dried for 30 min by using an 
exsiccator. RNA was diluted in 500 µL DECP water and purified by using miRNAeasy mini 
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kit (Qiagen). Concentration and purity was measured by using a spectrometer (NanoDrop 
2000c Thermo Fisher Scientific). 
Reverse transcription 
RNA was transcribed into cDNA by using the RevertAid Premium Reverse Transcriptase 
(Thermo Fisher Scientific) following the manufacturer’s instructions. The reaction mixture 
(5 µg RNA, 1 µL 100 pmol random primer, 0.5 mM dNTPs, 14.5 µL DECP water, 4 µL 5x 
buffer, 0.5 µL RiboLock, 20 µL RevertAid Premium Reverse Transcriptase) was incubated 
for 10 min at 20°C, following 30 min at 50°C and 5 min at 85°C. 
Quantification of gene expression 
Gene expression was measured by qPCR using the Peqstar 96Q (Peqlab) cycler. 10 µL 
reaction mixture was prepared by mixing 1 µL cDNA (diluted 1:10), 0.5 µL per primer 
(primer pairs listed in Table 2-10), 3 µL DECP water and 5 µL Gotag Mastermix (Promega). 
Gene expression was measured by qPCR as indicated in Table 2-14 and relative transcription 
levels compared to the wildtype were calculated by the 2-ΔΔCt method173 and normalized to 
16S rRNA. 
Table 2-14: qPCR cycler adjustments. 
Step Temperature [°C] Time [min] Repeat [x-fold] 
Denaturation 95 7 1  
Denaturation 95 10 40 
Annealing/elongation X[a] 1 40 
Melting curve 1.step 95 0.25 1 
Melting curve 2.step 60 1 1 
Melting curve 3.step 95 0.25 1 
[a] ramA: 54, acrA: 55, acrB: 55 
 
2.2.18 LIPID BINDING 
* Direct binding assays were performed as described by Makino et al.174. In brief, 50 µL 
lipid-mix (2.56 µM in EtOH) and lipoteichoic acid (LTA)-mix (2.65 µg/mL in EtOH) were 
transferred to surface treated 96-well plates (Nunc Polysorp). After the evaporation of EtOH 
(2 h) final concentrations of 128 pmol/well (lipids) and 128 ng/well (LTA) were achieved. 
Wells were blocked with 100 µL of 3 % BSA (Albumin Fraction V, biotin-free, Roth) in 
PBS by incubation overnight at 4°C. Plates were washed three times with 300 µL PBS-T per 
well and compounds were added at a final concentration of 0.7 µM/well (in 1 % BSA in 
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PBS). After 2 h incubation at room temperature, plates were washed six times with 300 µL 
PBS-T per well and a click reaction was performed by adding 100 µL click-mastermix (1 mL 
mastermix: 920 µL 1 % BSA in PBS, 20 µL CuSO4, 50 µL sodium ascorbate, 10 µL azide-
PEG3-biotin conjugate) per well for 2 h at room temperature. After six times of washing 
with PBS-T (300 µL per well), 100 µL streptavidin-coupled horseradish peroxidase (HRP; 
1:1000 in 1 % BSA in PBS) was added per well for 1 h at room temperature. Plates were 
washed six times with PBST (300 µL per well) and 100 µL 1-fold TMB ELISA substrate 
solution (eBioscience) was added per well. After 15 min incubation at room temperature 
(protected from light), the colour reaction was stopped by adding 50 µL H3PO4 (1M) per 
well. Within 15 min optical densities were determined at 450 nm by using a microplate 
reader. To determine concentration dependent binding effects to cardiolipin, the procedure 
was performed as described above and additionally CaCl2 and EDTA were added during the 
blocking step at final concentration of 10 mM. Cardiolipin was diluted in 1:2 serial dilutions 
to achieve final concentrations ranging from 4-128 pmol/well. 
2.2.19 LIPID EXTRACTION 
Lipid extraction was carried out as described by Bligh et al.175 with minor modifications. 50 
mL overnight culture of S. aureus Newman wildtype and S. aureus Newman cls1 or cls2 
deficient mutants was centrifuged for 15 min at 4,000 rpm and 4°C (5180R Eppendorf). Cell 
pellets were lyophilized (freeze dryer; Christ) and re-suspended in PBS (pH 7.2) at 10 mL/10 
mg cell pellet. 1 mg/mL lysozyme was added per sample and incubated for 30 min at 37°C. 
Lipids were extracted by chloroform-methanol-ddH2O (2:2:1) extraction. 10 mL chloroform 
and 20 mL MeOH were added to lysed cells, mixed briefly and additional 10 mL chloroform 
were added. Following brief mixing, 10 mL ddH2O was added and mixed again. The mixture 
was filtered (Whatman No.1; GE Healthcare Europe GmbH) and chloroform and alcohol 
layers were separated by using separating funnels. The chloroform layer was dried using a 
vacuum concentrator (SpeedVac Concentrator plus; Eppendorf) and re-dissolved 1:10 in 
chloroform.  
2.2.20 THIN-LAYER CHROMATOGRAPHY 
Lipids were extracted as described in section 2.2.19 and applied to silica thin-layer 
chromatography (TLC) plates (Sigma-Aldrich) by adding twice 1 µL per sample. TLC plates 
were developed with chloroform-methanol-acetic acid (8:2:0.1). The plates were sprayed 
with CuSO4 and heated to detect the lipids 
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2.2.21 PROTEIN ISOLATION 
Proteins isolation from B. subtilis DSM-10 was performed as described by Jin et al.176 with 
minor modifications. Overnight cultures were sub-cultivated in 200 mL fresh medium at 
37°C to obtain an inoculum at an OD600 of 1.0. Cells were centrifuged for 10 min at 
4,000 rpm (5180R Eppendorf) and washed twice with 10 mL TSB-T. EDTA-free cocktail 
protease inhibitor (Sigma-Aldrich) was added and cells were broken by French Press 
(Thermo Fisher Scientific), followed by centrifugation at 4000 rpm and 4°C (5180R 
Eppendorf) for 10 min to remove unbroken cells and membrane debris. Protein concentration 
was measured by Bradford protein assay.177 
2.2.22 PROTEIN PULL DOWN AND ENZYMATIC DIGESTION 
Proteins were isolated as described in section 2.2.21 and pull down was carried out as 
described by Jin et al.176 with minor modifications. 50 µM compound was added to 900 μL 
cell lysate and incubated for 60 min at 4°C (gently rolling). 100 μL Streptavidin Magentic 
beads (M-280 Dynabeads Invitrogen) was added and incubated for 1 h at 4°C. Beads were 
washed three times with TBS-T and 1-fold SDS sample buffer was added. After boiling for 
10 min at 95°C proteins were separated by SDS-PAGE178 and desired protein bands were 
prepared for MALDI-TOF analysis as described by Shevchenko et al179. In brief, SDS-
PAGE was washed in MQ overnight and desired protein bands were cut out and incubated 
with 500 µL acetonitrile (ACN) for 10 min. All liquid was removed and 50 µL DTT (10 mM 
in 100 mM NH4HCO3) was added for 30 min at 56°C. Samples were cooled down to room 
temperature and 500 µL ACN was added for 10 min. All liquid was removed and 30 µL 
iodoacetamide solution (55 mM IAA in 100 mM NH4HCO3) was added and samples were 
incubated for 10 min at room temperature (protected from light). Again, 500 µL ACN was 
added for 10 min and after removal of all liquid, gel bands were de-stained by washing twice 
with 100 mM NH4HCO3/ACN (1:1). 500 µL ACN was added for 10 min and after removal, 
30 µL sequencing-grade trypsin (13 ng/µL in 10 mM NH4HCO3/10% (v/v) ACN) was added. 
After 3 h incubation at 4°C 15 µL NH4HCO (100 mM) was added and samples were 
incubated overnight at 37°C and further analysed by mass-spectrometry (see 2.2.23). 
2.2.23 PROTEIN IDENTIFICATION BY MADLI-TOF/MS OR LC-MS/MS 
* Proteins separated by SDS-PAGE, were prepared as described in section 2.2.22. The 
resulting peptides were extracted, desalted using ZipTip (18C Millipore) and analysed by 
MALDI-TOF/MS using a Bruker Ultraflex TOF mass spectrometer (Bruker Daltonics, 
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Bremen) with alpha-cyano-4-hydroxycinnamic acid as matrix. Proteins were identified from 
the peptide mass fingerprints using the MASCOT search engine. Alternatively, LC-MS/MS 
analyses were performed on a DionexUltiMate 3000 n-RSLC system connected to an LTQ 
Orbitrap Velos mass spectrometer (Thermo Scientific). Peptides were loaded onto a C18 
pre-column (3 μm, Acclaim, 75 μm x 20 mm, Dionex) and washed for 3 min (flow rate of 6 
μL/min). Peptide separation was performed on an analytical column (2 μm, Acclaim 
PepMap RSLC, 75 μm x 25 cm, Dionex) at 350 μL/min via a linear 60 min gradient with 
HPLC buffer A (0.1 % FA in water) and 25 % HPLC buffer B (0.1 % formic acid in ACN), 
followed by a 30 min gradient from 25 to 50% of buffer B. MS/MS raw data files were 
searched against UniProtKB/Swiss-Prot protein database on a MASCOT server. 
2.2.24 HETEROLOGOUS PROTEIN EXPRESSION AND PURIFICATION 
* For biochemical experiments, truncated versions of QoxA and YcdA were used. Final 
constructs were generated by insertion of the respective gene sequences into a modified 
pCOLADuet-1 (EMD Millipore) plasmid using sequence and ligation independent cloning 
(SLIC) with primers listed in Table 2-9 (YcdA_fwd, YcdA_rev; QoxA_fwd; QoxA_rev). 
This resulted in fusion proteins composed of an N-terminal MBP tag followed by a StrepII-
tag180 and a TEV protease cleavage site. The fusion proteins were expressed in E. coli BL21 
CodonPlus (DE3) RIL (8× 1 L auto-induction medium181) for 24 h at 20 °C. The cell pellets 
were re-suspended in lysis buffer (20 mM HEPES, 200 mM NaCl, 5 % (v/v) glycerol, pH 7.6 
supplemented with DNaseII and lysozyme), homogenized and centrifuged. Subsequently, 
supernatants were applied separately onto columns packed with StrepTactin Sepharose High 
Performance resin on an ÄKTA protein purification system (both GE Healthcare Life 
Sciences). The proteins were eluted with 5 mM D-Desthiobiotin (Sigma-Aldrich) in the same 
buffer and the N-terminal tags were cleaved off using TEV protease during overnight dialysis 
against 20 mM HEPES, 200 mM NaCl, 5 % (v/v) glycerol (pH 7.6). To remove the tag, a 
second StrepTactin purification step was performed and the flow-through containing the 
respective proteins was concentrated using a Vivaspin 6 10 kDa cutoff concentrator (GE 
Healthcare Life Sciences). As a polishing step, each protein was passed through a Superdex 
75 16/60 pg column (GE Healthcare Life Sciences) using the same buffer and fractions 
containing YcdA or QoxA were concentrated. Protein purity was assessed by SDS-PAGE 
and protein concentration was determined spectrophotometrically using extinction 
coefficients calculated via the ProtParam web server182. 
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2.2.25 SURFACE PLASMON RESONANCE 
Surface plasmon resonance (SPR) analysis was performed with a Biacore X100 device (GE 
Healthcare). Proteins were immobilized on a CM5 chip (Biacore) by standard amine 
coupling. YcdA and QoxA were diluted to 40 µg/mL and 20 µg/mL, respectively in sodium 
acetate buffer (pH 4.5) and immobilized for 100 to 200 sec. Compounds were injected at 
increasing concentrations in the presence or absence of 5 mM CaCl2. Binding interactions 
were monitored at 25 °C with a flow rate of 30 μL/min in HBS-EP/1% (v/v) DMSO (± 5 mM 
CaCl2) as running buffer. The theoretical maximal RU (Rmax; RU: resonance units) was 




× immobilized ligand level (RU)  
The equilibrium dissociation constants (KD) were either determined by the ratio of 
association rate (ka) to dissociation rate constant (kd) or by steady-state affinity analysis using 
the Biacore X100 evaluation software 2.0.1. 
2.2.26 CULTIVATION OF EUKARYOTIC CELL LINES 
Cell lines were obtained from the German Collection of Microorganisms and Cell Cultures 
(Deutsche Sammlung für Mikroorganismen und Zellkulturen, DSMZ) and the American 
Type Culture Collection (ATCC) and handled as recommended by the depositor. Cultivation 
was performed in the respective medium in a saturated water vapour atmosphere at 37°C 
and 5% CO2. Cell splitting took place twice a week. Medium of adherent cell cultures was 
discarded and cells were washed with PBS (pH 7.4) followed by detaching the cells by the 
addition of trypsin. The reaction was stopped by the addition of fresh FBS-containing 
medium and splitting was performed at 1:5 to 1:20 ratios in fresh medium. Suspension 
cultures were split directly at 1:5 to 1:20 ratio into fresh medium. 
2.2.27 IC50 DETERMINATION (MTT) 
Cells were seeded at a cell density of 5 x 104 cells per well in sterile 96-well plates 
(CellBIND® Corning) in 180 µL of the respective medium supplemented with 10 % FBS 
and incubated for 2 h at 37 °C and 5 % CO2 followed by treatment with compounds in serial 
dilutions. After 5 d of incubation, 20 µL of 5 mg/mL stock MTT (thiazolyl blue tetrazolium 
bromide) in PBS (pH 7.4) were added per well and incubated for additional 2 h at 37°C and 
5 % CO2. The medium was discarded and 100 µL 2-propanol/10 N HCl (250:1) were added 
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to dissolve the formazan granules. The absorbance was measured at 570 nm using a 
microplate reader (Tecan Infinite Pro M200) and cell viability was determined relative to the 
respective solvent control. IC50 values (half maximal inhibitory concentration) were 
determined by sigmoidal curve fitting using Origin6.1G software. 
2.2.28 KILLING OF INTRACELLULAR BACTERIA 
Murine macrophages (RAW264.7) were seeded at 2.5 x 105 cells per well in 24-well plates 
(CellBIND® Corning) and incubated overnight at 37°C and 5 % CO2. To infect the cells, an 
overnight culture of S. aureus N315 was diluted to 3 x 107 CFU/mL and 100 µL cell 
suspension was added per well RAW264.7 (MOI of 10) and incubated for 2 h at 37°C and 
5 % CO2. After three times of washing with PBS (pH 7.4), extracellular bacteria were killed 
by the addition of 50 µg/mL gentamicin for 90 min followed by three times washing with 
PBS. Compounds were added at the assigned concentration and cells were treated for 18 h 
at 37°C and 5 % CO2. After three time washing with PBS (pH 7.4), 1 mL ice cold MQ was 
added per well and after 5-10 min, the cell suspension was diluted 1:100 and 1:1000 in 0.9 % 
(w/v) NaCl and plated on CASO agar. Intracellular S. aureus concentration was determined 
by CFU count after 24 h incubation at 37°C. 
2.2.29 TMRM STAINING 
Human bone osteosarcoma cells (U-2 OS) cells were seeded at a cell density of 5 x 103 cells 
per well in 96-well imaging plates and incubated for 2 d at 37°C and 5 % CO2. Compounds 
were added at the assigned concentration and cells were treated for 3 h at 37°C and 5 % CO2. 
After two washing steps with assay buffer (100 µL/well), 100 µL staining solution (5 µg/mL 
Hoechst33342 and 20 nM TMRM in assay buffer) were added per well and cells were stained 
for 1 h at 37°C and 5% CO2. Cells were washed (100 µL/well assay buffer) and examined 
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3.1.1 MECHANISM OF ACTION 
3.1.1.1 ANTIMICROBIAL SPECTRUM 
The antibacterial activity of chelocardin (CHD) and its amidated derivative 2-carboxamindo-
2-deacetyl-CHD (CDCHD, Figure 3-1) against Gram-positive and Gram-negative bacteria, 
as well as against Mycobacteria, was determined. Growth inhibition was assessed in standard 
micro-broth dilution assays by visual inspection and MIC (minimal inhibitory concentration) 
values were determined as the lowest concentration of antibiotic at which no visible growth 
was observed. For Gram-positive bacteria, both compounds showed inhibitory activities 
predominantly in the 1-digit µg/mL range (MIC = 2-8 µg/mL), including methicillin-
resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus 
(VISA) and multidrug-resistant (MDR) Staphylococcus aureus (Table 3-1). However, 
against Bacillus subtilis, Enterococcus spp. and Micrococcus luteus activity dropped 2- to 
8-fold (MIC = 8-32 µg/mL) in comparison to all other tested Gram-positive pathogens. 
Compared to Gram-positive bacteria, susceptibility of Gram-negative bacteria was generally 
higher. For Proteus species, Serratia marcescens, Escherichia coli, Citrobacter freundii, 
Klebsiella pneumoniae and Haemophilus influenza MIC values between 0.25 and 4 µg/mL 
were achieved. Only Enterobacter aerogenes and Pseudomonas aeruginosa were less 
susceptible with MIC values ranging from 4 to 64 µg/mL depending on the strain. Against 
Mycobacteria, both compounds showed good activities with MIC values of 1-4 µg/mL. 
Throughout, CDCHD showed slightly improved inhibitory activities compared to the parent 
molecule CHD, in particular against P. aeruginosa.  
 




Table 3-1: MIC values of CHD, CDCHD and tetracycline (TET) against Gram-positive and Gram-negative bacteria. 




CHD CDCHD TET 
Gram-positive 
Bacillus subtilis DSM-10 16 8 1 
Enterococcus faecium DSM-20477 8 4 1 
Enterococcus faecalis DSM-20478 8 4 1 
Micrococcus luteus DSM-20030 32 16 4 
Mycobacterium smegmatis mc2155 4 4 n.d. 
Mycobacterium bovis BCG DSM-43990 1 4 n.d. 
Mycobacterium tuberculosis H37RvMA 1 4 n.d. 
Staphylococcus aureus    
DSM-346 4 2 0.125 
DSM-11822[a] 4 2 n.d. 
ATCC-29213 4 8 0.125 
Newman 4 4 0.125 
N315[b] 4 4 0.125 
Mu50[b,c] 2 4 0.125 
Staphylococcus carnosus DSM-20105 4 4 0.25 
Gram-negative 
Citrobacter freundii DSM-30039 1 1 2 
Enterobacter aerogenes DSM-30053 16 8 32 
Escherichia coli    
DSM-1116 1 0.5 0.5 
ATCC-25922 2 2 n.d. 
TolC-deficient 0.5 0.25 0.5 
Haemophilus influenzae DSM-11970 4 1 2 
Klebsiella pneumoniae DSM-30104 1 0.5 0.5 
Proteus vulgaris DSM-2140 0.25 0.25 1 
Proteus mirabilis DSM-4479 0.5 1 4 
Pseudomonas aeruginosa    
DSM-11128 32 16 64 
DSM-24599 64 16 32 
PA14 32 4 32 
Serratia marcescens DSM-30121 4 2 32 
In comparison to tetracycline (TET), Gram-positive bacteria were less susceptible to CHD 
and CDCHD. Against Gram-negative bacteria, overall comparable activities were observed, 
except for S. marcescens against which both chelocardins showed 8- to 16-fold improved 
activities compared to TET. Additionally, activities of CHD and CDCHD against TET-
resistant E. coli, K. pneumoniae, Pseudomonas pseudoalcaligenes and Serratia liquefaciens 
were determined, in which resistance is mediated via efflux (tetA, tetB), ribosomal protection 
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(tetM, tetW), or enzymatic inactivation (tet34). MIC values revealed the potency of CHD 
and CDCHD, as they inhibited growth of all tested tetracycline resistant bacteria (Table 3-2). 
Table 3-2: MIC values of CHD, CDCHD and TET against tetracycline-resistant strains. n.d.: not determined.*values were 
determined by the authors, all other listed values were determined at SANOFI as part of a collaboration. 





CHD CDCHD TET 
*E. coli XL-1 blue tetA Efflux 2 n.d. > 64 
*E. coli Hs996pTOTepoE tetA Efflux 1 n.d. > 64 
E. coli tetB Efflux n.d. 4 > 64 
E. coli tetM ribosomal protection n.d. 0.5 64 
E. coli tetW ribosomal protection n.d. 1 > 64 
E. coli 49 tetB Efflux n.d. 4 > 64 
E. coli 74 tetB Efflux n.d. 8 > 64 
S. liquefaciens tetB; tet34 efflux; enzymatic inactivation n.d. 2 > 64 
P. pseudoalcaligenes tetB; tet34 efflux; enzymatic inactivation n.d. 2 > 64 
K. pneumoniae 3 tetA Efflux n.d. 8 > 64 
K. pneumoniae 8 tetA Efflux n.d. 32 > 64 
K. pneumoniae 24 tetA Efflux n.d. 8 > 64 
 
To investigate the drop in activity of CHD against Pseudomonas spp., CHD and CDCHD 
were tested against a panel of P. aeruginosa PA14 efflux pump deficient mutants (ΔmexAB, 
ΔmexCD, ΔmexEF, ΔmexXY). A deletion of the major efflux pump encoded by mexAB led 
to a 16-fold increase of CHD activity and 8-fold increase of CDCHD activity, as well as a 
16-fold increase of TET activity (Table 3-3). Efflux pumps encoded by mexCD, mexEF and 
mexXY, which are usually expressed only under stress conditions, did not affect activities of 
CHD and CDCHD.  
Table 3-3: Minimal inhibitory concentration (MIC) of CHD and CDCHD against P. aeruginosa PA14 wildtype and efflux 
pump deficient mutants (ΔmexAB, ΔmexCD, ΔmexEF, ΔmexXY). 
P. aeruginosa PA14 
MIC [µg/mL] 
CHD CDCHD TET 
Wildtype 32 4 32 
ΔmexAB 2 0.5 2 
ΔmexCD 32 8 n.d. 
ΔmexEF 16 8 n.d. 




To determine if CHD exerts bactericidal or bacteriostatic effects, S. carnosus DSM-20501 
was exposed to CHD at concentrations between 0.0625- and 64-fold MIC over 24 h and cell 
viability was assessed by CFU (colony forming units) count (Figure 3-2). At concentration 
of 0- to 0.125-fold MIC, an exponential cell growth and no influence of CHD on the growth 
behaviour was observed. An increase to 2-fold MIC led to delayed growth in the exponential 
phase and overall lower cell numbers in the stationary phase. Treatment with 16 to 256 
µg/mL CHD (4- to 64-fold MIC) resulted in 2- to 3-log10 reduction of counted CFU after 24 
h, representing a bactericidal effect.  
 
Figure 3-2: Time-kill curves of S. carnosus DSM-20105 exposed to CHD (MIC: 4 µg/mL) at concentration between 
0.0625- and 64-fold MIC. Cell viability was determined by CFU (colony forming units) count over 24 h. 
 
To compare the time-kill effects of CHD and CDCHD, K. pneumoniae DSM-30104 was 
exposed to CHD and CDCHD at 0.5- and 2-fold MIC over 24 h (Figure 3-3). As expected, 
bacteria exposed to 0.5-fold MIC of either CHD or CDCHD showed a retarded growth 
behaviour and both compounds used at 2-fold MIC caused a time-dependent decline of CFU 
by a 1-log10 (CHD) and 3-log10 (CDCHD) reduction of counted bacteria. In both cases, the 
effect of delayed growth or killing was more pronounced when cells were exposed to 
CDCHD.  
 
























































Figure 3-3: Time-kill curves of K. pneumoniae DSM-30104 exposed to CHD (MIC: 1µg/mL) and CDCHD 
(MIC: 0.5 µg/mL) at 0.5- and 2-fold MIC. Cell viability was determined over 24 h by three independent CFU (colony 
forming units) counts. Data are represented as mean ± standard deviation (SD). 
 
The bactericidal effect of CHD was also compared to the effect of tetracycline by using the 
BacLight™ LIVE/DEAD Bacterial Viability Kit (Invitrogen). E. coli DSM-1116 was 
exposed to 5-fold MIC of either CHD or TET for 4 h. Cells were stained with nucleic acid 
binding dyes propidium iodide (PI) and SYTO9 and fluorescence was measured on a 
microplate reader [excitation: 485 nm; emission: 530 nm (green), 630 (red)]. The green 
fluorescent dye SYTO9 penetrates bacterial membranes and stains all nucleic acid 
containing cells, whereas the red fluorescent dye PI is membrane impermanent and only 
penetrates cells with damaged membranes. When both dyes are present within the cell (cells 
with destroyed membranes), SYTO9 fluorescence is displaced by PI fluorescence and its 
green emission is quenched due to fluorescence resonance energy transfer (FRET)183,184. The 
percentage of live cells was determined by the ratio of green and red fluorescence. Treatment 
with CHD led to a 40 % reduction of live cells, whereas TET only killed around 15 %, 
revealing a stronger bactericidal behaviour of CHD compared to TET (Table 3-4).  
Table 3-4: Bactericidal effect of CHD and TET after exposure of E. coli DSM-1116 for 4 h at 5-fold MIC compared to 
untreated cells. 
 Untreated CHD TET 
% live bacteria 99.1 59.3 84.3 







































CHD 0.5 x MIC
CHD 2 x MIC
CDCHD 0.5 x MIC
CDCHD 2 x MIC
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Since both compounds showed inhibitory activity against typical uropathogenic bacterial 
species (P. aeruginosa, K. pneumoniae, E. aerogenes, Proteus spp., Enterococcus spp. and 
E. coli) CHD and CDCHD were screened against uropathogenic clinical isolates, including 
multidrug-resistant isolates [resistance via extended-spectrum β-lactamases (ESBL) or 
TEM-β-lactamases; colistin-resistant isolates]. MIC and MBC (minimal bactericidal 
concentrations) values were determined and in contrast to all tested laboratory strains (Table 
3-1), CHD showed by tendency better antibacterial activities compared to CDCHD (Table 
3-5). No major differences in susceptibility were observed when multidrug-resistant strains 
were tested compared to sensitive strains. CDCHD showed higher bactericidal activities with 
a marginal shift of MIC vs. MBC compared to CHD. Clinical P. aeruginosa isolates were 
not susceptible to both compounds.  
 
Table 3-5: Minimal inhibitory concentrations (MIC) and minimum bactericidal concentration (MBC) of CHD and CDCHD 
against uropathogenic clinical isolates. Values denote median of MIC/MBC values per group and were determined in three 
independent measurements per isolate. ESBL: extended-spectrum β lactamases.  
Isolate (n=) 
MIC [µg/mL] MBC [µg/mL] 
CHD CDCHD CHD CDCHD 
Escherichia coli     
sensitive (15) 2 4 16 4 
TEM β-lactamase (8) 2-4 8 16 8 
ESBL (7) 4 4 32 8 
colistin-resistant (5) 8 8 32 16 
Enterococcus faecalis (19) 8 16 > 64 16 
Enterococcus faecium (6) 4 8 32 16 
Enterobacter spp. (8) 4 4 16 8-16 
Klebsiella spp.     
sensitive (7) 4 4 16 8 
ESBL (2) 4 4-8 32 8-16 
carbapenem-resistant (2) 4 4-8 32-64 8 
Proteus spp.     
sensitive (7) 4 8 8 64 
ESBL (2) 4 16-32 4-8 32-64 






In initial studies, reported MIC values139 were determined by using chelocardins prepared as 
HCl adducts in methanol. Due to later on discovered stability issues (e.g. spontaneous 
epimerization), a modified formulation for both chelocardins was provided and both 
compounds were further on used as sodium salts with citrate as stabilizer (in water). To 
exclude that the changed formulation caused reverted potency of CHD and CDCHD, a 
comparison of CHD and CDCHD in either MeOH (HCl adducts) or water (Na salts with Na-
citrate) was performed on some exemplary pathogens (Table 3-6, Table 3-7). Throughout, 
MIC values were comparable and thus, it was confirmed that CDCHD is by tendency less 
active compared to CHD on uropathogenic clinical isolates. 
Table 3-6: Comparison of MIC and MBC values of CHD as Na-salt with Na-citrate (CHD) to HCl-salt (CHD-HCl). 
Isolate  
MIC [µg/mL] MBC [µg/mL] 
CHD CHD-HCl CHD CHD-HCl 
K. pneumoniae 30 2 1.5 16 12 
K. pneumoniae 40 4 3 16 12 
E. coli 51 1 1.5 16 12 
E. coli 57 2 1.5 32 24 
E. coli AF48 4 3 16 12 
 
Table 3-7: Comparison of MIC and MBC values of CDCHD as Na-salt with Na-citrate (CDCHD) to HCl-salt (CDCHD-
HCl). 
Isolate  
MIC [µg/mL] MBC [µg/mL] 
CDCHD CDCHD-HCl CDCHD CDCHD-HCl 
K. pneumoniae 30 2 1.5 4 1.5 
K. pneumoniae 40 2 1.5 4 1.5 
E. coli 51 1 0.8 2 0.8 
E. coli 57 2 1.5 4 12 
E. coli AF48 4 1.5 4 1.5 
 
For selected K. pneumoniae and E. coli isolates, MIC and MBC values were additionally 
determined in artificial urine at different pH values (Table 3-8). Both compounds showed 
pH-independent antibacterial activities, but pH-dependent bactericidal activities with MBC 
values varying by factor 2-16 depending on the adjusted pH. Compared to values determined 
in standard test medium (cation-adjusted Müller-Hinton broth, CAMHB), CHD and 
CDCHD showed 4-fold improved antibacterial activities with a concurrent increase of 
bactericidal activity in artificial urine (Table 3-9). 
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Table 3-8: Minimal inhibitory concentrations (MIC) and minimum bactericidal concentration (MBC) of CHD and CDCHD 
against E. coli and K. pneumoniae clinical isolates determined in artificial urine at different pH values. Values denote 
median of three independent measurements per isolate.  
Isolate pH 
MIC [µg/mL] MBC [µg/mL] 
CHD CDCHD CHD CDCHD 
E. coli 
5.5 1 0.5 4 8 
6.5 1 1 4 2 
7.5 1 1 8 4 
8.5 1 1 8 2 
K. pneumoniae 
5.5 1 1 8 2 
6.5 1 1 8 4 
7.5 2 2 16 4 
8.5 2 2 16 32 
 
Table 3-9: Minimal inhibitory concentrations (MIC) and minimum bactericidal concentration (MBC) of CHD and CDCHD 
against E. coli and K. pneumoniae clinical isolates determined in artificial urine and standard CA-MHB test medium. 
Values denote median of three independent measurements per isolate.  
Test condition Isolate (n=) 
MIC [µg/mL] MBC [µg/mL] 
CHD CDCHD CHD CDCHD 
Artificial urine 
Escherichia coli (7) 1 1 8 2 
Klebsiella pneumoniae (3) 1 1 8 4 
CAMHB 
Escherichia coli (7) 4 4 32 8 
Klebsiella pneumoniae (3) 4 4 32 8 
 
To estimate plasma protein binding (PPB), MIC values of CHD and CDCHD were assessed 
against S. aureus, K. pneumoniae, A. baumannii and P. aeruginosa in the presence of 50 % 
foetal calf serum (FCS). A shift of MIC was observed for both compounds, reflected in a 4- 
to 32-fold decrease of MIC values in the presence of 50 % FCS (Table-3-10). 
Table-3-10: Serum effect on MIC values of CHD and CDCHD against Gram-positive and Gram-negative bacteria in the 





 + 50% FCS  + 50% FCS 
Staphylococcus aureus ATCC-29213 8 64 8 64 
Klebsiella pneumoniae DSM-30104 4 16 4 16 
Acinetobacter baumannii ATCC-19606* n.d. n.d. 8 > 64 
Escherichia coli 35218* n.d. n.d. 0.25 8 
Pseudomonas aeruginosa ATCC-27853* n.d. n.d. 32 > 64 
Pseudomonas aeruginosa PA14* n.d. n.d. 32 > 64 
To examine the intracellular killing effect of CHD and CDCHD, murine macrophages 
(RAW264.7 cell line) were infected with S. aureus N315 at a multiplicity of infection (MOI) 
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of 10 and killing of intracellular bacteria was determined by CFU count after 18 h of 
treatment with 0.1- and 0.5-fold MIC of CHD and CDCHD. CHD was not able to reduce the 
number of intracellular bacteria at both tested sub-MIC concentrations (Figure 3-4) and for 
CDCHD no killing effect was observed at 0.1-fold MIC. CFU counts of macrophages treated 
with 0.5-fold MIC CDCHD indicated a killing effect, but microscopic investigations 
revealed a concurrent killing of RAW 264.7 cells. Due to high cytotoxic effects of CDCHD 
(section 3.1.1.3), no killing of intracellular S. aureus was achieved after treatment with 
CDCHD without affecting the host cells. 
 
 
Figure 3-4: Killing of intracellular Staphylococcus aureus by CHD (MIC: 4µg/mL) and CDCHD (MIC: 4 µg/mL). Murine 
macrophages (RAW264.7 cell line) were infected with S. aureus N315 and treated with CHD and CDCHD for 18 h at 0.5- 
and 2-fold MIC. Intracellular bacterial load was determined by three independent CFU counts. Effects observed at 2 µg/mL 
CDCHD rely on the bactericidal and cytotoxic effect of CDCHD. Data represent mean ± standard deviation (SD). Images 
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3.1.1.2 STRUCTURE-ACTIVITY RELATIONSHIP 
Several derivatives of CHD and CDCHD were generated through semisynthesis and genetic 
engineering (Figure 3-5, Table 3-11) and their antibacterial activities were tested against a 
panel of Gram-positive and Gram-negative bacteria including S. aureus, K. pneumoniae, 
P. aeruginosa and E. coli TolC (efflux-deficient, Table 3-12). Positions R1, R2, R3, R4 and 
R5 were chosen for derivatization (Figure 3-5). 
 
 
Figure 3-5: Positions used for CHD and CDCHD derivatives generated by semisynthesis (grey, blue ovals, compounds 
12-25) or genetic engineering (green, blue ovals, compounds 3-11). Residues R1-R5 are listed in Table 3-11. 
 
The efflux-deficient E. coli strain was virtually insusceptible to C-9 demethylated 
derivatives of CHD (1, 2). With S. aureus, 1 and its C-4 epimer 2 displayed a 4- and 8-fold 
drop in MIC, respectively. Substitutions of R4 to an N-dimethyl group (3-5) led to a drop in 
activity against Gram-negative bacteria of 5 by 16-fold, whereas 3 and 4 were inactive (MIC: 
> 64 µg/mL). Against S. aureus, 5 showed the same activity as the parent compound 
CDCHD, whereas 3 lost activity by 4-fold of the MIC value. Further derivatization of 
dimethylated derivatives by a glycosylation at position C-10 did not improve activity. 
Against S. aureus, 8 and 11 showed the same MIC values as determined for the parent 
dimethylated compound (4 µg/mL), whereas 9 and 10 were 16-fold less potent against Gram-
positive bacteria. For all glycosylated and simultaneously dimethylated derivatives, 
activities against Gram-negative bacteria were completely abolished when tested against 
E. coli TolC. Furthermore, substitutions at C-4 by various functional groups (e.g. furoic acid, 
acetyl, biotin group 12-25) led to a complete loss of activity against Gram-negative bacteria. 
Against S. aureus, 12-14, 16, 18 and 21-24 showed no improvement in comparison to 
CDCHD, but a 2- to 32-fold increased MIC value or a completely abolished activity 
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(MIC: > 64 µg/mL) was observed. Only 17 showed a slight improvement in activity against 
Gram-positive bacteria (2-fold increase) and 15, 19 and 20 were as potent as the parent 
molecule CDCHD (4 µg/mL). Changes at C-7 by an addition of chlorine (26), bromine (27) 
or fluorine (29) led to a 2- to 8-fold decrease in Gram-negative activity and when tested 
against S. aureus, MIC values comparable to the parent compound CDCHD (4 µg/mL) were 
determined. Addition of a quinolone (28) or a nitrite (30) on C-7 were not tolerated and 
activity on all test Gram-negative bacteria was completely abolished (MIC: > 64 µg/mL). 
For several derivatives (1, 4, 6, 8, 12, 15, 17, 19) the respective C-4 epimer (2, 5, 7, 9, 13, 
16, 18, 20) was available. Only for 8 and 17 the S-configured epimer was 16-fold less potent 
than the R-configured one and for all other derivatives, no difference in activities were 
observed when the compounds were compared to their respective epimer. However, it has 





Table 3-11: CHD and CDCHD derivatives generated by semisynthesis or genetic engineering. [a]Position used for 
derivatization (R1 – R5) are presented in Figure 3-5 (grey/green/blue ovals). 
Compound Abbreviation 
Position[a] 
R1 R2 R3 R4 R5 
CHD CHD CH3 NH2 H CH3 OH 
CDCHD CDCHD NH2 NH2 H CH3 OH 
desmethyl-CHD 1 CH3 NH2 H H OH 
desmethyl-epi-CHD 2 CH3 NH2 H H OH 
dimethyl-epi-CHD 3 CH3 N(CH3)2 H CH3 OH 
dimethyl-CDCHD 4 NH2 N(CH3)2 H CH3 OH 
dimethyl-epi-CDCHD 5 NH2 N(CH3)2 H CH3 OH 
586 6 CH3 N(CH3)2 H CH3 Rhamnosyl 
epi-586 7 CH3 N(CH3)2 H CH3 Rhamnosyl 
572 8 CH3 N(CH3)2 H H Rhamnosyl 
epi-572 9 CH3 N(CH3)2 H H Rhamnosyl 
epi-587  10 NH2 N(CH3)2 H CH3 Rhamnosyl 
epi-573 11 NH2 N(CH3)2 H H Rhamnosyl 
CDCHD-Phe 12 NH2 L-phenylalanine H CH3 OH 
epiCDCHD-Phe 13 NH2 L-phenylalanine H CH3 OH 
CDCHD-Asn 14 NH2 L-asparagine H CH3 OH 
CDCHD-FuA 15 NH2 furoic acid H CH3 OH 
epi-CDCHD-FuA 16 NH2 furoic acid H CH3 OH 
CDCHD-AHA 17 NH2 aminohexanoic acid H CH3 OH 
epi-CDCHD-AHA 18 NH2 aminohexanoic acid H CH3 OH 
CDCHD-pFBA 19 NH2 p-fluorobenzoic acid H CH3 OH 
epi-CDCHD-pFBA 20 NH2 p-fluorobenzoic acid H CH3 OH 
CDCHD-NAc 21 NH2 acetyl H CH3 OH 
CDCHD-NSO2Me 22 NH2 methylsulfonyl H CH3 OH 
CDCHD-CBz 23 NH2 benzyloxycarbonly H CH3 OH 
CDCHD-biotin-A 24 NH2 biotin H CH3 OH 
CDCHD-biotin-B 25 NH2 biotin H CH3 OH 
CDCHD-Cl 26 NH2 NH2 Cl CH3 OH 
CDCHD-Br 27 NH2 NH2 Br CH3 OH 
CDCHD-Qu 28 NH2 NH2 quinolone CH3 OH 
CDCHD-F 29 NH2 NH2 fluor CH3 OH 




Table 3-12: MIC values of CHD and CDCHD derivatives against Gram-positive and Gram-negative bacteria. 
[a]Compounds (cpd) are listed in Table 3-11 and positions used for derivatization are presented in Figure 3-5; [b]TolC efflux 

















CHD 4 4 8 2 16 64 0.5 
CDCHD 4 4 > 64 2 1 8 0.25 
1 16 n.d. n.d. n.d. n.d. n.d. 64 
2 32 n.d. n.d. n.d. n.d. n.d. 64 
3 16 n.d. n.d. > 64 > 64 n.d. n.d. 
4 n.d. n.d. n.d. > 64 n.d. > 64 n.d. 
5 4 n.d. n.d. 32 > 64 n.d. n.d. 
6 n.d. n.d. n.d. n.d. n.d. n.d. > 64 
7 n.d. n.d. n.d. n.d. n.d. n.d. > 64 
8 4 n.d. n.d. n.d. n.d. n.d. > 64 
9 64 n.d. n.d. n.d. n.d. n.d. > 64 
10 64 n.d. n.d. n.d. n.d. n.d. > 64 
11 4 n.d. n.d. n.d. n.d. n.d. > 64 
12 n.d. 32 n.d. > 64 n.d. > 64 n.d. 
13 n.d. > 64 n.d. > 64 n.d. > 64 n.d. 
14 n.d. 64 n.d. > 64 n.d. > 64 n.d. 
15 n.d. 4 n.d. > 64 n.d. > 64 n.d. 
16 n.d. 8 n.d. > 64 n.d. > 64 n.d. 
17 n.d. 2 n.d. > 64 n.d. > 64 n.d. 
18 n.d. 32 n.d. > 64 n.d. > 64 n.d. 
19 n.d. 4 n.d. > 64 n.d. > 64 n.d. 
20 n.d. 4 n.d. > 64 n.d. > 64 n.d. 
21 n.d. n.d. > 64 > 64 n.d. > 64 n.d. 
22 n.d. n.d. > 64 > 64 n.d. > 64 n.d. 
23 n.d. n.d. > 64 > 64 n.d. > 64 n.d. 
24 n.d. > 64 n.d. > 64 n.d. > 64 n.d. 
25 > 256 128 n.d. > 256 n.d. n.d. > 256 
26 n.d. 4 n.d. 8 n.d. 16 n.d. 
27 n.d. 8 n.d. 8 n.d. 32 n.d. 
28 n.d. 32 n.d. > 64 n.d. > 64 n.d. 
29 4 n.d. n.d. 8 8 n.d. n.d. 





Cytotoxicity against human (HCT-116: colon carcinoma; HepG2: hepatocellular carcinoma; 
THP-1: acute monocytic leukemia; U-2 OS: bone osteosarcoma) and murine (RAW264.7: 
leukemia macrophages; L929: subcutaneous connective tissue, fibroblasts) eukaryotic cell 
lines was determined by tetrazolium salt-based assays (MTT) after 5 d treatment of cells 
with CHD and CDCHD in serial dilution. The half-inhibitory concentration (IC50) was 
determined by sigmoidal curve fitting using Origin 6.1G software.  
Against all tested human cell lines, CHD showed moderate toxicity with IC50 values around 
20 µg/mL, whereas CDCHD showed IC50 values between 1 and 5 µg/mL (Table 3-13). 
Murine cell lines were less affected when tested against CHD (IC50: 50-60 µg/mL) and 
CDCHD generally displayed more pronounced inhibitory effects (IC50: 4-12 µg/mL). 
 




Human   
HCT-116 18.06 2.91 
HepG2 22.97 1.15 
THP-1 23.08 4.98 
U-2 OS 16.09 4.98 
Murine   
L929 58.54 11.63 
RAW264.7 47.74 3.74 
 
3.1.1.4 MACROMOLECULE BIOSYNTHESIS 
To examine the effect of CHD and CDCHD on essential cellular processes, macromolecule 
synthesis (MMS) assays were carried out and the incorporation of radioactive precursor 
molecules in S. carnosus DSM-20501 was assessed. The incorporation of 3H-uridine (RNA), 
3H-thymidine (DNA), 3H-methionine (protein) and 3H-glucosamine (peptidoglycan) was 
determined over 180 min in cells treated with CHD and CDCHD at 0.5-fold MIC. Nisin, 
rifampicin, TET and ciprofloxacin served as positive controls for peptidoglycan, RNA, 
protein and DNA synthesis, respectively. For RNA, DNA and protein synthesis, CHD and 
CDCHD showed an unspecific slight inhibitory effect but final incorporation levels as 
determined by scintillation counts nearly reached the values of untreated control cells after 
180 min of treatment (Figure 3-6). However, cell wall synthesis was delayed by 
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approximately 60 min compared to control cells in both cases (CHD and CDCHD treatment), 































































Figure 3-6: Effects of CHD and CDCHD on synthesis of macromolecules. S. carnosus DSM-20105 was treated with 0.5-
fold MIC (MIC: 4 µg/mL) of CHD and CHD over 180 min and incorporation of and 3H-glucosamine (peptidoglycan), 3H-
uridine (RNA), 3H-methionine (protein) and 3H-thymidine (DNA) was determined. Nisin (4-fold MIC), rifampicin (2-fold 
MIC), TET (4-fold MIC) and ciprofloxacin (2-fold MIC) served as positive controls, respectively. Radioactivity was 
measured in counts per minute (cpm) and data are represented as mean (n=3) ± standard deviation (SD). 
 

















































3.1.1.5 IN VITRO TRANSLATION INHIBITION 
Effects of CHD and CDCHD on translation compared to TET were examined using the RTS 
100 E. coli HY Kit (5PRIME). For CHD and CDCHD a concentration range between 50 and 
150 µM was chosen and TET was tested at concentrations between 3.06 and 50 µM. After 1 
h exposure to compounds, luminescence was recorded and inhibition on in vitro translation 
was observed for all compounds, but the effect of CHD and CDCHD was less pronounced 
than observed for TET (Figure 3-7). Inhibition of translation by TET was already observed 
at 20 µM (approximate half-inhibitory concentration, IC50), whereas CHD and CDCHD 
concentrations of ≥ 100 µM were needed to trigger similar inhibitory effects.  
 
Figure 3-7: Effects of CHD, CDCHD and TET on in vitro translation. Luminescence was measured after 1 h of treatment 
with CHD and CDCHD at concentrations between 50 and 150 µM and TET between 3.06 and 50 µM. Data are represented 
as mean (n=3) ± standard deviation (SD). 
 
3.1.1.6 MEMBRANE DEPOLARIZATION 
Changes on the membrane potential (MP) after treatment with CHD, CDCHD and TET were 
examined using the BacLight™ Bacterial Membrane Potential Kit (Invitrogen). S. aureus 
Newman was exposed to compounds at 0.5-, 2- and 4-fold MIC and MP was measured after 
0.5 and 2 h of treatment. To determine the MP, samples were stained with the cyanine dye 
3,3‘-diethyloxacarbocyanin iodide (DiOC2(3)) for 30 min and fluorescence was measured 
using a microplate reader [excitation.: 488nm; emission: 675 nm (green), 525 nm (red)]. In 































maximum turns towards red. A collapse of the MP leads to a decrease of the intracellular 
dye concentration and the emission maximum shifts towards green fluorescence. MP was 
calculated by the ratio of red to green fluorescence relative to untreated control cells. The 
proton ionophore carbonyl cyanide 3- chlorophenylhydrazone (CCCP) served as positive 
control.185,186 Cells treated with 0.5-fold MIC of either CHD or CDCHD exerted only minor 
effects on the MP compared to untreated cells, displayed by a reduction of the MP by 10 % 
and 15 %, respectively (Figure 3-8). An increase of CHD and CDCHD concentrations up to 
4-fold MIC led to a more pronounced effect showing a time- and concentration-dependent 
increase of membrane depolarization. After 2 h treatment at 2-fold MIC, CHD and CDCHD 
led to an MP decrease of 60 % and 70 %, respectively, approaching the effect caused by 
CCCP (90 % depolarization). For TET, neither a concentration- nor a time-dependent change 
of the MP was observed. MP of cells treated with TET showed an overall constant MP with 
a minor decline of 20 % at all tested conditions.  
 
 
Figure 3-8: Membrane depolarization of S. aureus Newman caused by CHD (MIC: 4 µg/mL), CDCHD (MIC: 4 µg/mL) 
and TET (MIC: 0.125 µg/mL). Cells were treated with CHD, CDCHD and TET at 0.5-, 1- and 2- fold MIC for 0.5 and 2 h. 
CCCP (15 µM) served as positive control. Results show membrane potential relative to untreated cells and are represented 
as mean ± standard deviation (SD) of three independent samples. CCCP: carbonyl cyanide 3- chlorophenylhydrazone. 
 
3.1.1.7 OUTER MEMBRANE PERMEABILIZATION 
Permeabilization of the outer membrane was evaluated by the uptake of 1-N-
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hydrophobic environments and weakly in aqueous environments. The lipopolysaccharide 
(LPS) layer of the outer membrane of intact cells serves as barrier to external lipophilic 
substances and a disruption of the membrane integrity enables NPN to pass into the 
hydrophobic lipid interior of outer and inner membrane, which in turn leads to an increase 
in fluorescence.187,188 E. coli DSM-1116 was treated with CHD, CDCHD and TET at 0.5-, 
1- and 2-fold MIC and kanamycin (KAN) and polymyxin B (PMB) served as negative and 
positive controls, respectively. After 2 h treatment, NPN was added and fluorescence was 
monitored within three minutes using a microplate reader [excitation: 355 nm; emission: 
405 nm]. Effects on membrane permeability were represented as the relative NPN uptake 
factor, calculated as described in part 2.2.7. No increased uptake was observed when cells 
were treated with CHD, CDCHD, TET or KAN at all tested conditions, indicating no 
membrane permeabilizing effects (Figure 3-9). For PMB, membrane permeabilizing was 
observed, represented by an increased uptake of NPN compared to untreated control cells. 
 
Figure 3-9: Membrane permeabilizing effects of CHD (MIC: 1 µg/mL), CDCHD (MIC: 0.5 µg/mL) and TET 
(MIC: 1 µg/mL). KAN and PMB (MIC for both: 4 µg/mL) served as negative and positive controls, respectively. E. coli 
DSM-1116 was treated with CHD, CDCHD and TET at 0.5-, 1- and 2- fold MIC, and KAN and PMB at 2-fold MIC for 
2 h. Results show relative NPN uptake factors and data are represented as mean ± standard deviation (SD) of three 
independent samples. CHD: chelocardin; CDCHD: 2-carboxamindo-2-deacetyl-CHD; TET: tetracycline: KAN: 
kanamycin; PMB: polymyxin B. 
 
Nevertheless, further studies on membrane permeabilization in an 18 h assay revealed effects 
on the membrane integrity of Gram-negative species by CHD comparable to those mediated 
by polymyxins. The effect of increased permeability towards hydrophobic agents was 
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the presence of CHD at sub-inhibitory concentrations. The addition of CHD led to an 8-fold 
increased MIC value compared to the activity of rifampicin in test medium without enhancer 
antibiotic; the same effect was observed when polymyxin B nonapeptide (PMBN) was 
present (Table 3-14). 
Table 3-14: MIC values of rifampicin against A. baumannii DSM-30008 in the presence of CHD and PMBN (polymyxin 
B nonapeptide). 
Test medium 
MIC of rifampicin 
[µg/mL] 
CAMHB 8 
+ 3 μg/mL PMBN 1 
+ 1 μg/mL CHD 1 
 
3.1.2 RESISTANCE MECHANISM 
The development of resistance against CHD was investigated by the generation of resistant 
mutants in two approaches with different wildtype strains. Despite several attempts, it was 
not possible to obtain CDCHD-resistant mutants. 
 
3.1.2.1 CHD-RESISTANT ESCHERICHIA COLI MUTANTS 
Wildtype E. coli DSM-1116 was exposed to stepwise increasing CHD concentrations (2.5, 5, 
7.7, 12.5, 15, 20, 30 µg/mL) obtaining seven independent resistant mutants (Mt30.1, Mt30.2, 
Mt30.4, Mt30.5, Mt30.6, Mt30.8, Mt30.10). At 30 µg/mL CHD, all mutants were able to 
grow but a concurrent fitness loss was observed, reflected in generation times of 2-3 weeks, 
compared to the wildtype which showed a normal growth behaviour. Cross-resistance was 
assessed directly after mutants had been generated and resistance against CHD was 
confirmed due to an observed 8- to ≥ 64-fold increase of determined MIC values (Table 
3-15). All mutants were only 2- to 8-fold cross-/co-resistant to CDCHD, tetracycline, 
tigecycline, rifampicin and ciprofloxacin. With all other tested standard antibiotics, no 
changes in susceptibility of the mutants compared to the wildtype were observed. 
Genomic DNA of wildtype and four mutants (Mt30.1, Mt30.2, Mt30.4, Mt30.8) was 
prepared by standard phenol-chloroform isolation and genome sequencing was performed. 
In silico comparison of genomic data from wildtype to mutants revealed the presence of 
serval single-nucleotide polymorphisms (SNPs) or frameshift mutations (FS) within the 
mutant genomes (Table 3-16). In total, 19 SNPs and 5 FS were present, but changes were 
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not consistent as no common mutant genotype was present. Of all SNPs, six were found in 
upstream regions without impact on amino acid sequences (of the respective genes; marked 
with °). Additionally, Mt30.2 and Mt.30.8 lost a naturally occurring 100kb plasmid, which 
was still present in Mt.30.1 and Mt30.8 as well as within the wildtype. 
 




Wt Mt30.1 Mt30.2 Mt30.4 Mt30.5 Mt30.6 Mt30.8 Mt30.10 
CHD 2 8 8 16 8 > 64 16 8 
CDCHD 0.5 2 2 2 1 2 4 2 
Tetracycline 1 2 2 2 2 2 4 4 
Tigecycline 1 2 1 2 4 1 2 2 
Rifampicin 8 32 32 16 16 16 16 32 
Kanamycin 4 8 4 4 2 2 1 4 
Erythromycin 32 > 64 > 64 64 32 64 64 > 64 
Polymyxin B 0.5 0.5 1 0.5 1 0.25 0.5 0.5 
Chloramphenicol 4 8 8 8 8 8 8 16 
Ciprofloxacin 0.006 0.05 0.025 0.0125 0.0125 0.025 0.0125 0.05 
Vancomycin > 128 > 128 > 128 > 128 128 128 > 128 > 128 





Table 3-16: List of mutations identified in CHD-resistant E. coli DSM-1116 mutants. °mutation found in upstream region 
of locus without impact on amino acid sequence; FS: frameshift; amino acids are denoted by three letter code, base pairs 
as single letter.  
Locus Gene product and function 
Mutation (base pair/amino acid #) 
Mt30.1 Mt30.2 Mt30.4 Mt30.8 
ECW_m0440 







Putative operator region of AcrR190,191: 
repressor of AcrAB MDR efflux 
system192–194  
AC (32)    
ECW_m0536 
AcrR: repressor of AcrAB MDR efflux 
system192–194 
 FS (190)   
ECW_m0905 
Protein belonging to XerC family of 
integrase proteins 
   
LysAsn 
(5) 
ECW_m1039 OmpF: outer membrane porin F195–197 FS (123)    
ECW_m1113 Protein with uncharacterized function 
LysAsn 
(41) 
   
ECW_m1122 
RutA: pyrimidine monooxygenase; 






ECW_m1152 Protein with uncharacterized function 
GlnLeu 
(87) 
   
ECW_m1237 
PhoQ: sensor histidine kinase in two-







Hypothetical protein (containing a lytic 
transglycosylase203) 
   AT (27) 
ECW_m1551 LysR-type transcriptional regulator    FS (191) 
ECW_m1820 Putative ATP-dependent helicase FS (1420)    





Shikimate transporter (shikimic acid, 







PBP7: D-alanyl-D-alanine hydrolase 






kinase: catalyses phosphorylation of 
pseudouridine208,209 
AC (126)    
ECW_m3454 
PBP4: D-alanyl-D-alanine hydrolase 






protein involved in filamentation induced 






EnvZ: sensor histidine kinase in two-
component regulatory system with 
OmpR212,213 
   
LeuIle 
(189) 
ECW_m3728° Hypothetical protein (uncharacterized)  CA (69)   
ECW_m4224° 
Protein of XRE (xenobiotic response 
element) family of transcriptional 
regulators (comprise a helix-turn-helix 
DNA-binding motif.214,215) 





To further investigate the mechanism underlying resistance exerted by CHD-resistant 
mutants (Table 3-15), activities of all sequenced mutants (Mt30.1, Mt30.2, Mt30.4, Mt30.8) 
were determined in the presence of the efflux pump inhibitor phenylalanine arginine β-
naphthylamide dihydrochloride (PAβN) and in the presence of the membrane permeablizing 
agent PMBN. Susceptibility of all mutants against CHD, CDCHD, TET, ciprofloxacin and 
rifampicin increased in the presence of PAβN and MIC values approached activities 
determined for the wildtype (Table 3-17). The permeabilization of the outer membrane by 
PMBN led to similar result for all mutants, as an increase in susceptibility against all tested 
compounds was observed (Table 3-18). However, effects against rifampicin and 
ciprofloxacin were less pronounced than observed in the presence of PAβN and mutant 
Mt30.1 and Mt30.2, still showed co-resistance with ciprofloxacin. 
Table 3-17: MIC values of selected antibiotics against E. coli DSM-1116 wildtype and CHD-resistant E. coli DSM-1116 
mutants (Mt30.) in the presence of phenylalanine arginine β-naphthylamide dihydrochloride (PAβN). 
Compound 
MIC [µg/mL] 
Wildtype Mt30.1 Mt30.2 Mt30.4 Mt30.8 
- + PAβN - + PAβN - + PAβN - + PAβN - + PAβN 
CHD 2 2 8 4 8 2 16 1 16 0.5 
CDCHD 0.5 0.25 2 0.5 2 0.25 2 0.125 4 0.25 
Tetracycline 1 1 2 2 2 0.5 2 0.5 4 0.5 
Tigecycline 1 2 2 2 1 1 2 4 2 1 
Ciprofloxacin 0.006 0.006 0.05 0.006 0.025 0.006 0.0125 0.006 0.0125 0.003 
Rifampicin 2 ≤ 0.03 32 ≤ 0.03 32 ≤ 0.03 32 ≤ 0.03 16 ≤ 0.03 
 
Table 3-18: MIC values of selected antibiotics against E. coli DSM-1116 wildtype and CHD-resistant E. coli DSM-1116 
mutants (Mt30.) in the presence polymyxin B nonapeptide (PMBN). 
Compound 
MIC [µg/mL] 
Wildtype Mt30.1 Mt30.2 Mt30.4 Mt30.8 
- + PMBN - + PMBN - + PMBN - + PMBN - + PMBN 
CHD 2 2 8 4 8 2 16 2 16 0.5 
CDCHD 0.5 0.25 2 0.5 2 0.5 2 0.25 4 0.5 
Tetracycline 1 2 2 2 2 0.5 2 1 4 0.5 
Tigecycline 1 2 2 2 1 2 2 4 2 2 
Ciprofloxacin 0.006 0.006 0.05 0.025 0.025 0.025 0.0125 0.006 0.0125 0.006 




3.1.2.2 CHD-RESISTANT KLEBSIELLA PNEUMONIAE MUTANTS 
In a second in vitro resistance development experiment, nine independent CHD-resistant 
K. pneumoniae mutants were generated by exposing wildtype strain K. pneumoniae DSM-
30104 to stepwise increasing CHD concentrations (2, 4, 8 µg/mL). At 8 µg/mL all mutants 
were able to grow and no differences regarding fitness, compared to the wildtype were 
observed. Over 24 h, all mutants showed a normal, exponential growth behaviour with final 
cell densities comparable to the parent wildtype strain (Figure 3-10). 
 
 
Figure 3-10: Growth curves of K. pneumoniae DSM-30104 wildtype and CHD-resistant mutants (Mt) over 24 h. Data 
represent OD600 values at each time point.  
 
Co-/Cross-resistance studies revealed resistance of all nine mutants against CHD as well as 
against chloramphenicol, ciprofloxacin and all other tested tetracyclines, but not against 
CDCHD (Table 3-19). Against erythromycin, co-resistance was observed as well, except for 
Mt8.3 and Mt8.7, which were more sensitive towards erythromycin compared to all other 
mutants. Against polymyxin B an increased sensitivity of all mutants was observed, 
represented by up to 16-fold increased activity compared to the wildtype. Against all other 
tested antibiotics, no co-resistance was observed.  
To characterize the mechanism underlying resistance, genome sequencing of all mutants and 
the wildtype strain was performed. An in silico comparison of the wildtype genome to the 
mutants genomes revealed mutations to be present within the regulatory gene ramR 
(KPD_37740) in all nine mutants (Table 3-20). Mutations were identified as deletions 
(Mt.8.2, Mt8.3, Mt8.4, Mt.8.5, Mt8.6, Mt8.10), SNPs (Mt8.8) or insertions (Mt8.1, Mt8.7). 



























Additionally, a repeat expansion within a phosphoglyceromutase of Mt8.2 and Mt8.3 
(KPD_35200) and a SNP within an ABC transporter permease of Mt8.7 (KPD_11910) were 
present.  
 




Wt Mt8.1 Mt8.2 Mt8.3 Mt8.4 Mt8.5 Mt8.6 Mt8.7 Mt8.8 Mt8.10 
CHD 2 16 8 16 16 32 16 16 16 8 
CDCHD 2 4 4 4 4 4 4 4 4 4 
Tetracycline 4 64 32 64 64 64 64 64 16 32 
Minocycline 4 64 64 64 64 64 > 64 64 > 64 64 
Oxytetracycline 2 32 32 32 32 32 16 32 16 8 
Tigecycline 0.125 1 2 2 2 1 2 2 1 4 
Rifampicin 8 16 16 16 16 16 8 16 8 8 
Kanamycin 2 2 2 1 1 1 0.5 2 1 0.5 
Erythromycin 8 32 32 16 32 32 32 8 32 32 
Polymyxin B 4 0.5 0.5 0.25 0.25 0.5 0.5 1 1 0.5 
Chloramphenicol 1 32 32 32 16 8 8 16 16 8 
Ciprofloxacin < 0.03 0.125 0.025 0.125 0.125 0.125 0.125 0.125 0.125 0.125 
Vancomycin > 64 > 64 64 64 64 64 64 > 64 > 64 > 64 
Ampicillin > 64 > 64 > 64 > 64 > 64 > 64 > 64 > 64 > 64 > 64 
 
 
Table 3-20: Mutations identified in CHD-resistant K. pneumoniae DSM-30104 mutants. Ins: insertion; ∆: deletion; bp: 
base pair; #: number of affected bp; number in brackets denote number of affected amino acid (denoted in three letter code): 
RE: repeat expansion.  
Locus Gene product 
mutation 






11bp Ins Δ4bp Δ4bp Δ4pb 
Δ#550; 
11bp Ins 









2x  3x 
7bp RE 
2x  3x 
7bp RE 
      
KPD_11910 
branched-chain 
amino acid ABC 
transporter 
permease 






Further characterization focused on the function of ramR, as mutations within this gene were 
common within all mutants. A K. pneumoniae DSM-30104 ramR knockout mutant 
(KP∆ramR) was generated with a λ-red based knock-out system and the gene knock-out was 
confirmed by sequencing. As expected, KP∆ramR was less susceptible towards CHD with 
an 8-fold decrease in activity compared to wildtype K. pneumoniae and no significant 
changes in sensitivity were observed when CDCHD activity was determined (Table 3-21).  
 
Table 3-21: Activity of K. pneumoniae DSM-30104 wildtype and RamR knockout mutant (∆ramR) against CHD and 
CDCHD. 
K. pneumoniae DSM-30104 
MIC [µg/mL] 
CHD CDCHD 
Wildtype 4 4 
∆ramR 32 8 
 
 
To explore the regulatory function of RamR with respect to the AcrAB-TolC efflux system, 
transcriptional levels of ramA (encoding RamA; positive regulator of AcrAB-TolC efflux 
system), acrA and acrB (encoding AcrA and AcrB, respectively; subunits of AcrAB-TolC 
efflux system) were analysed. Gene expression of all nine CHD-resistant K. pneumoniae 
mutants and KP∆ramR was measured by qPCR and relative transcription levels compared 
to the wildtype were calculated by the 2-ΔΔCt method173 and normalized to 16S rRNA. 
Compared to the wildtype, upregulation of ramA up to 41-fold with a concurrent 
upregulation of acrA and acrB up to 12- and 67-fold, respectively (Table 3-22) was found 




Table 3-22: Relative transcription levels of ramA, acrA and acrB genes of CHD-resistant K. pneumoniae mutants in 
comparison to K. pneumoniae DSM-30104 wildtype. 
K. pneumoniae 
DSM-30104 
Relative transcription level (fold change) 
ramA acrA acrB 
 Wildtype 1 1 1 
 ΔramR 17.43 ± 2.42 1.38 ± 1.17 19.75 ± 0.73 
Mt8.1 18.47 ± 0.87 1.58 ± 0.74 n.d. 
Mt8.2 41.08 ± 1.05 11.78 ± 1.89 66.64 ± 0.58 
Mt8.3 14.01 ± 0.91 2.76 ± 0.73 n.d. 
Mt8.4 8.19 ± 0.55 8.40 ± 1.07 4.91 ± 0.80 
Mt8.5 23.46 ± 1.11 2.58 ± 0.71 1.41 ± 0.65 
Mt8.6 31.13 ± 1.30 4.33 ± 1.97 1.96 ± 1.13 
Mt8.7 17.78 ± 0.94 4.62 ± 2.11 1.28 ± 1.13 
Mt8.8 3.16 ± 0.97 9.37 ± 0.71 1.47 ± 0.94 
Mt8.10 10.40 ± 1.08 3.13 ± 1.87 1.28 ± 0.85 
 
MIC values of all mutants were re-examined in the presence of PAβN and as expected, all 
mutants showed increased sensitivity towards CHD and no changes were observed in 
activity of CDCHD (Table 3-23). Additionally, MIC values against tetracycline, tigecycline, 
chloramphenicol and ciprofloxacin were determined and all mutants showed activity values 
comparable to the wildtype, indicating that former observed co-/cross-resistance (Table 
3-19) relies on efflux. The inhibition of efflux pumps within the wildtype had no effect on 
activity, as same values were determined with and without PAβN. A comparison of MIC 
values of wildtype to mutants in the presence of PAβN showed a general recovery of activity 
upon efflux pump inhibition, however data indicated that a complete inhibition of efflux 
might have been not achieved, since mutants were overall less sensitive than the wildtype. 





Table 3-23: Activity of K. pneumoniae DSM-30104 wildtype and CHD-resistant mutants in the presence of phenylalanine 
arginine β-naphthylamide dihydrochloride (PAβN). TET: tetracycline; TIG: tigecycline; CM: chloramphenicol; CIP: 
ciprofloxacin. 




CHD CDCHD TET TIG CM CIP 
Wildtype 
- 2 1 2 0.125 1 ≤ 0.03 
+ 2 1 2 0.25 2 ≤ 0.03 
ΔramR 
- 16 4 8 2 8 0.06 
+ 8 2 4 0.25 1 ≤ 0.03 
Mt8.1 
- 8 2 16 1 32 0.125 
+ 8 2 4 0.125 2 ≤ 0.03 
Mt8.2 
- 16 2 32 2 32 0.25 
+ 8 2 4 0.5 2 ≤ 0.03 
Mt8.3 
- 16 2 32 2 32 0.125 
+ 8 2 4 0.125 1 ≤0.03 
Mt8.4 
- 16 2 16 2 16 0.125 
+ 2 2 4 0.25 1 ≤ 0.03 
Mt8.5 
- 16 2 16 1 8 0.125 
+ 4 2 4 0.25 0.5 ≤ 0.03 
Mt8.6 
- 16 2 16 2 8 0.125 
+ 4 2 2 0.5 1 ≤ 0.03 
Mt8.7 
- 16 2 32 2 16 0.125 
+ 2 1 4 0.125 2 ≤ 0.03 
Mt8.8 
- 8 2 16 1 16 0.125 
+ 4 1 2 0.125 1 ≤ 0.03 
Mt8.10 
- 16 2 32 4 8 0.125 
+ 8 1 4 0.5 1 ≤ 0.03 
 
To confirm that CHD resistance mechanisms and co-resistance with ciprofloxacin and 
rifampicin are not related to mechanisms commonly observed for the reference antibiotics, 
activities against rifampicin-resistant (RIFR) S. aureus Newman, ciprofloxacin-resistant 
E. coli (E. coli WT-3) and marR-deficient E. coli (E. coli WT-III; upregulated efflux) were 
determined. Against S. aureus RIFR [mutation within rpoB; encoding RNA polymerase β-
subunit] no co-resistance with CHD or any other tested tetracycline was observed. 
Resistance mediated by mutation of gyrA [encoding DNA gyrase A-subunit] led also to no 
co-resistance for CHD or any other tested antibiotic when activity was tested against E. coli 
WT-3 (Table 3-24). Against E. coli WT-III, an 8-fold decrease in activity was observed for 
CHD and CDCHD, and tigecycline showed 4-fold less activity compared to wildtype E. coli 
(E. coli WT), supporting the assumption that resistance relies on efflux events.  
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Table 3-24: Minimal inhibitory concentrations (MIC) of selected antibiotics against S. aureus Newman wildtype, 
[a]rifampicin-resistant S. aureus Newman (mutations within rpoB), [b]E. coli wildtype (served as wildtype for generation of 
[c] and [d]), [c]ciprofloxacin-resistant E. coli (mutation of gyrA within amino acid # 644 ) and [d]E. coli marR deficient mutant 







E. coli WT[b] E. coli WT-3[c] E. coli WT-III[d] 
CHD 4 8 4 4 16 
CDCHD 2 2 2 2 2 
Tetracycline ≤ 0.03 ≤ 0.03 2 2 2 
Tigecycline 8 8 8 16 32 
Ciprofloxacin 0.1 0.1 0.03 2 0.05 
Rifampicin ≤ 0.03 > 64 8 8 8 
 
To compare resistance mechanisms against CHD to mechanisms of CDCHD-resistant 
pathogens, it was planned to generate CDCHD-resistant mutants. Wildtype K. pneumoniae 
DSM-30104 and S. aureus N315 were exposed to stepwise increasing CDCHD 
concentrations (K. pneumoniae: 2, 4, 8 µg/mL; S. aureus: 4, 8, 12 µg/mL), generating eight 
independent mutants, respectively. K. pneumoniae mutants were able to grow at 8 µg/mL 
and S. aureus mutants at 12 µg/mL, but for all a tremendous fitness loss was observed, 
reflected in generation times up to 2 weeks, compared to the wildtype which showed a 
normal growth behaviour. Finally, repeating MIC assays with these mutants, resistance 
against CDCHD or CHD could not be confirmed for any K. pneumoniae or S. aureus mutant 
(Table 3-25, Table 3-26). Additionally, some mutants (K. pneumoniae: Mt8.7, Mt8.8, Mt8.9; 
S. aureus: Mt12.1, Mt12.9) were not able to grow after cryo-storage, underlining the strong 





Table 3-25: Resistance pattern of K. pneumoniae CDCHD-resistant mutants (Mt). Wt: K. pneumoniae DSM-30104 





Wt 8 4 
Mt8.1 16 8 
Mt8.2 16 8 
Mt8.3 16 4 
Mt8.4  16 4 
Mt8.7 n.d. n.d. 
Mt8.8 n.d. n.d. 
Mt8.9 n.d. n.d. 
Mt8.10 16 8 
 
Table 3-26: Resistance pattern of S. aureus CDCHD-resistant mutants (Mt). Wt: S. aureus N315 wildtype. n.d.: not 
determined. 
S. aureus N315 
MIC [µg/mL] 
CHD CDCHD 
Wt 8 4 
Mt12.1 n.d. n.d. 
Mt12.2 8 4 
Mt12.3 8 4 
Mt12.5 8 8 
Mt12.6 8 4 
Mt12.7 8 8 
Mt12.8 8 8 










3.2.1 ANTIBACTERIAL ACTIVITY 
Chelocardin belongs to the family of atypical tetracyclines127,135,217 and is known to be a 
broad-spectrum antibiotic with activity against Gram-positive and Gram-negative bacteria, 
including multidrug-resistant bacteria, but it lacks activity against Pseudomonas 
aeruginosa.107,108,139 Compared to clinically used typical tetracyclines, CHD exhibits some 
structural differences and depicts a more planar and rather lipophilic molecule, which is 
thought to be the main reason for a different mode of action.48,139 Typical tetracyclines are 
known to inhibit protein biosynthesis by blocking the acceptor site of aminoacyl-tRNA at 
the 30S subunit of the ribosome to prevent translation.217–219 In contrast, atypical 
tetracyclines such as CHD are not believed to be involved in translation inhibition, but they 
rather interfere with the cytoplasmic bacterial membrane which leads to a disrupted function 
and a bacteriolytic effect.127–129 One main difference of CHD to typical tetracyclines with 
regard to structural properties is a different aromatization pattern of ring C of CHD (Figure 
3-11). This chemical feature leads to a more planar molecule, the reason why CHD might 
not be able to bind to the ribosome. Moreover, CHD bears an acetyl group at C-2, which is 
replaced by a carboxamido group at typical tetracyclines and known to be the main feature 
for tetracyclines antibacterial activities.130,131 Based on this knowledge, biosynthetic 
engineering studies aimed at improving chelocardin and yielded a new chelocardin 
derivative, 2-carboxamindo-2-deacetyl-CHD (CDCHD, Figure 3-11), bearing a 
carboxamido group at C-2 and exhibiting improved antibacterial activities including 





Figure 3-11: Combination of typical and atypical structural features within 2-carboxamindo-2-deacetyl-CHD (CDCHD). 
Main structural characteristics of atypical tetracyclines (CHD, CDCHD) that differ from typical tetracyclines 
(oxytetracycline) are marked in blue. 
 
Antibacterial activities of CHD and CDCHD were determined against Gram-positive and 
Gram-negative bacteria and broad-spectrum effectiveness, including inhibitory activity 
against TET-resistant pathogens, of both compounds were confirmed (Table 3-1, Table 
3-2).139 Throughout, CDCHD exhibited an improved activity pattern, especially against 
P. aeruginosa with overall 2- to 8-fold increased activities, compared to CHD. The 
difference of CHD to CDCHD in P. aeruginosa activity was further investigated by MIC 
determination against efflux-deficient P. aeruginosa PA14 mutants (ΔmexAB, ΔmexCD, 
ΔmexEF, ΔmexXY). It was shown that susceptibility relied on efflux mechanisms exhibited 
mainly by the MexAB-OprM efflux pump of P. aeruginosa (Table 3-3). A deletion of the 
efflux pump encoded by mexAB increased susceptibility of both compounds up to 16-fold, 
the same effect as observed for TET. Efflux pumps encoded by mexCD, mexEF and mexXY 
did not affect activities as they are thought not to be expressed under normal growth 
conditions. They are rather involved in acquired resistance based on mutations of regulatory 
genes what leads to an increased expression of the efflux systems.46,220–223 In contrast, 
MexAB-OprM is known to cause intrinsic resistance towards antibiotics, including 
D C B A D C B A
D C B A
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tetracyclines.224,225 Since CHD and TET are only effective against P. aeruginosa upon efflux 
pump inhibition and CDCHD was shown to be able to inhibit wildtype species of 
P. aeruginosa139 (Table 3-1), the difference in activity must rely on structural characteristics 
of CDCHD, which enable the compound to at least partially overcome efflux. This is also in 
accordance to results from in vitro resistance development in Klebsiella pneumoniae, where 
it was not possible to obtain CDCHD resistant mutants and all CHD resistant clones 
displayed increased efflux via the AcrAB system (see chapter 3.2.3). Compared to typical 
tetracyclines, chelocardins contain a non-methylated amino group at C-4, as well as different 
aromatization patterns in the western part of the molecules (Figure 3-11). Since those 
features do not seem to be sufficient to cause inhibition of P. aeruginosa spp. (see CHD 
activity pattern), the combination of chemical features from typical and atypical 
tetracyclines, including a charged primary amine, merged within CDCHD, seems to be the 
reason to overcome intrinsic resistance mediated by P. aeruginosa and CDCHD’s improved 
activity pattern.  
Bringing together the facts that chelocardins are in general able to inhibit MDR species and 
tetracycline-resistant pathogens (Table 3-2) and the overall improved activity pattern of 
CDCHD compared to CHD, depicts CDCHD as a frontrunner molecule in the class of 
chelocardins. To further improve the potency of chelocardins and to generate a lead 
molecule, several derivatives were prepared through semisynthesis and genetic engineering, 
with a main focus on derivatization of CDCHD (Figure 3-5, Table 3-11). Structure activity 
relationships (SAR) of 30 derivatives bearing different moieties (Figure 3-5, Table 3-11) 
were investigated by determining activities against Gram-positive and Gram-negative 
bacteria including S. aureus, K. pneumoniae, P. aeruginosa and efflux-deficient E. coli TolC 
(Table 3-12). Modifications by structural features from typical tetracyclines, such as 
dimethylation of the amino group at C-4 or a demethylation at C-9, as well as substitutions 
or additions of several active groups were performed (Figure 3-12, Figure 3-13). So far, none 
of the generated derivatives showed improved antibacterial activity. A demethylation at C-
9 of CHD led to a complete abolishment in antibacterial activity, confirming the importance 
of a methyl group at this position for the effectiveness of CHD226. A dimethylation or 
substitutions of various active groups at C-4 led to a loss or complete abolishment in activity 
for CHD and CDCHD against Gram-negative bacteria. However, S. aureus was still 
susceptible towards both compounds upon substitution of R4 to a N-dimethyl group (at C-4), 
but no improvement in activity was achieved. In general, the N-dimethyl group (tertiary 
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amine) at C-4 leads to a declined activity pattern for both compounds and it seems to be 
crucial to bear a primary amine at C-4 to exert their broad-spectrum activity pattern. 
However, so far only the relative stereochemistry in CHD and CDCDH is known. It might 
be that difference in the overall topology of chelocardins in comparison to typical 
tetracyclines account for different binding and activity pattern. A combinatorial 
derivatization by a substitution of C-4 to a N-dimethyl group and a glycosylation at C-10 of 
either CHD or CDCHD led to a complete loss in activity and as expected, a concurrent 
demethylation at C-9 did not change the molecules properties. The addition of a sugar moiety 
to either CHD or CDCHD could positively influence the molecules properties, including an 
increased water-solubility or a decrease of their cytotoxicity227,228. However, to examine the 
properties of a glycosylated molecule in detail, it would be preferable to add the 
glycosylation to the parent molecules (CHD and CDCHD) bearing no further modification. 
Regarding derivatization at C-7, not all active groups were tolerated upon addition, but so 
far, this position seems to be promising to perform further derivatization. The addition of a 
chlorine or a fluorine still led to compounds inhibiting Gram-positive as well as Gram-
negative bacteria comparable to the parent molecule CDCHD. Even though no improvement 
in activity was achieved, the molecule’s broad-spectrum activity pattern was still present. 
Derivatization at C-7 of CDCHD seems to be a promising starting point to optimize the 
scaffold in terms of pharmacological properties including besides bioactivity also 
bioavailability or the molecules solubility. 
From eight derivatives, their respective C-4 epimer was available for activity determination. 
For two derivatives their S-configured epimer was 16-fold less potent than the R-configured 
molecule, whereas for all other derivatives a comparison between both types of configuration 
did not show differences in terms of their antibacterial activity. In general, tetracyclines are 
known to undergo reversible epimerization at C-4 at acidic pH conditions which leads to a 
decrease of antibacterial potency.229–232 Overall, chelocardins in (4S)-configuration did not 
seem to loose antibacterial activity, but it cannot be excluded that spontaneous epimerization 
to the (4R)-epimers takes place under assay conditions, which causes the observed 








Figure 3-13: Structure activity relationship (SAR) of CDCHD derivatives in comparison to the parent molecule.  
 
addition of rhamnosyl group
(on dimethylated molecule) 
 no effect
demethylation
 abolishment of G+/G- activity
dimethylation
 abolishment of  G+/G- activity (except 
for S. aureus)
dimethylation
 abolishment of  G+/G- activity (except 
for S. aureus)
substitution by various active groups
 abolishment of G- activity, 2- to 32-
fold drop of G+ activity
addition of Cl, Br, F 
 2- to 32-fold drop of G- activity, no 
changes on  G+ activity
addition of quinolone, nitrate 
 8-fold drop in G+ activity, abolishment 
of G- activity
addition of rhamnosyl group
(on dimethylated molecule) 
 no effect
demethylation
 abolishment of G+/G- activity
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3.2.2 MECHANISM OF ACTION 
One key element in the optimization of antibiotics is the elucidation of their mechanism of 
action and identification of the target molecules. Based on this information, molecules can 
be adapted to provide antibacterial agents with improved pharmaceutical properties to assure 
an optimum in effectiveness and to overcome the ability of bacteria to exert resistance 
towards antibiotics.24,41 The target molecule of CHD is yet not identified and ever since the 
discovery of CHD107, its mode of action is controversially discussed. Studies in the 1970s 
revealed CHD to exert the same mechanism of action as typical tetracyclines by inhibiting 
protein translation upon binding to ribosomal subunits140, whereas more recent studies 
describe cell lysis as the primary effect, which is mediated by interference with the cell 
membrane, and no interaction with the ribosome.127–129,135 Additionally, a current study 
predicted a dual mechanism of action involving both, inhibition of protein biosynthesis and 
targeting of the cell membrane in a concentration dependent manner.141 To get further insight 
into the predicted mechanisms of chelocardins, effects on the outer membrane as well as 
effects on membrane integrity were analysed. Typical tetracyclines are known to enter 
Gram-negative cells through porins without affecting the permeability of the outer 
membrane.48,233,234 This was also observed for E. coli treated with CHD and CDCHD at 
concentrations ranging from sub-inhibitory to 2-fold MIC over 2 h. None of the tested 
antibiotics increased permeability towards the lipophilic dye NPN (Figure 3-9), indicating 
that chelocardins are not able to change the composition and integrity of the OM under these 
conditions. However, in a 18 h assay, CHD revealed a similar effect than observed for 
polymyxins by sensitizing the outer membrane towards hydrophobic agents like rifampicin 
(Table 3-14), which are under normal conditions not able to penetrate the OM.235,236 This 
may be triggered by membrane disturbing antibacterial effects at sub-lethal concentrations, 
which do not directly rely on membrane re-organization as observed with e.g. polymyxins. 
Thus, the observed sensitizing of A. baumannii could be caused indirectly and after CHD 
exerts its primary antibacterial mechanism.  
Additionally, changes on the membrane potential (MP) caused by treatment with CHD and 
CDCHD in comparison the TET were examined. A concentration- and time-dependent 
depolarization of the MP was observed when S. aureus was treated with CHD or CDCHD 
(Figure 3-8). After 2 h treatment at 8 µg/mL both compounds affected MP (approx. 70 % 
depolarization) in a similar way as observed for the control CCCP, which caused almost a 
complete collapse (90 % decrease) of the MP by eliminating the proton gradient.185,186 For 
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TET, neither a concentration- nor a time-dependent change of the MP was observed. Those 
results are in accordance with published data on the membrane potential upon treatment with 
CHD and TET in a short term study (6 min treatment).141 Stepanek et al. described effects 
on the MP only at high CHD concentrations (12 µg/mL) and no effect at lower 
concentrations (3-6 µg/mL). The fact that Stepanek et al. had to use higher concentrations 
of CHD to observe membrane depolarization in a shorter time period (only 6 min treatment) 
supports the result (Figure 3-8) of a concentration and time-dependent depolarization effect 
caused by chelocardins. Differences of typical and atypical tetracyclines in terms of their 
membrane depolarization effects seem to rely on structural differences. Typical tetracyclines 
exist in an equilibrium of a lipophilic, non-ionized and a hydrophilic form.128,132,237 To enter 
Gram-negative cells, typical tetracyclines form a positively charged cation complex, 
presumably with Mg2+, what enables the uptake through porins (OmpF, OmpC) of the outer 
membrane.233,234 The tetracycline-ion complex accumulates within the periplasm and 
presumably dissociates resulting in equilibrium of the zwitterion and a non-ionized form of 
the antibiotic. The neutral form is needed to further proceed through the cytoplasmic 
membrane. Once the molecule is present within the cytoplasm, a chelation is likely to happen 
again, which results in a hydrophilic ionized molecule which is able to bind to the 
ribosome.48,233 This relies on a higher pH and a higher ion concentration within the cell 
compared to the periplasm.234 In contrast, atypical tetracyclines solely exist in a lipophilic 
form which is probably caused by their more planar structure.128 Due to the increased 
lipophilicity of CHD, the molecule is thought to stay longer in the membrane compared to 
typical tetraclycines141, which might trigger membrane damaging effects, followed by a 






Figure 3-14: Formational changes during tetracycline (TET) uptake. A chelation of a TET-ion (Mg2+) complex is needed 
to cross the outer membrane (OM). The complex dissociates within the periplasm and an equilibrium of the zwitterion and 
a non-ionized form is present. The latter form dissociates through the cytoplasmic membrane into the cytoplasm, where the 
molecule predominantly exists in a hydrophilic from. A reformation of the TET-ion complex is likely to happen and is 
required for ribosome binding.238–240 
 
Besides membrane associated mechanisms, inhibitory effects of CHD on the synthesis of 
macromolecules were described.128 In comparison to the nearly complete inhibition of RNA, 
DNA and protein synthesis described by Rasmussen et al.128, contrary data were achieved 
within the present study (Figure 3-6). S. carnosus DSM-20105 was incubated with CHD and 
CDCHD at 0.5-fold MIC and macromolecule synthesis (MMS) was monitored over 180 min. 
Both compounds showed only a slight inhibition of RNA, DNA and protein synthesis, which 
can be neglected, as final incorporation levels of precursor molecules nearly reached the 
values achieved for untreated control cells. Additionally, effects on cell wall synthesis were 
analysed and apart from a delay in the synthesis by approximately 60 min compared to 
control cells, treatment with both compounds did not lead to complete inhibition. One 
limiting factor within this study was the concentration range of both chelocardins. Results 
depicted (Figure 3-6) were generated at sub-inhibitory concentrations (2 µg/mL), as the use 
of higher concentrations was not suitable within the assay set-up. Concentrations ≥ MIC led 
to fast killing and complete lysis of cells due to the strong bactericidal effect of 
chelocardins127. On the contrary, Rasmussen et al. performed their studies at higher 
concentrations (20-fold MIC), what might account for the discrepancies in observed effects. 
In contrast to the above described minor effects on protein synthesis on living cells, both 
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chelocardins displayed inhibition of translation in a cell-free system (Figure 3-7). However, 
> 5-fold higher concentrations of CHD and CDCHD compared to TET were needed to 
trigger similar inhibitory effects. Those findings are contradictory to the predicted 
mechanism of CHD by Stepanek et al.141, as they stated that CHD caused inhibition of 
translation through ribosome binding at low CHD concentrations. Based on their data, results 
on MMS study would have been expected to be different, i.e. an early breakdown of 
methionine incorporation was expected. Indeed, cell wall synthesis appeared to be most 
affected when S. carnosus was treated at the 0.5-fold MIC. However, the discrepancies on 
the mechanism of CHD cannot be explained so far. Regarding results of the in vitro 
translation in a cell-free system, ribosome inhibition seems to contribute to CHD’s 
antibacterial activity. However, based on the cell-based studies (MMS), translation 
inhibition was excluded as primary mechanism. Furthermore, effective concentrations in 
cells cannot be extrapolated form inhibitory concentrations in the in vitro experiment. The 
cell-free system overcomes the already mentioned bactericidal activity of CHD127,129, which 
was shown to happen in a concentration dependent manner (Figure 3-2). Sub-inhibitory 
concentrations led to an either exponential growth or a bacteriostatic effect, whereas higher 
antibiotic concentrations (≥ MIC value) led to a 2- to 3-log10 reduction of counted CFU. For 
CDCHD, a similar bactericidal activity was observed and the effect was even more 
pronounced compared to CHD, killing > 3-log10 cells (Figure 3-3). Additionally, it was 
shown that chelocardins exert in general a stronger activity than observed for typical 
tetracyclines (Table 3-4), since they act more bacteriostatic.127 Combining those results with 
the observed effects on translation, leads to the conclusion that the concentration range used 
in the cell-free translation assay would trigger a bactericidal effect in an assay with live cells 
by a rapid killing of the cells. It might be possible that membranes of bacterial cells are 
already affected irreversibly after CHD treatment and that simultaneous effects on the 
ribosome are negligible. This shows that the main mechanism of action of chelocardins rely 
on membrane associated effects and that it is not based on the inhibition of protein synthesis. 
Although the mode-of-action of chelocardin is still not completely understood, a potential in 
vivo use was already described in the 1970s. A small Phase II clinical study in the 1970s 
reported the cure of twelve patients suffering from urinary tract infections after treatment 
with CHD138. To compare in vivo efficacy of CHD to CDCHD, both compounds were 
initially investigated in a thigh infection mouse model (data not shown; Dr. Katharina Rox, 
HZI, Braunschweig). Both compounds were tolerated up to 50 mg/kg/day and reduction of 
bacterial burden (K. pneumoniae) was determined in muscles, blood and kidneys. Based on 
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CFU count, antibacterial effects in blood samples were more pronounced compared to 
effects in muscles. However, both compounds revealed best potency in kidneys and similar 
or even better effects compared to the control levofloxacin were observed. The overall 
promising results from in vivo infection experiments along with results from extensive 
pharmacokinetic (PK) studies in mice, that were performed by Dr. K. Rox as part of a DZIF-
funded project, hinted towards an accumulation of the compounds in kidneys and urine and 
the potential use of chelocardins to treat urinary tract infections (UTI). Thus, both 
chelocardins were assessed in an E. coli UTI mouse model at Statens Serum Institute in 
Copenhagen, Denmark.241 As expected, CHD as well as CDCHD were able to induce a 
significant reduction of bacterial burden in urine and bladder, but antibacterial effects in 
kidneys were somewhat less pronounced and only CDCHD treatment resulted in significant 
reduction of bacterial load. Due to limitations with respect to solubility of CHD and CDCHD 
and their bioavailability further scaffold improvement is required to achieve even better in 
vivo efficacy. However, the results from in vivo mouse models, in particular from the E. coli 
UTI model, qualify CDCHD as a valid starting point for lead generation (hit-to-lead 
program). UTIs are classified into complicated an uncomplicated infections, whereas the 
latter type is additionally subdivided into lower UTI (cystitis) and upper UTI 
(pyelonephritis).242,243. Uncomplicated UTIs are typically described in otherwise healthy 
patients whereas complicated UTIs occur in association with urinary tract abnormalities 
including structural or neurological changes.244 UTIs are mainly caused by 
Enterobacteriaceae, with an annual estimated occurrence of about 150 million cases.245 
Uropathogenic E. coli (UPEC) are the most common pathogens causing UTI, but e.g. 
K. pneumoniae, P. mirabilis, Enterobacter spp. and P. aeruginosa are also associated with 
UTIs (Figure 3-15). Besides Gram-negative bacteria, Gram-positive bacteria such as 
Enterococci or Staphylococci, and fungi are also capable of causing UTI.242,246 The 
increasing number of MDR pathogens, in particular among Gram-negative species, severely 
hampers the effectiveness of drugs such as fluoroquinolones or β-lactam antibiotics, which 
are typically used to treat UTIs.247–249 Elderly patients appear to be most affected by drug-
resistant uropathogens. Furthermore, the spread from hospitals to the community including 
special-care homes is alarming.250,251 The combination of increasing prevalence of MDR 
bacteria among uropathogenic strains, an extensive spread of the pathogens into the 
community, and a concurrent emergence of ineffective drugs depicts the importance of 




Figure 3-15: Epidemiology of uncomplicated urinary tract infections (UTI) and complicated UTI. UPEC: uropathogenic 
E. coli; GBS: group B Streptococcus. Adapted from Flores-Mireles et al.242 
 
To further investigate the potential use of CHD and CDCHD against UTIs, the in vitro 
activity of both compounds was determined against uropathogenic laboratory strains and 
clinically relevant isolates, including MDR isolates. Both chelocardins inhibited laboratory 
strains (Table 3-1) and as expected CDCHD showed improved activity compared to CHD 
(2- to 8-fold increased MIC values). In addition, CHD and CDCHD revealed inhibitory 
effects against clinical isolates and intriguingly, they were able to inhibit colistin-resistant 
pathogens and pathogens expressing TEM-β lactamases or extended-spectrum β-lactamases 
(Table 3-5). Moreover, approximately 4-fold improved potency of both compounds was 
observed when tested against selected isolates in artificial urine, compared to standard test 
medium (Table 3-8, Table 3-9) and determined MIC values were pH-independent (pH 5.5 
to pH 8.5). However, MBC values varied by a factor 2-16 depending on the adjusted pH. 




























values and it was more pronounced with the K. pneumoniae isolate (compared to E. coli), 
whereas potency at acidic pH was by tendency better. Remarkably, an opposite line-up of 
CHD and CDCHD in terms of their antibacterial potency was observed. CDCHD showed 
better activities against laboratory strains, whereas CHD was the more potent molecule 
against clinical isolates and additionally, CDCHD lost its ability to efficiently inhibit P. 
aeruginosa when tested against clinical isolates. Those data are contradictory to initial 
reported MIC values139 on clinical isolates. It was assumed that a changed formulation of 
CHD and CDCHD caused the reverted potency. Initially, chelocardins were prepared as HCl 
adducts in methanol and reported data139 rely on using CHD and CDCHD in this solution. 
Due to stability issues (e.g. spontaneous epimerization), which were discovered later on, 
both chelocardins were provided in a modified formulation as sodium salts with citrate as 
stabilizer. However, it was shown, that the change in formulation did not cause reverted 
potency of CHD and CDCHD (Table 3-6, Table 3-7). Throughout, MIC values determined 
with CHD and CDCHD in either MeOH (HCl adducts) or water (Na salts with Na-citrate) 
were comparable and thus, it could be confirmed that CDCHD is by tendency less active 
compared to CHD on uropathogenic clinical isolates. In addition, both compounds were in 
general less potent against clinical isolates compared to laboratory strains, which probably 
relies on intrinsic resistance mechanism (e.g. higher efflux rates) that are per se found 
frequently in clinical isolated pathogens. Moreover, the slight difference in potency can 
probably also be neglected as CDCHD appears to be the preferred scaffold due to its 
significantly more pronounced bactericidal effects, which was throughout shown to be 
stronger compared to CHD, regardless if determined against laboratory strains (Figure 3-3) 
or clinical isolates (Table 3-5, Table 3-8, Table 3-9). 
These results further substantiate the assumption that chelocardins, in particular CDCHD-
derived compounds, are useful early lead structures for the preclinical development towards 
an UTI drug. Moreover, experimental in vivo PK/PD studies in mice and reports on the phase 
II clinical trial with CHD did not reveal any severe in vivo toxicity or adverse effects.138 
Those results underline a good tolerance of chelocardins in vivo and leading to the 
conclusion, that cytotoxic effect observed in vitro can be neglected. However, in vitro 
cytotoxicity against human (HCT-116: colon carcinoma; HepG2: hepatocellular carcinoma; 
THP-1: acute monocytic leukemia; U-2 OS: bone osteosarcoma) and murine (RAW264.7: 
leukemia macrophage; L929: subcutaneous connective tissue, fibroblasts) cell lines (Table 
3-13) hampered some of the cell-based studies. The analysis of killing efficacy on 
intracellular bacteria within macrophages by CHD and CDCHD failed as the assay set-up 
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was particularly limited; half-inhibitory concentrations of CHD and CDCHD on eukaryotic 
cells (IC50 on RAW264.7: 4.5 and 0.7 µg/mL) were in the same range than MIC values on 
the intracellular pathogen (S. aureus MIC: 4 µg/mL) (Figure 3-4). Concentrations 
≥ MIC/IC50 would have led to killing of bacteria with a concurrent disruption and lysis of 
macrophages. For CDCHD, the general higher toxicity was even more limiting as 
concentrations ≤ IC50 (0.7 µg/mL) would have been too low to cover the concentration ranges 
needed to determine any antibacterial effect (MIC: 4 µg/mL). In vitro cytotoxicity probably 
relies on membrane interaction of CHD and CDCHD similar to that observed for bacterial 
species. The lack of pronounced in vivo toxicity might be explained by the fact that cells, 
which are organized in e.g. a tissue are usually more tolerant to external stressors.252 
 
3.2.3 RESISTANCE MECHANISM 
The development of resistance against CHD and CDCHD was investigated in Gram-positive 
and Gram-negative bacteria. Despite several attempts, it was not possible to obtain CDCHD-
resistant mutants. The exposure of stepwise increasing concentrations of CDCHD to 
wildtype K. pneumoniae DSM-30104 and S. aureus N315 led to a severe loss in fitness of 
the treated bacteria and MIC determination revealed all mutants not to be resistant (Table 
3-25, Table 3-26). However, by exposing wildtype E. coli DSM-1116 and K. pneumoniae 
DSM-30401 to stepwise increasing CHD concentrations, independent CHD-resistant 
mutants were obtained. The exposure to wildtype E. coli yielded seven independent CHD-
resistant mutants, but the generation was accompanied by a severe reduction in fitness of the 
mutants compared to the wildtype. This was reflected in generation times of the mutants of 
2-3 weeks. A second in vitro resistance development performed with wildtype 
K. pneumoniae DSM-30104 yielded nine independent mutants, which were all able to grow 
at 8 µg/mL Compared to CHD-resistant E. coli mutants, no influence on fitness compared 
to the respective wildtype was observed for CHD-resistant K. pneumoniae DSM-30104 
mutants (Figure 3-10). 
In silico comparison of four CHD-resistant E. coli mutants (Mt30.1, Mt30.2, Mt30.4, 
Mt30.8) to wildtype E. coli DSM-1116 revealed the presence of an inconsistent mutation 
pattern within each mutant (Table 3-15) and no common genotype was observed. Moreover, 
the loss of the natural occurring 100kb plasmid (pRK1) in mutants Mt30.2 and Mt30.8 does 
not seem to rely on mechanisms of resistance towards CHD. The characterization of pRK1 
by Archer et al. revealed no resistance genes present on the plasmid and additionally, they 
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suggested pRK1 to be unstable.253,254 Even though no direct evidence pointing towards 
plasmid stability were stated, this might explain the loss of pRK1in Mt30.1 and Mt30.2. In 
summary, it was not possible to draw any conclusion on the major CHD resistance 
mechanism in E. coli but data hinted towards a combination of several physiological 
alterations that probably contributes to resistance of all four genome sequenced mutants. 
Bacteria are able to adapt towards antibiotic use via different resistance mechanisms. Those 
include the production of detoxifying enzymes which can lead to antibiotic degradation, 
increased efflux to export compounds or the alteration of the composition of the outer 
membrane to act as barrier for the influx of antibiotics.22,23 The latter two mechanisms are 
the most common pathways bacteria undergo to protect themselves. Increased efflux is 
carried out by overexpression of efflux systems through alteration of transcriptional or post-
transcriptional mechanisms which are involved in efflux pump regulation.255 Structural 
changes of the outer membrane are known to be mediated by altered porin profiles like the 
expression of different types of porins or by mutations leading to decreased expression of 
porins.23 Importantly, different resistance mechanisms are often carried out simultaneously 
like alteration of the outer membrane with a concurrent increased efflux.56 With regard to 
this, several mutations identified within CHD-resistant E. coli mutants can be correlated to 
general resistance mechanisms. In summary, major putative resistance factors identified 
within CHD-resistant E. coli mutants were increased efflux via AcrAB modification of 
porins and interestingly, some peptidoglycan modifying enzymes were found to be mutated 
(PhoQ, PBP4, PBP7). The latter supports the finding from MMS assays where an influence 
on cell wall biosynthesis was observed after treatment of S. carnosus with sub-lethal 
concentrations of CHD and CDCHD. Furthermore, co-/cross-resistance studies revealed the 
involvement of efflux systems and the outer membrane as barrier for antibiotic uptake. The 
increase of the permeability of the outer membrane by PMBN as well as the presence of the 
efflux pump inhibitor PAβN increased sensitivity of all E. coli mutants towards all tested 
antibiotics (Table 3-18). However, mutants Mt30.1 and Mt30.2 were still co-resistant to 
ciprofloxacin (CIP) in the presence of PMBN and without PAβN (permeabilized cells; efflux 
mechanisms unaffected). This can be correlated to the mutations identified within acrR and 
its putative operator region in these mutants (Table 3-15). acrR encodes the repressor (AcrR) 
of the AcrAB multidrug efflux system of E. coli spp. and mutations of acrR lead to a 
malfunction of AcrR as repressor, what in turn leads to a permanent expression of the efflux 
pump AcrB (encoded by acrB) and the efflux of CIP.192–194 PAβN represents an inhibitor of 
major efflux pumps that are involved in multidrug-resistance256, including the AcrAB-TolC 
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system of E. coli spp.. Thus, the increased efflux of CIP, which is based on the identified 
mutations of Mt30.1 and Mt30.2, is inhibited by PAβN, but still ongoing when only PMBN 
is present, as no efflux inhibition occurs. Regarding resistance mediated by the alteration of 
the outer membrane, Mt30.1 and Mt30.8 revealed mutations of genes involved in porin 
formation, ompF195–197 and envZ212,213, respectively. ompF encodes the outer membrane 
protein F (OmpF) which is a major component of the outer membrane and involved in 
transport systems of E. coli cells.195–197A loss of the OmpF or mutations within ompF are 
known to be involved in antibiotic resistance54,257 by structural changes of porins. Those 
changes hinder hydrophilic antibiotics to traverse the outer membrane. In this context, the 
mutation of envZ of Mt30.8 can also be linked to changes of porin levels within the 
membrane of bacterial cells. envZ encodes a senor histidine kinase (EnvZ) within the two-
component regulatory system with OmpR and enables the phosphorylation of OmpR what 
leads to the expression of the porins encoded by ompF and ompC.22,212,213 A loss in functional 
envZ might prevent the phosphorylation of OmpR, what hinders the enzyme to mediate 
further steps and leads in turn to a hampered porin expression. Mutations that might lead to 
modifications of the cell envelope were present within mutant Mt30.2 and Mt30.4. Mutant 
Mt30.4 yielded mutations within phoQ, a gene encoding the sensor histidine kinase PhoQ, 
which is part of a two component regulatory system together with the response regulator 
PhoP and is involved in the regulation of transcription.201,202 By interaction with metal ions 
(such as Mg2+), PhoQ autophosphorylates and leads to a transphosphorylation of PhoP. This 
enables PhoP to bind the DNA and triggers downstream events like the regulation of the 
PmrA-PmrB system which is involved in the modification of lipopolysaccharides 
(LPS).258,259 Mutations of phoQ were previously shown to be involved in antibiotic 
resistance which is mediated by altered LPS of Gram-negative bacteria.258–260 An altered 
lipid composition of the OM acts as a barrier to hydrophobic compounds which hinders the 
antibiotic to enter the cell through the lipid layer.56 Additionally, mutations in genes that are 
linked to the synthesis of the cell wall were present in mutant Mt30.2 and Mt30.4. The 
affected genes dacB (Mt30.4) and pbpG (Mt30.2) encode enzymes PBP4 and PBP7, 
respectively. Both enzymes depict periplasmic peptidoglycan (PG) hydrolases which are 
involved in hydrolysing peptide bridges of PG during cell growth.207,261 They contribute to 
the metabolism of the PG layer by hydrolysing polymers enabling the incorporation of 
subunits into the murein sacculus. Even though it seems obvious that mutations of these 
genes might contribute to resistance by an altered cell wall, previous studies described that 
a loss of either PBP4 or PBP7 did not contribute to cellular changes.262,263 This indicates that 
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the resistance mediated by mutant Mt30.2 and Mt30.4 rather relies on changes caused by the 
additional mutations that are present in both mutants (efflux; porin altering).  
Taking together the above summarized findings, resistance of CHD-resistant E. coli mutants 
relies on general mechanisms executed by the bacteria to protect against antibacterial 
compounds, but no CHD-specific resistance mechanism was identified.  
In order to gain further insights into CHD resistance mechanisms, a second in vitro resistance 
development with K. pneumoniae DSM-30104 was performed. The genomic comparison of 
CHD-resistant K. pneumoniae mutants to the wildtype strain (Table 3-20) revealed a repeat 
expansion of 7 bp in gpmA of Mt8.2 and Mt8.3, a gene encoding a phosphoglyceromutase 
(2,3-bisphosphoglycerate-dependent) which is involved in energy metabolism by catalysing 
the interconversion of 2-phosphoglycerate to 3-phosphoglycerate.264 Within Mt8.7 an amino 
acid transition from alanine to glutamine was found in a gene which encodes a permease of 
the branched-chain amino acid ABC transporter family.265 For all nine CHD-resistant K. 
pneumoniae DSM-301014 mutants, mutations in ramR were present. ramR encodes the TetR 
family transcriptional regulator RamR which is found within the ram locus (ramR-romA-
ramA). So far, the ram locus was described to be present in Klebsiella spp., Citrobacter spp., 
Enterobacter spp., and Salmonella spp., whereas the latter lacks the romA gene. The ramR 
gene was first described in Salmonella enterica and it was identified as repressor of ramA.266 
Its protein product RamA is a positive regulator of the AcrAB-TolC efflux system.255 This 
efflux system belongs to the resistance-nodulation-division (RND) family and pumps of this 
family are involved in intrinsic as well as acquired resistance of Gram-negative bacteria.267–
269 RND efflux pumps (AcrB in the present case) are located in the inner membrane and are 
associated with a periplasmic membrane fusion protein (MFP; AcrA in the present case) and 
with an outer membrane channel protein (OMF: outer membrane factor family of proteins; 
TolC in the present case; Figure 3-16).270,271 Among the RND family of efflux pumps, AcrB 
is a major, constitutively expressed pump and is involved in resistance towards compounds 
of multiple classes of antibiotics, including tetracyclines (incl. glycylcyclines such as 
tigecycline) or quinolones.268,272,273 The AcrAB-TolC efflux system is one of the best 
characterized efflux systems and is found in Enterobacteriaceae including K. pneumoniae 
and E. coli.255,256 Among other Gram-negative bacterial species, homologous of the AcrAB-
TolC efflux system are described, like the Mex systems (major systems: MexAB-OprM, 
MexCD-OprJ, MexEF-OprN, MexXY-OprM) present in Pseudomonas spp..255,274 RND 
family efflux pumps are regulated by global transcription factors as well as via local 
repression. In E. coli, Klebsiella spp. and Salmonella spp. the local repression of AcrAB-
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TolC is mediated by the regulatory gene acrR194,255 (encoding AcrR) as already mentioned 
in context with CHD-resistant E. coli. AcrR belongs to the TetR family of transcriptional 
regulators which control genes involved in metabolism or the production of antibiotics as 
well as in antibiotic resistance.275 
 
Figure 3-16: Schematic representation of the AcrAB-TolC efflux system. OMF: out membrane factor; MFP: membrane 
fusion protein; RND: resistance-nodulation-division; OM: outer membrane; PP: periplasm; IM; inner membrane; CP: 
cytoplasmic membrane. Adapted from Poole271 
 
Global transcriptional events in E. coli are regulated by the multiple antibiotic resistance 
(Mar) operon.255,276 The Mar operon consists of three genes: marR, marA and marB. The 
repressor protein of the Mar operon (MarR) is encoded by marR and constitutively expressed 
under normal conditions. Genomic changes mediated for instance by mutations of marR lead 
to an increase in the expression of the Mar operon. This leads to further downstream events 
such as the expression of marA. The global transcriptional activator MarA (encoded by 
marA) belongs to the AraC/XylS family of proteins, whose expressions lead to activation of 
genes involved in efflux, like acrAB and tolC.277,278 MIC determination of a marR-efflux-
deficient E. coli mutant compared to the respective E. coli wildtype illustrated the above 
described resistance mechanism mediated by mutations of marR. A decrease in activity for 
chelocardins as well as tigecycline due to the upregulation of the AcrAB pump were 















homologue of MarA, RamA is present.266 As already mentioned above, the expression of 
RamA is regulated by the repressor protein RamR and induces the activation of the AcrAB-
TolC efflux system (Figure 3-17). Studies in S. enterica and K. pneumoniae identified the 
binding site of the RamR protein in the upstream region of the romA-ramA locus (only ramA 
locus in Salmonella), where RamR binds to a palindromic conserved region that overlaps 
with the transcriptional starting site in the promoter region of romA-ramA (Figure 3-17, 
black box).279–281 Moreover, mutations in ramR were shown to be involved in resistance of 
clinical isolates of Salmonella spp. against ciprofloxacin and Klebsiella spp. against 
tigecycline.282,283 The identified mutations disabled RamR to bind to the ramA promoter 




Figure 3-17: Schematic representation of the genetic regulation by RamR. ramR encodes the repressor protein RamR 
whose expression leads to repression of romA-ramA. A repression of RamR leads to the expression of RamA, which induces 
the expression of acrAB, encoding the AcrAB efflux system. Inserted black box: upstream region of romA-ramA locus. 
Bold triplets indicate start codons of either ramR and romA genes and bold underlined bases indicate the palindromic 
binding site of RamR. Adapted from Majumdar et al.280 and Yamaski et al..284 
 
Determination of the expression levels of genes regulated by RamR/RamA (AcrAB efflux 
system) of CHD-resistant K. pneumoniae mutants revealed increased expression, compared 
to wildtype K. pneumoniae DSM-30104 genes (Table 3-22). Gene expression measured by 
qPCR revealed upregulation of ramA up to 41-fold with a concurrent upregulation of acrA 
and acrB up to 12- and 67-fold. A complete deletion of ramR in K. pneumonia led to 














the involvement of RamR and the AcrAB-TolC efflux pump in the resistance mechanism of 
CHD. Additionally, co-/cross-resistance studies in the presence of PAβN proved furthermore 
the involvement of efflux systems in resistance towards CHD (Table 3-23) and explained 
resistance of all mutants towards all other tested antibiotics including ciprofloxacin, 
chloramphenicol, tetracyclines and tigecycline (Table 3-19). Tigecycline depicts the first 
member of the glycylcyclines123,285, a family of semisynthetic derivatives of minocycline. It 
exhibits broad-spectrum antibacterial activity including inhibition of tetracycline-resistant 
pathogens124, comparable to chelocardins. In the context of resistance, several cases of 
resistance towards tigecycline in clinical isolates of K. pneumoniae were described and 
assigned to inactivation-mutations of ramR279,283,286, the same resistance mechanism as 
observed for CHD. Surprisingly, all mutants were more susceptible to polymyxin B 
treatment compared to the wildtype strain. Underlying mechanisms are not entirely clear, 
but the CHD-resistant phenotype of Klebsiella might involve some alterations of the 
bacterial membrane, which facilitate the interaction of polymyxins.287,288  
Importantly, CHD-resistant mutants as well as the ramR knockout mutant were not cross-
resistant to CDCHD. This result shows that resistance through mutations of ramR 
exclusively affects CHD but not CDCHD, which indicates – along with the fact that no 
CDCHD-resistant mutant could be generated in vitro – resistance-breaking properties for 
CDCHD. Taken together, the results from studies on chelocardin-related resistance 
mechanisms in Gram-negative species, qualifies CDCHD as a new early lead structure for 
further development of urgently needed broad-spectrum antibiotics. However, further 
scaffold improvements including studies to enhance better physicochemical and 
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3.3 SUMMARY AND OUTLOOK 
Chelocardin depicts a natural product produced by Amycolatopsis sulphurea with broad-
spectrum antibacterial activity including antibacterial activity against MDR pathogens. 
Previous bioengineering studies yielded the amidated analogue CDCHD, which exhibits 
improved antibacterial activities compared to the parent molecule CHD. Both compounds 
belong to the family of atypical tetracyclines and are able to overcome resistance 
mechanisms of tetracycline-resistant pathogens. The mode of action of CHD is 
controversially discussed, but previous studies hint towards a mechanism different to that of 
typical tetracyclines. In the course of this study, CHD and CDCHD along with several 
derivatives from semi-synthesis and bioengineering were profiled in terms of their in vitro 
antibacterial properties with the goal to identify a preferred molecule as starting point for 
preclinical development. Structure-activity relationships (SAR) of 30 derivatives bearing 
structural features from typical tetracyclines or substitutions/additions of several active 
groups were investigated. However, none of the so far generated derivatives showed an 
improved profile in terms of physicochemical properties (e.g. solubility) or antibacterial 
activities. Thus, further studies with the aim to elucidate CHD’s mechanism of action and 
associated resistance mechanisms were solely performed with the parent molecules CHD 
and CDCHD. The biological characterization revealed both compounds to be toxic on 
murine and human cell lines at low micromolar concentrations. However, in vitro 
cytotoxicity was rated to be negligible since chelocardins show a good tolerance in vivo. 
Both compounds revealed broad-spectrum activities against Gram-positive and Gram-
negative bacteria laboratory strains, including inhibition of clinical isolates and multidrug-
resistant pathogens. Throughout, CDCHD exhibited improved activities in comparison to 
CHD. Both molecules exert strong bactericidal (and bacteriolytic) effects as shown with 
some laboratory strains and clinical isolates of uropathogenic strains. This compound 
behaviour, in turn, hampered some of the cellular assays and CHD and CDCHD could 
mostly be assessed only at sub-inhibitory concentrations to avoid false-positive results due 
to rapid cell lysis. Thus, in standard MMS assays, CHD and CDCHD did not show a 
differential response in S. carnosus and none of the typical antibiotic mechanisms (inhibition 
of RNA, DNA, protein or cell wall synthesis) could be proven or ruled out. However, both 
compounds led to a concentration-dependent membrane depolarization, confirming the 
proposed membrane-associated mechanism. Even though no unambiguous insight into the 
mechanism of action of CHD could be gained, the assumption of a mode of action away 
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from protein synthesis inhibition and towards a cell membrane-based mechanism was 
consolidated. However, to completely understand the mechanism underlying chelocardin 
activity, more detailed studies in particular on cell wall activity need to be performed. 
Additionally, it was shown that CDCHD exerts a similar mechanism that is even more 
pronounced compared to CHD and importantly, CDCHD exhibits resistance-breaking 
properties. Compared to CHD, CDCHD is able to inhibit P. aeruginosa wildtype species 
and the generation of CDCHD-resistant mutants in vitro could not be achieved. Moreover, 
the resistance mechanism towards CHD, which was identified as increased efflux mediated 
by mutations of ramR, does not affect the activity of CDCHD. The amidated compound was 
still able to inhibit the growth of all CHD-resistant mutants bearing mutations or a loss of 
ramR.  
Even though the mechanism of action is still not completely understood CDCHD (and CHD) 
was progressed in the course of a DZIF-funded project to further development as an 
antibiotic with broad-spectrum antibacterial activity. Both chelocardins showed in vitro and 
in vivo potency against UTI pathogens. Interestingly, a discrepancy of the efficacies of CHD 
compared to CDCHD was observed when activity was determined against uropathogenic 
clinical isolates compared to laboratory strains. CHD was more potent against clinical strains 
whereas CDCHD showed improved activities against laboratory strains. However, due to an 
overall significantly more pronounced bactericidal activity of CDCHD compared to CHD, 
CDCHD appears to be the preferred scaffold. Nevertheless, further synthesis to improve 
pharmacological properties including bioavailability or increased solubility need to be 
performed. Additionally, to further develop the scaffold of chelocardins, in particular 
CDCHD and to obtain a lead molecule, it is crucial to identify the target molecule and to 
achieve a full characterization of the molecule.  
In summary, chelocardins depict a promising class of molecules with potent broad-spectrum 
antibacterial activity and they exhibit a mode of action different to typical tetracycline 
antibiotics Bioengineering yielded an improved derivative, CDCHD, which was shown to 
be more efficient with regards to in vivo efficacy and resistance-breaking properties. Thus, 
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4.1.1 MECHANISM OF ACTION 
4.1.1.1 DETERMINATION OF MINIMAL INHIBITORY CONCENTRATIONS 
Initially, the antibacterial activity of TM and two derivatives, TM-Dodec and TM-N-Oct 
(Figure 4-1), was evaluated against a panel of Gram-positive bacteria in EBS medium. 
Growth inhibition was assessed by visual inspection and MIC (minimal inhibitory 
concentration) values were determined as the lowest concentration of antibiotic at which no 
visible growth was observed. Against all tested bacteria, TM was 16- to 128-fold less active 
compared to the two semi-synthetic derivatives, which were active in the low µg/mL range 
(0.5-4 µg/mL, Table 4-1). A re-screen of the activity of all telomycins (TMs) against 
Staphyloccocus aureus str. Newman in medium containing various concentrations of CaCl2 
(0-50 mM) revealed a Ca2+-dependent increase of TM’s antibacterial activity. At Ca2+ 
concentrations around the physiological level of free calcium in blood (1.25 mM), an 8-fold 
improvement of activity was observed and at concentrations over 10 mM no further 
improvement was observed (Table 4-2). TM displayed an MIC of 2 µg/mL at highest Ca2+ 
concentrations (≥ 10 mM) and thus, was comparably active to the two semi-synthetic 
derivatives with MIC values of 2 and 0.5 µg/mL for TM-Dodec and TM-N-Oct, respectively. 
Interestingly, the addition of calcium ions had no effect on the activity of both derivatives.  
 




Table 4-1: MIC values of TM, TM-Dodec and TM-N-Oct against Gram-positive bacteria.  
Strain 
MIC [µg/mL] 
TM TM-Dodec TM-N-Oct 
Enterococcus faecium     
DSM-20477 16 2 1 
DSM-17050 8 2 0.5 
Staphylococcus aureus     
Newman 32 2 1 
N315[a] 32 2 1 
Mu50[b,c] > 64 4 1 
Streptococcus pneumoniae DSM-11865[d] 64 1 0.5 
[a]methicillin-resistant S. aureus (MRSA); [b]multidrug-resistant (MDR) S. aureus; [c]vancomycin-
intermediate S. aureus (VISA); [d]penicillin-resistant  
 
Table 4-2: MIC values of TM, TM-Dodec and TM-N-Oct against S. aureus Newman in the presence of various 
concentrations of CaCl2.  
Ca2+ [mM] 
MIC [µg/mL] 
TM TM-Dodec TM-N-Oct 
0 32 2 0.5 
0.1 16 2 0.5 
0.5 8 2 0.5 
1 4 2 0.5 
5 4 2 0.5 
10 2 2 0.5 
25 2 2 0.5 
50 2 2 0.5 
 
A follow-up screen of all TMs in the presence of 1.25 mM CaCl2 was performed against a 
panel of Gram-positive and Gram-negative bacteria and mycobacteria. All TMs were 
inactive against all tested Gram-negative bacteria, including a membrane permeabilized 
Escherichia coli TolC-efflux deficient strain (addition of polymyxin B nonapeptide as 
permeabilizer), indicating an intrinsic resistance pattern (Table 4-3). In contrast, all TMs 
display broad spectrum antibacterial activity against Gram-positive bacteria, except for 
Mycobacterium smegmatis and Nocardia asteroides, which were not susceptible. In contrast, 
slow-growing mycobacteria (M. tuberculosis, M. bovis) are susceptible. On average, TM 
was 2- to 8-fold less potent compared to the semi-synthetic derivatives and by tendency, 
TM-N-Oct was slightly more active than TM-Dodec, in particular on Staphylococci. 
Interestingly, TM was virtually inactive on two resistant S. aureus strains, S. aureus DSM-
11822 (MDR) and S. aureus Mu50 (VISA/MRSA). A comparison of the activity of all TMs 
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to daptomycin (DAP) revealed TMs to be as potent as daptomycin and activity spectra are 
overlapping. 
Table 4-3: MIC values of TM, TM-Dodec, TM-N-Oct and DAP against Gram-positive and Gram-negative bacteria in the 
presence of 1.25 mM CaCl2.  
Classification Strain 
MIC [µg/ml] 
TM TM-Dodec TM-N-Oct DAP 
Gram-negative 
Acinetobacter baumannii DSM-30008 > 64 > 64 > 64 > 64 
Burkholderia cenocepacia DSM-16553 > 64 > 64 > 64 > 64 
Citrobacter freundii DSM-30039 > 64 > 64 > 64 > 64 
Enterobacter aerogenes DSM-30053 > 64 > 64 > 64 > 64 
Escherichia coli      
DSM-1116 > 64 > 64 > 64 > 64 
ATCC-25922 > 64 > 64 > 64 > 64 
TolC (+ PMBN) > 64 > 64 > 64 > 64 
Klebsiella pneumoniae DSM-30104 > 64 > 64 > 64 > 64 
Pseudomonas aeruginosa      
PA14 > 64 > 64 > 64 > 64 
DSM-24599 > 64 > 64 > 64 > 64 
Proteus vulgaris DSM-2140 > 64 > 64 > 64 > 64 
Serratia marcescens DSM-30121 > 64 > 64 > 64 > 64 
Gram-positive 
Bacillus subtilis DSM-10 2 1 0.5 0.5 
Bacillus megaterium DSM-32 0.25 1 0.25 1 
Corynebacterium glutamicum DSM-20300 0.5 1 0.5 0.5 
Enterococcus faecalis DSM-20478 16 8 8 4 
Enterococcus faecium DSM-20477 32 8 4 16 
Streptococcus pneumoniae DSM-11865 4 1 1 0.25 
Micrococcus luteus      
DSM-1790 0.25 1 0.25 0.25 
DSM-20030 0.25 1 0.25 ≤ 0.03 
Mycobacterium smegmatis mc2155 > 64 > 64 64 > 64 
Mycobacterium bovis BCG DSM-43990 4-8 32 4-8  
Mycobacterium tuberculosis H37RvMA 3.8 7.2 2.7  
Nocardia asteroides DSM-43757 64 64 64 > 64 
Staphylococcus epidermidis DSM-28765 1 2 0.5 1 
Staphylococcus carnosus DSM-20501 1 1 0.5 0.25 
Staphylococcus aureus      
DSM-346 1 1 1 0.5-1 
DSM-11822[a] > 64 8 4 1 
ATCC-29213 32 4 4 1 
Cowan1 2-4 1 1 1 
Newman 2 2 1 1 
N315[b] 2 2 1 1 
Mu50[a,c] 64 8 4 4 
DAP: daptomycin. PMBN: polymyxin B nonapeptide. [a]multidrug-resistant (MDR) S. aureus; [b]methicillin-resistant S. aureus 
(MRSA); [c]vancomycin-intermediate S. aureus (VISA) 
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Screening of TMs against clinical isolates (n=98) of Staphylococcus aureus confirmed the 
potency of both derivatives (Table 4-4). MIC50 and MIC90 values demonstrated superior 
activity of TM-Dodec and TM-N-Oct compared to TM. For TM, a MIC50 value of 8µg/mL 
and MIC90 value of 64 µg/mL was determined, whereas TM-Dodec and TM-N-Oct showed 
8-fold and 32-fold lower MIC50 and MIC90 values, respectively (MIC50: 1 µg/mL; 
MIC90: 2µg/mL). 
Table 4-4: MIC50 and MIC90 values of TM, TM-Dodec and TM-N-Oct against S. aureus isolates.  
Compound n = 
Number of S. aureus isolates inhibited by the indicated concentration (MIC in µg/mL) MIC50 MIC90 
≤ 0.03 0.03 0.06 0.13 0.25 0.5 1 2 4 8 16 32 64 > 64   
TM 98[a]       2 12 13 23 16 18 12 2 8 64 
TM-Dodec 98[a]      17 44 32 5      1 2 
TM-N-Oct 98[a]    1 8 22 39 26 2      1 2 
[a]90 clinical isolates, 8 laboratory strains. 
 
4.1.1.2 KILLING OF INTRACELLULAR BACTERIA 
To examine the intracellular killing effect of TMs, murine macrophages (RAW264.7 cell 
line) were infected with Staphyloccocus aureus N315 at a multiplicity of infection (MOI) of 
10 and killing of intracellular bacteria was determined by CFU count after 18 h of treatment 
with 1- and 4-fold MIC of TMs (Figure 4-2). At 1-fold MIC of TM, only a slight killing of 
intracellular Staphylococcus was achieved (approx. 0.5-log10 reduction) but an increase to 4-
MIC led to 2-log10 reduction of bacterial load. TM-N-Oct and TM-Dodec were already able 
to reduce bacterial concentration up to 2-log10 at 1-fold MIC and increasing concentrations 




Figure 4-2: Killing of intracellular Staphyloccocus aureus by TM (MIC: 2 µg/mL), TM-Dodec (MIC: 2 µg/mL) and TM-
N-Oct (MIC: 1 µg/mL). Murine macrophages (RAW264.7) were infected with S. aureus N315 and treated with TMs for 
18 h at 1- and 4-fold MIC. Intracellular bacterial concentrations were determined by three independent CFU counts. Data 
represent mean ± standard deviation (SD). 
 
4.1.1.3 CALCIUM-DEPENDENT MEMBRANE DEPOLARIZATION 
Due to TM‘s similarity to the lipopeptide antibiotic daptomycin in terms of calcium-
dependency and antibacterial spectrum, the influence on the membrane potential (MP) of S. 
carnosus was assessed after treatment with TM in the presence of increasing concentrations 
of Ca2+ by using the BacLight™ Bacterial Membrane Potential Kit (Invitrogen). S. carnosus 
DSM-20501 was exposed to 5-fold MIC of TM in the presence of 0-10 mM CaCl2 and MP 
was measured after 2.5 h of treatment. In order to determine the relative MP, samples were 
stained with the cyanine dye 3,3‘-diethyloxacarbocyanin iodide (DiOC2(3)) for 30 min and 
fluorescence was measured using a microplate reader [excitation.: 488 nm; emission: 675 
nm (green), 525 nm (red)]. In cells with intact MP, an intracellular accumulation of DiOC2(3) 
is observed and the emission maximum turns towards red. A collapse of the MP leads to a 
decrease of the intracellular dye concentration and the emission maximum shifts towards 
green fluorescence. Relative MP was calculated as the ratio of red to green fluorescence and 
the value of untreated control cells was set to 100 %. The proton ionophore carbonyl cyanide 
3- chlorophenylhydrazone (CCCP) served as positive control185,186. As expected, the effect 
of membrane depolarization increased proportional to the concentration of CaCl2 along with 
improved antibacterial activity of TM in the presence of Ca2+ at concentrations higher than 




























0.5 mM (MIC in one-digit µg/mL range). A drop of MP to less than 20 % was observed 
when calcium was present at concentrations ≥ 0.25 mM (Figure 4-3), indicating a membrane 
associated mechanism of action of TM in the presence of calcium. The results are also in 
accordance with previously determined MIC values. 
 
Figure 4-3: Membrane depolarization of S. carnosus DSM-20501 caused by TM (MIC: 1 µg/mL) in a Ca2+-dependent 
manner (c = 0-10 mM). Cells were treated with TM at 5-fold MIC in the presence of 0-10 mM CaCl2 for 2.5 h. CCCP 
(15 µM) served as positive control. Results show membrane potential (MP) relative to untreated cells. Positive control 
CCCP: carbonyl cyanide 3- chlorophenylhydrazone. 
 
4.1.1.4 CALCIUM-DEPENDENT CONFORMATIONAL CHANGES 
Potential conformational changes upon calcium addition were analysed by proton (1H) 
NMR. The interaction of TMs with Ca2+ was studied in the presence of increasing amounts 
of a 0.1 M CaCl2 solution. Broadening of some proton signals (Figure 4-4 A-C, black boxes), 
which was observed in a Ca2+-concentration-dependent manner, indicating binding of Ca2+ 
to TM, TM-Dodec and TM-N-Oct. The more Ca2+ ions were present, the broader the 
recorded signal was. This effect was slightly more pronounced in the case of TM compared 
to the two semi-synthetic derivatives. In addition, preliminary 2D ROESY NMR data (not 
shown) indicated potential conformational changes of TM upon the addition of calcium 
which seemed to affect mostly amino acids 3Thr, 4Thr, 2Ser and iso-1Asp (Figure 4-4 D). 
This was not observed for TM-Dodec and TM-N-Oct. Additionally, the interaction of TM 
with other metal ions was tested and monovalent ions did not show any effect even at high 
concentrations, whereas Cu2+ showed the most pronounced effect, followed by Ba2+ and Ca2+ 
(Figure 4-5, Table 4-5). In terms of biological activity, calcium ions had a major effect when 
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to TM resulted in only minor effects on NMR spectra, which is in accordance to the results 
from MIC testing (Table 1.6), where the antibacterial effect of TM did not improve at 
physiological concentration of Mg2+ (0.8 mM). Ba2+ and Cu2+ could not be used for activity 
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Figure 4-4: 1H-NMR studies on the interaction of TM (A), TM-Dodec (B) and TM-N-Oct (C) with increasing amounts of 
CaCl2 (0.1 M). NMR shifts pointing towards binding of TMs to Ca2+ (broadening of some signals; black boxes). The 
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Figure 4-5: 1H-NMR structural studies on TM and its interaction with various monovalent and divalent metal ions. NMR 
shifts pointing towards binding of TM to the respective ions (broadening of some signals upon addition of CuCl2, BaCl2, 
and NiCl2; black boxes). 
 
Table 4-5: Interaction (signal broadening in 1H NMR spectra) of monovalent and divalent ions with TM. -: no binding; 
+: binding (the more +, the stronger the effect). 










Table 4-6: Influence of Ca2+ and Mg2+ on biological activity of TM in MHB medium (contains 0.4 mM Mg2+ and 0.25 mM 
Ca2+). Bold values: adjusted to physiological concentration. 
c(Mg2+/Ca2+) 
[mM] 







































4.1.2 RESISTANCE MECHANISM AND BINDING TO CARDIOLIPIN 
4.1.2.1 GENERATION OF TELOMYCIN-RESISTANT MUTANTS 
Wildtype S. aureus Newman was exposed to stepwise increasing concentrations of either 
TM (8, 30, 50, 100 µg/mL) or TM-Dodec (10, 20, 50, 100 µg/mL) in the presence of either 
10 or 0.25 mM CaCl2, respectively. This yielded seven independent TM-resistant mutants 
(Mt-T.1, Mt-T.3, Mt-T.4, Mt-T.6, Mt-T.7, Mt-T.8, Mt-T.9) and nine independent TM-
Dodec-resistant mutants (Mt-D.1, Mt-D.3, Mt-D.4, Mt-D.5, Mt-D.6, Mt-D.7, Mt-D.8, Mt-
D.9, Mt-D.10). All mutants finally grew at a concentration of 100 µg/mL TM and TM-
Dodec, respectively, without any obvious fitness cost. The frequency of developing 
S. aureus Newman resistant mutants was determined by exposing the wildtype strain to 4-
foldMIC of the respective compound at a final cell concentration of 107 (TM) or 108 (TM-
Dodec) CFU/plate. S. aureus Newman resistant mutants developed at frequencies of 4 x 10-
6 for TM and 8.5 x 10-9 for TM-Dodec. 
The resistance phenotype of all TM-resistant mutants was confirmed 
(MIC of TM > 64 µg/mL). However, these mutant strains were still susceptible towards 
TM-Dodec, TM-N-Oct and DAP with a maximum two-fold MIC shift (Table 4-7). 
Resistance of TM-Dodec-resistant mutants towards TM-Dodec was also confirmed by MIC 
determination and interestingly, all nine mutants showed additionally cross-resistance with 
TM and TM-N-Oct but not with DAP (Table 4-8). TM- and TM-Dodec-resistant mutants 
displayed no co-resistance with reference antibiotics, indicating that TMs may have a new 
antibacterial target and probably exhibit a novel mechanism of action that differs from that 




Table 4-7: Resistance pattern of S. aureus Newman TM-resistant mutants. Wt: S. aureus Newman. 
Antibiotic compound 
MIC [µg/mL] 
Wt Mt-T.1 Mt-T.3 Mt-T.4 Mt-T.6 Mt-T.7 Mt-T.8 Mt-T.9 
TM 4 > 64 > 64 > 64 > 64 > 64 > 64 > 64 
TM-Dodec 2 4 4 4 4 4 4 4 
TM-N-Oct 2 2 4 4 2 2 2 2 
Daptomycin 1 1 0.5 1 1 1 1 1 
Vancomycin 1 2 2 1 0.5 1 2 2 
Ciprofloxacin 0.125 0.125 0.125 0.06 0.125 0.125 0.125 0.125 
Erythromycin 0.5 0.25 0.125 0.125 0.25 0.25 0.25 0.25 
Kanamycin 2 4 2 2 2 4 4 4 
Ampicillin 1 1 0.5 1 1 1 1 2 
Tetracycline 1 0.06 0.25 1 0.5 1 0.5 0.5 
Rifampicin ≤ 0.03 ≤ 0.03 ≤ 0.03 ≤ 0.03 ≤ 0.03 ≤0.03 ≤ 0.03 ≤ 0.03 
Polymyxin B > 64 64 > 64 64 64 64 64 64 
Chloramphenicol 2 2 4 4 2 4 4 2 
 




Wt Mt-D.1 Mt-D.3 Mt-D.4 Mt-D.5 Mt-D.6 Mt-D.7 Mt-D.8 Mt-D.9 Mt-D.10 
TM 4 > 64 > 64 > 64 > 64 > 64 > 64 > 64 > 64 > 64 
TM-Dodec 2 32 32 32 > 64 32 8 > 64 32 64 
TM-N-Oct 2 16 16 16 16 16 > 64 16 16 32 
Daptomycin 1 0.5 2 0.5 0.5 1 2 1 0.5 0.5 
Vancomycin 1 2 1 2 4 4 2 1 4 4 
Ciprofloxacin 0.125 0.25 0.25 0.25 0.06 0.125 0.03 0.25 0.25 0.25 
Erythromycin 0.5 0.5 0.25 0.5 0.25 0.5 0.25 0.5 0.5 0.25 
Kanamycin 2 2 4 4 4 4 2 4 2 4 
Ampicillin 1 0.5 0.5 0.5 0.5 1 1 1 1 1 
Tetracycline 1 1 1 1 1 ≤ 0.03 1 1 2 1 
Rifampicin ≤ 0.03 ≤0.03 ≤ 0.03 ≤ 0.03 ≤ 0.03 ≤ 0.03 ≤ 0.03 ≤ 0.03 ≤ 0.03 ≤ 0.03 
Polymyxin B > 64 64 > 64 > 64 64 > 64 64 64 > 64 > 64 





4.1.2.2 GENOME SEQUENCING AND ANALYSIS OF MUTATIONS 
To further investigate the mechanisms underlying resistance towards TMs, genomic DNA 
of all TM- and TM-Dodec-resistant mutants, as well as from wildtype S. aureus Newman 
was prepared by standard phenol-chloroform extraction and samples were sequenced 
(Illumina). Sequencing reads based on Illumina technology were mapped to the published 
reference genome (accession number NC_009641). An alignment of the wildtype genome 
to the mutant genomes revealed several single-nucleotide polymorphisms (SNPs) and 
deletions to be present within all mutants. All TM-resistant mutants contained mutations 
within cls2 gene (NWMN_1992), identified as base pair deletions (Mt-T.1, Mt-T.6) or SNPs 
(Mt-T.3, Mt-T.4, Mt-T.7, Mt-T.8, Mt-T.9) leading to the formation of an in frame stop codon 
in MT-T.4, MT-T.7, MT-T.8 and MT-T.9. In addition, SNPs within a gene encoding for a 
diacylglycerol kinase (NWMN_1836) were present in Mt.T-1, Mt-T.4, Mt-T.7, Mt-T.8 an 
Mt-T.9 (Table 4-9). Additionally, inconsistent mutations were identified in the genomes of 
Mt-T.3 (NWNM_1272), Mt-T.7 (NWNM_1591) and Mt-T.9 (NWNM_0285/1344/2133), 
whereas Mt-T.9 was the most affected with three additional mutated genes. Interestingly, all 
TM-Dodec-resistant mutants contained SNPs (Mt-D.1, Mt-D.3, Mt-D.4, Mt-D.8, Mt-D.10) 
or base pair deletions (Mt-D.5, Mt-D.6, Mt-D.7, Mt-D.9) within the same cls2 gene 
(NWMN_1992) as identified for TM-resistant mutants. SNPs found within cls2 of MT-D.1 
and MT-D.3 led to a stop codon, whereas all other SNPs were identified as base pair 
deletions (MT.D-5, MT-D.6, MT-D.7, MT-D.9) or missense point mutations (MT-D.4, MT-
D.8, MT-D.10). Additionally, in all TM-Dodec-resistant mutants deletions (Mt-D.3, Mt-
D.10) or SNPs (Mt-D.1, Mt-D.4, Mt-D.5, Mt-D.6, Mt-D.7, Mt-D.8, Mt-D.9) were present 
within the gene pmtR encoding the GntR family regulator PmtR (NWMN_1870, Table 
4-11). For seven TM-Dodec-resistant mutants (MT.D-1, MT-D.4, MT-D.4, MT-D.6, MT-
D.7, MT-D.8, MT-D.9) which bear a mutation within the gene encoding PmtR, the same 
amino acid was affected and the mutation led to a premature stop codon. Besides these 
commonly found genetic changes, serval inconsistent mutations in other genes were present 
within eight TM-Dodec-resistant mutants, identified as SNPs (Mt-D.1, Mt-D.3, Mt-D.4, Mt-
D.5, Mt-D.6, Mt-D.8, Mt-D.9), deletions (Mt-D.4) or insertions (Mt-D.7, Mt-D.8).  
As all TM-resistant mutants (TM-/TM-Dodec-resistant) had mutations of cls2 in common, 
its gene product seems to play an important role to mediate resistance against TMs. Due to 
this overlap, further steps to characterize resistance to TMs focused on the function of the 
cls2 gene. However, data indicated that further genetic changes are needed to gain higher 
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resistance towards acylated TM derivatives (mutations of PmtR found in all TM-Dodec 
resistant mutants). 
 
Table 4-9: Mutations identified in TM-resistant S. aureus Newman mutants. Amino acids are denoted by three letter code. 
Locus Gene product and function 
Mutation (amino acid position is given in brackets, WTmutant) 
Mt-T.1 Mt-T.3 Mt-T.4 Mt-T.6 Mt-T.7 Mt-T.8 Mt-T.9 





domain MprF: involved in 





     
NWMN_1344 
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IS1272289,290 


































NWMN_2133 50S ribosomal protein L15       
AspVal  
(137) 





Table 4-10: Mutations identified in TM-Dodec-resistant S. aureus Newman mutants. Amino acids are denoted by three 
letter code. 
Locus Gene product and function 
Mutation (amino acid position is given in brackets, WTmutant) 




involved in the conversion of 











SaeS: two-component sensor 

















    
ProSer 
(57) 
    
NWMN_1120 
guanylate kinase: catalyses 
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(241) 
     




Ins: insertion; ∆: deletion; bp: base pair 
 
4.1.2.3 S. AUREUS CLS1 AND CLS2 DISRUPTION MUTANTS 
The cls2 gene of S. aureus encodes for the main cardiolipin synthase and an alternative 
enzyme is encoded by the cls1 gene. However, the latter one was not mutated in any of the 
TM- and TM-Dodec-resistant strains. To examine the effects of a loss in function of cls1 
and cls2 towards susceptibility of S. aureus Newman against TMs and on cellular levels of 
cardiolipin, S. aureus disruptions strains of both genes were generated through gene 
disruption by intron insertions by using TargeTron®-Gene-Knockout-System Kit (Sigma 
Aldrich). MIC values confirmed that only an inactivation of cls2 led to a decrease in activity 
against all TMs, with a significantly more pronounced effect on TM activity 
(MIC > 64 µg/mL; Table 4-11). Semi-synthetic derivatives were only 4- to 8-fold less active 
on the cls2 mutant strain and the activity of DAP was not affected. A disruption of cls1 had 
no effect on the sensitivity of S. aureus Newman towards TM, TM-Dodec and TM-N-Oct 
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and against DAP, compared to the wildtype. In addition, the disruption of cls1 and cls2 had 
no influence on the fitness of mutants, reflected in a similar growth behaviour as observed 
for S. aureus Newman wildtype (Figure 4-6). 
 
Table 4-11: MIC values of TM, TM-Dodec, TM-N-Oct and DAP on S. aureus Newman wildtype compared to mutants 
with disruption within cls1 and cls2. 
S. aureus Newman 
MIC [µg/ml] 
TM TM-Dodec TM-N-Oct DAP 
Wildtype 1 0.5 0.5 0.5 
disrupted cls2 > 64 4 2 0.25 




Figure 4-6: Growth curves of S. aureus Newman wildtype and cls1 and cls2 disruption mutant over 24 h. Data represent 
OD600 values of each time point. 
 
The presence of phospholipids within S. aureus Newman wildtype and cls disrupted mutants 
was analysed by thin-layer chromatography (TLC). Lipids were extracted with a mixture of 
chloroform-MeOH-H2O (2:2:1; v/v/v), applied to silica TLC plates and developed with 
chloroform-hexane-MeOH-acetic acid (50:30:10:5; v/v/v/v). Plates were sprayed with 
CuSO4 and heated to detect lipids. For S. aureus Newman wildtype and cls1 disrupted 
mutant, all common lipid species (CL: cardiolipin; PG: phosphatidylglycerol; PE: 
phosphatidylethanolamine; LPG: lysyl-phosphatidylglycerol) were detected, whereas the 




















inactivation of cls2 led to a loss of CL (Figure 4-7) with a concurrent increase of PG 
compared to wildtype and cls1 mutant. 
 
Figure 4-7: Composition of phospholipids of S. aureus Newman wildtype and cls1 and cls2 disrupted mutants. 
Wt: wildtype; cls1: cls1 disrupted mutant; cls2: cls2 disrupted mutant; CL: cardiolipin; PG: phosphatidylglycerol; 
PE: phosphatidylethanolamine; LPG: lysyl-phosphatidylglycerol. 
 
As the alternative cardiolipin synthase 1 (Cls1) is able to compensate the loss of functional 
Cls2 under conditions of osmotic or pH stress292,293, it was investigated whether the cls2 
disrupted mutant regains susceptibility towards TM under stress conditions. S. aureus 
Newman wildtype and cls2 disrupted mutant were incubated under osmotic stress 
(4 M NaCl), low pH (pH 2, pH 4) and normal (PBS buffer) growth conditions for 60 min, 
followed by lipid extraction and MIC determination. All tested stress conditions had no 
major influence on the susceptibility of S. aureus Newman wildtype towards TM, TM-
Dodec and TM-N-Oct (Table 4-12). However, low pH stress (pH 2) led to a slight 
improvement of activity of TM, as MIC values dropped from > 64 to 32 µg/mL. Against 
DAP, wildtype and mutant showed 16- and 8-fold increased susceptibility, respectively, 
under pH 2 stress conditions. The other stress-inducing conditions (4 M NaCl; pH 4) did not 
or only marginally influence the susceptibility towards DAP. To analyse the presence of CL 
in S. aureus Newman wildtype and cls2 disrupted mutant under stress, lipids were extracted 
and analysed by LC-MS. Only trace amounts of CL were detected (partly below limit of 
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Control  
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Control (PBS) 4 4 2 1 > 64 8 4 1 
4 M NaCl 8 4 1 0.5 > 64 8 4 1 
pH 2 4 4 1 0.0625 32 8 4 0.125 
pH 4 8 8 2 1 > 64 8 4 0.5 
 
4.1.2.4 FITNESS OF MUTANTS AND BIOFILM FORMATION 
TM-resistant mutants bearing disruptions mutations in cls2 showed a similar growth 
behaviour as wildtype S. aureus Newman (Figure 4-8 A) but some grew slightly slower, 
particularly in early exponential phase (Figure 4-8 A inserted diagram). However, this 
slightly reduced growth profile cannot be linked to any common genotype of the mutants. 
Mutants generated under exposure of TM-Dodec (mutations in cls2 and pmtR) showed a 
retarded growth compared to the wildtype (Figure 4-8 B) indicating a significant fitness loss 
due to the additional mutations in the gene encoding the GntR-type transcriptional regulator 
PmtR. However, final cell densities of mutants were comparable to the bacterial cell number 
in wildtype culture (24 h cultivation). 
 
4.1.2.5 IMPACT OF MUTATED GNTR-TYPE REGULATOR ON S. AUREUS 
BIOFILM 
The gene that was additionally affected by mutations within TM-Dodec-resistant mutants 
was characterized to encode the GntR-type regulator PmtR.294 Since its gene product is 
involved in the regulation of an export system for toxins and the presence of toxins is 
furthermore related to influence biofilm formation294,295 (structuring and detachment), the 
impact on biofilm formation of TM-Dodec-resistant mutations was investigated. Compared 
to wildtype S. aureus Newman, an impaired biofilm formation for TM-Dodec-resistant 
mutants was observed (Figure 4-9). The biofilm formation was measured after 24 and 48 h 
by staining with crystal violet and determination of the optical density at 450 nm. Compared 
to S. aureus Newman wildtype, all mutants revealed a decreased biofilm formation after 24 h 
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and 48 h. In contrast to the wildtype, no further increase of biofilm formation after the initial 
24 h incubation period was observed. For some mutants (Mt-D.4, Mt-D.6) biofilm mass even 
decreased after prolonged incubation.  
 
Figure 4-8: A) Growth curves of S. aureus Newman wildtype and TM-resistant mutants (Mt-T) over 24 h. Inserted 
diagram: growth over 8 h (early exponential phase). B) Growth curves of S. aureus Newman wildtype and TM-Dodec-
resistant mutants (Mt-D) over 24 h. Data represent OD600 values of each time point. 
 
 































































Figure 4-9: Biofilm formation of TM-Dodec-resistant S. aureus mutants (Mt-D.) in comparison to wildtype (Wt) S. aureus 
Newman monitored over 24 and 48 h. Data are represented as mean ± standard deviation (SD). 
 
4.1.2.6 BINDING OF TELOMYCINS TO CARDIOLIPIN 
Direct Binding Assay 
Two semi-synthetic alkyne-coupled TM derivatives, bearing a pentynoic acid (TM-pentyne) 
or an undecynoic acid group (TM-decyne, mimicking TM-Dodec; Figure 4-10) were 
synthetized to characterize the binding of TM to membrane lipids and lipoteichoic acid 
(LTA). Both derivatives were determined to exhibit antibacterial activities against Gram-
positive bacteria in low µg/mL ranges comparable to the parent molecule TM (Table 4-13). 
Several lipid species (PE: phosphatidylethanolamine, PC: phosphatidylcholine, PG: 
phosphatidylglycerol, CL: cardiolipin, LPG: lysyl-phosphatidylglycerol) and LTA coated to 
surface treated 96-well plates (Nunc Polysorp; lipids: 128 pmol/well: LTA: 128ng/well) and 
incubated with alkyne-coupled TM derivatives at a final concentration of 0.7 µM/well. A 
click reaction was performed with biotin-azide and subsequent incubation with streptavidin-
coupled horseradish peroxidase (HRP), revealed lipid binding partners of the two tool 
compounds in a colorimetric reaction using 1x TMB ELISA substrate solution 
(eBiosciences) as the substrate for HRP. Binding was exclusively observed for CL; all other 
lipid species as well as LTA showed no interaction with TM (Figure 4-11). As TM exerts a 
calcium-dependent mechanism, the binding of TM-pentyne to different amounts of CL (4-
128 pmol/well) was assessed in the same assay in the presence of 10 mM CaCl2. As expected, 




















concentration (Figure 4-12). Additionally, binding was clearly dependent on the amount of 
coupled CL with a maximum binding capacity in the presence of 64 pmol CL per well. 
Interestingly, no binding to CL was observed under calcium-depleted conditions, which were 
simulated by the addition of 10 mM of the strong chelating agent ethylenediaminetetraacetic 
acid (EDTA). 
  
Figure 4-10: Chemical structure of semi-synthetic alkyne-coupled TM derivatives. 
 
 
Table 4-13: MIC values of TM and alkyne coupled TM-derivatives on Gram-positive bacteria. 
Indicator strain 
MIC [µg/ml] 
TM TM-pentyne TM-decyne 
S. aureus Newman 2 2 4 
B. subtilis DSM-10 2 2 1 








Figure 4-11: Relative binding affinity of TM to membrane lipids and LTA. Lipids and LTA were coated to surface treated 
96-well plates (lipids: 128 pmol/well: LTA: 128ng/well) and incubated with alkyne-modified TM derivatives. After 
clicking to biotin-azide and incubation with streptavidin-coupled HRP, lipid binding partners of TM were analysed in a 
colorimetric reaction by measuring OD at 450nm. Data represent mean ± SEM. PE: phosphatidylethanolamine; PC: 




Figure 4-12: Binding affinity of TM-pentyne to CL in the presence of CaCl2 and varying amounts of chip-coupled CL. 
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To localize TMs within or attached to Gram-positive cells, fluorescein- (-F) and rhodamine 
(-R) coupled TM (TM-F/R), TM-Dodec (TM-Dodec-R) and TM-N-Oct (TM-N-Oct-F/R) 
were prepared via the established semi-synthesis route. The fluorophore-tagged derivatives 
were less active than the respective parent compounds and displayed MIC values in the low 
to mid µg/mL range, whereas TM-Dodec-R and TM-F were virtually inactive (Table 4-14, 
Table 4-15). Bacillus megaterium was chosen as BSL1 model organism and was initially 
incubated with 50 µM of the respective fluorophore-tagged TM derivative and 50 µM 
fluorescein or rhodamine (control) for 30 min. Imaging of live cells revealed an 
accumulation of all TMs at septa and poles of treated cells (Figure 4-13 A,B). Both negative 
controls (fluorescein, rhodamine) showed an unspecific distribution within the cells. 
Incubation of S. aureus SG511 with 10 µg/mL of either TM-R or TM-N-Oct-R led to the 
same results, as an accumulation within septa and poles of both TMs was observed (Figure 
4-13 C). To confirm the presence of CL within these regions, B. megaterium was treated 
with fluorescein-labelled TMs and co-incubated with acridine orange 10-nonyl bromide 
(NAO), a red fluorescent indicator for CL in membranes and bilayers296. Accumulation of 
telomycin was observed again at septa and poles of the cells and the co-incubation with NAO 
further confirms that TMs preferentially localize in CL-rich compartments (complete 
overlap of TM and NAO fluorescence).  




TM TM-F TM-N-Oct TM-N-Oct-F 
B. megaterium DSM-32 0.25 32 0.25 2 
S. aureus Newman 2 > 64 1 4 
 










B. subtilis DSM- 10 2 4 1 64 0.5 2 
B. megaterium DSM-32 0.25 2 1 64 0.25 0.5 





Figure 4-13: Localization of TM, TM-Dodec and TM-N-Oct within in Gram-positive cells (indicated by arrows). A/B) B. 
megaterium DSM-32 was incubated for 30 min with 50 µM fluorescein- (-F) or rhodamine (-R) labelled TM (TM-F/R), 
TM-Dodec (TM-Dodec-F/R) TM-N-Oct (TM-N-Oct-F/R) and 50 µM fluorescein/rhodamine as control. C) S. aureus 
SG511 was incubated with 10 µg/mL rhodamine-labelled TM (TM-R) and TM-N-Oct (TM-N-Oct-R).  
 
 
Figure 4-14: Localization of fluorophore-tagged TMs in CL-rich (NAO stained) regions of Gram-positive cells (indicated 
by arrows). B. megaterium DSM-32 was incubated with 50 µM fluorescein-labelled TM (TM-F) or TM-N-Oct (TM-N-











4.1.3  PROTEIN TARGET IDENTIFICATION 
Although CL was found to be a binding partner of TMs, it seemed likely that additional 
targets for TMs exist. Thereof, a protein pull down experiment was performed to identify 
potential binding partners of TMs. Proteins were isolated from Bacillus subtilis DSM-10, 
incubated for 2 h with biotin-tagged TM (TM-b) or TM-N-Oct (TM-N-Oct-b), and 
streptavidin-captured proteins were separated by SDS-PAGE. Proteins that were only 
present within samples incubated with TM-b or TM-N-Oct-b or appeared to be enriched in 
the presence of biotin-tagged TMs were regarded as potential binding partners (Figure 4-15, 
protein bands A-E). Generally, all tested conditions (50 µg TM-b, 50 µg TM-N-Oct-b, 200 
µg TM-N-Oct-b) led to the same protein band pattern on the SDS gel. Only bands B and C 
(Figure 4-15) were not present in the TM-b incubated samples. As proteins “fished” from 
B. subtilis lysate in the presence of 200 µg TM-N-Oct-b showed the highest intensity, only 
those proteins were selected for further analysis by mass spectrometry (Figure 4-15 A black 
box). Trypsin digested proteins were analysed by matrix-assisted laser desorption ionization-
time of flight mass spectrometry (MALDI-TOF/MS) or liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) and identified by searching against a protein database 
(UniProtKB/Swiss-Prot) on a MASCOT server. Proteins were identified as αβ-subunit of 
ATP synthase, a putative lipoprotein YcdA, subunit II (QoxA) of the quinol oxidase, and 
flagellin (Figure 4-15 B). As binding of TMs to flagellin is unlikely to be an antibiotic 
mechanism of action (as depicted in chapter 4.2.3), the binding to flagellin was excluded, 
therefor only YcdA, QoxA and ATP synthase were chosen for further characterization. 
 
TMs were analysed in terms of direct binding to YcdA and QoxA (heterologously expressed 
in E. coli and purified) by surface plasmon resonance (SPR) spectroscopy on a Biacore 
instrument. Proteins were immobilized to a sensor chip by standard amine coupling and 
binding to increasing concentrations of either TM, TM-Dodec, TM-N-Oct or DAP in the 
presence or absence of 5 mM CaCl2 was monitored. In accordance to results from protein 
pull-down, binding to YcdA was exclusively observed for TM-N-Oct (Table 4-16, Figure 
4-16) with an equilibrium dissociation constant (KD) of 1.1 and 0.7 µM in the absence and 
presence of calcium, respectively. Dissociation rates (kd) were 4.3 x 10
-3s-1 and association 
rates were in the range of approximately 4000 M-1s-1. A direct interaction with QoxA was 
only detected for TM with a KD of 50 µM in the absence of calcium and an improved binding 
affinity in the presence of calcium ions (KD: 8 µM, Figure 4-17). The determination of the 
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association and dissociation rates of TM to QoxA was not possible, thus, KD values were 
determined by steady-state affinity analyses.  
 
Figure 4-15: Identification of protein binding partners for TMs. A) A cell lysate of B. subtilis DSM-10 was incubated for 
2 h with biotin-tagged TM (TM-b, 50 µM) or TM-N-Oct (TM-N-Oct-b, 50 and 200 µM) and proteins were separated by 
SDS-PAGE. Untreated cell lysate (Control) as well as untagged compounds (TM, TM-N-Oct) and D(+)-biotin 
(at concentrations respective to free biotin per molecule telomycin) served as controls. Unspecific protein bands were 
identified as streptavidin (~12 kDa), biotin-carrier proteins (~20 kDa) or pyruvate carboxylase (~ 130 kDa). Black arrows 
indicate potential binding partners (protein bands that were only present or appeared enriched within biotin-tagged TMs 
samples). B) Proteins identified by MALDI-TOF/MS and LC-MS/MS. Black box: analysed protein bands; Table: identified 
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Sample Identified protein Mass [kDa]
A.3 ATP synthase subunit αβ 55
B.2 YcdA: putative lipoprotein 39
C YcdA: putative lipoprotein 39
D.3 flagellin 33














Table 4-16: Binding affinity of TM, TM-Dodec, TM-N-Oct and DAP to YcdA and QoxA in the absence (- CaCl2) or 
presence (+ CaCl2) of 5 mM CaCl2. Equilibrium dissociation constants (KD) were either determined by the ratio of 




- CaCl2 + CaCl2 
KD [µM] kd [s
-1] ka [M




TM 0.8 - 50 - - - - - - 
TM-Dodec 0.04 - 30 - - - - - - 
TM-N-Oct 0.04 - 30 1.13 4.3 x 10-3 3752 0.73 4.3 x 10-3 5941 
DAP 0.8 - 50 - - - - - - 
QoxA 
TM 0.8 - 50 50 n.d. n.d. 8 n.d. n.d. 
TM-Dodec 0.04 - 30 - - - - - - 
TM-N-Oct 0.04 - 30 - - - - - - 




Figure 4-16: SPR sensorgrams of binding of increasing concentrations TM-N-Oct (0.04-30 µg/mL) to YcdA in the absence 


































































Figure 4-17: Steady-state analysis plots of binding of increasing concentrations TM (0 - 4x10-5 M) to QoxA in the absence 
(A) and presence (B) of 5 mM CaCl2. 
 
Due to experimental limitations regarding the heterologous expression of ATP synthase, a 
functional assays on cell viability and a concurrent influence on the amount of ATP within 
cells treated with TM, TM-Dodec, TM-N-Oct or DAP, was performed using the 
luminescence-based BacTiter-Glo™ Microbial Cell Viability Kit (Promega). S. aureus 
Newman wildtype and the cls2 disrupted mutant were treated with compounds at 2-fold MIC 
for 1 h, followed by addition of the BacTiter-Glo reagent and measurement of luminescence 
on a microplate reader (Infinite M200 Pro, Tecan). The recorded luminescence signal relies 
on the mono-oxygenation of luciferin, catalysed by firefly luciferase in the presence of Mg2+ 
(supplied with assay reagent), molecular oxygen and ATP, with an increase of the 
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(wildtype and cls2 mutant), no significant decrease of ATP within cells treated with TM, 
TM-Dodec, TM-N-Oct or DAP was observed (Figure 4-18). 
 
Figure 4-18: Cell viability based on ATP quantification of S. aureus Newman wildtype and disrupted cls2 mutant over 1 h 
in the presence of 2-fold MIC of TM, TM-Dodec TM-N-Oct and DAP. Data are represented as mean ± standard deviation 
(SD). 
 
4.1.4 ACTIVITY ON EUKARYOTIC CELLS 
4.1.4.1  CYTOTOXICITY 
Cytotoxicity against human (U-2 OS: bone osteosarcoma) and murine (RAW264.7: 
leukemia macrophage; L929: subcutaneous connective tissue fibroblasts) eukaryotic cell 
lines was determined by a tetrazolium salt-based assay (MTT) after 5 d treatment of cells 
with TMs in serial dilution. The half-inhibitory concentration (IC50) was determined by 
sigmoidal curve fitting using Origin 6.1G software.  
Against human U-2 OS cells and murine macrophages (RAW 264.7), no in vitro cytotoxicity 
was observed for all TMs (IC50: > 60 µg/mL, Table 4-1). Against murine L929 cells, both 
derivatives (TM-Dodec, TM-N-Oct) showed increased inhibitory effects compared to the 
parent compound TM (IC50: > 100 µg/mL), but IC50 values were still in a moderate range 
between 30 and 50 µg/mL. 
S. aureus Newman 
wildtype





































































Table 4-17: IC50 values of TMs against human and murine cell lines. 
Cell line 
IC50 [µg/mL] 
TM TM-Dodec TM-N-Oct 
human    
U-2 OS > 100 > 100 > 100 
murine    
L929 > 100 33.12 45.53 
RAW264.7 > 60 > 60 > 60 
 
4.1.4.2 MITOCHONDRIAL MEMBRANE POTENTIAL 
As cardiolipin is not only found in the bacterial membrane but also in the inner mitochondrial 
membrane297 of eukaryotic cells, effects of TMs on the mitochondrial membrane potential 
(MMP) were determined. U-2 OS cells were treated with TMs at 10 µg/mL for 18 h followed 
by a staining with tetramethyl rhodamine methyl ester (TMRM). The cationic, cell 
permeable fluorescence probe TMRM reacts sensitive towards changes of MMP, whereas a 
red-orange fluorescence indicates the presence of active mitochondria in living cells298. The 
relative MMP was calculated based on TMRM fluorescence intensity in the cytoplasm. Cells 
treated with 10 µg/mL TM, TM-Dodec or TM-N-Oct led to a negligible reduction of MMP 
(≤ 10 %) compared to untreated control cells (Figure 4-19), demonstrating no activity of 
TMs on the mitochondrial membrane potential of mammalian cells under these conditions 




Figure 4-19: Determination of the mitochondrial membrane potential (MMP) in U-2 OS cells upon 18 h treatment with 
10 µg/mL TM, TM-Dodec and TM-N-Oct. MMP was calculated based on TMRM fluorescence intensity in the cytoplasm. 
Cells were labelled with TMRM (mitochondria) and Hoechst33342 (nuclei). Data represent mean TMRM intensity 









































4.2.1 CALCIUM-DEPENDENT ANTIBACTERIAL ACTIVITY 
The natural product telomycin (TM) is produced by Streptomyces canus and was already 
described in 1950.145–147 It depicts a cyclic depsipeptide antibiotic with potent antibacterial 
activity against Gram-positive bacteria including multidrug-resistant (MDR) 
pathogens.146,148 Only recently, the biosynthesis of TM was characterized in order to 
optimize production yields and to generate novel TM derivatives.148 Through genetic 
engineering, enzymes involved in the biosynthetic machinery of the natural producer strain 
were characterised and several TM intermediates were identified. One key finding was the 
identification of naturally occurring lipopeptides as precursor for TM, which exhibited 
improved antibacterial activity compared to TM. These studies embossed the development 
of semi-synthetic lipopeptides, which aimed to provide chemically optimized telomycin 
derivatives with a main focus on the synthesis of acyl derivatives via modification at the iso-
1Asp terminus of the natural molecule. Two promising derivatives (TM-Dodec148, TM-N-
Oct) were generated through structural modifications by the addition of unlike linear acyl 
chains to the amino group and carboxylic acid group of iso-1Asp, respectively (TM-Dodec: 
dodecanoic acid; TM-N-Oct: ethylamine octanoic acid; Figure 4-1). Their antibacterial 
effects in terms of minimal inhibitory concentrations were determined against a panel of 
Gram-positive bacteria and both derivatives display on average 16- to 128-fold improved 
potency compared to TM (Table 4-1). The cyclic structure of telomycin resembles the 
structure of daptomycin (DAP, Figure 4-20), a calcium-dependent antibiotic (CDA) used as 
last resort treatment for infections caused by MDR Gram-positive bacteria.158,299,300 The 
lipopeptide DAP acts in a calcium-dependent manner on the cellular membrane which, in 
turn, implicates depolarization of the membrane potential, and finally induces cell death as 
part of a bactericidal mechanism of action.151,301–303 However, the mechanism of action of 
DAP is still not completely understood but one important feature is its dependency on Ca2+ 
ions.304–306 So far, it seems like that the DAP-Ca2+ complex is formed in order to obtain a 
more amphiphilic molecule, which enables DAP to interact with anionic phospholipids 
(primarily phosphatidylglycerol).151,307 By inserting its lipid side chain, DAP binds to the 
cell membrane and due to interaction with a second calcium ion oligomerization takes 
place308,309; presumably due to conformational changes of the molecule.301,308,310 This seems 
to trigger a deeper insertion of DAP into the membrane and leads to a rearrangement of lipid 
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domains, followed by impairing several cellular processes.309 Based on structural similarities 
of DAP and TM, the antibacterial activity of TM and both derivatives were re-assessed 
against S. aureus Newman in the presence of different concentrations of calcium. 
Interestingly, a Ca2+-dependent increase of TM’s activity was indeed observed and TM, in 
the presence of Ca2+, displayed a comparable potency to both derivatives (TM-N-Oct, TM-
Dodec). Intriguingly, the activity of these modified derivatives did not rely on the presence 
of Ca2+ (Table 4-2). 
 
 
Figure 4-20: Structure of calcium-dependent antibiotics (CDA) telomycin and daptomycin. 
 
Since TM and DAP are structurally related and show similarities in antimicrobial activity, 
the effect of Ca2+ on TM was assessed in NMR studies as previously reported for DAP.304,306 
The interaction of TM with Ca2+ was studied in the presence of increasing amounts of a 
0.1 M CaCl2 solution by NMR. After the addition of CaCl2, 
1H NMR spectra showed 
broadening of specific signals (Figure 4-4 A, black boxes) which indicates binding of TM to 
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Ca2+. In order to determine if TM oligomerizes in the presence of Ca2+ – as observed for 
DAP – or if conformational changes of TM occur, 2D ROESY NMR spectra were recorded 
(data not shown). Preliminary assessment of these data indicated that four amino acids, 3Thr, 
4Thr, 2Ser and iso-1Asp (Figure 4-4 D) seem to be mostly affected by the addition of Ca2+. 
For instance, cross-peaks between iso-1Asp - 4Thr and 2Ser - 4Thr disappeared when calcium 
was present. Moreover, our data led to the assumption that Ca2+ binds between 3Thr and 4Thr 
(Figure 4-21), which could lead to the exposure of the side chain (iso-1Asp, 2Ser) of TM. 
This presumed mechanism is crucial for TM’s antibacterial activity as it is only biologically 
active in the presence of Ca2+ ions. Regarding TM-Dodec and TM-N-Oct, binding to Ca2+ 
was observed as indicated by broadening of certain 1H signals (Figure 4-4 B, C). However, 
no conformational changes were observed in 2D ROESY NMR spectra as all cross-peaks 
remained identical. This might explain why both derivatives are able to act calcium-
independent. It is likely that their lipophilic side chains are per se exposed (‘active 
conformation’), which might contribute to the mechanism of action, similar to DAP, whose 
lipid tail interacts with the cytoplasmic membrane.151,301 Moreover, to prove the hypothesis 
on TM’s conformational changes and eliminate the possibility of oligomerization, quantum 
mechanical calculations to generate 3D structures based on 2D-ROSEY experiments are in 
progress (Dr. Matthias Köck, HIPS-MINS). Besides Ca2+, several monovalent and divalent 
ions were tested for their interaction with TM. Monovalent ions showed no interaction with 
the molecule at any concentration. In contrast, divalent ions seem to interact with TM as 
indicated by the broadening of some proton signals, with Cu2+ exhibiting the strongest effect, 
followed by Ba2+ and Ca2+ (Figure 4-5, black boxes, Table 4-5). Regarding their influence 
on the biological activity of TM, only Ca2+ and Mg2+ were suitable for MIC determination, 
due to toxicity of Ba2+ and Cu2+ ions. Overall, only ions which showed interaction with TM 
and which are mainly involved in the physiology of the human body were of main interest 
(e.g. Ca2+, Mg2+, Na+ or Zn2+). At physiological concentrations, solely Ca2+ revealed a 





Figure 4-21: Proposed binding site of Ca2+ between 3Thr and 4Thr of telomycin. 
 
Due to these observed differences between natural and semi-synthetic TMs, and in order to 
assess if the antibacterial mechanism of action of TM-Dodec and TM-N-Oct is identical to 
that of Ca2+-activated TM, co-resistance studies were performed (see chapter 4.2.2). 
Interestingly, both acyl derivatives exhibited only marginal or no co-resistance with TM as 
assessed by MIC testing with TM-resistant and cardiolipin (CL)-depleted mutant strains of 
S. aureus (Table 4-7). In conclusion, semi-synthetic TM derivatives most probably hit 
additional targets and their antibacterial effect does not exclusively rely on CL binding, 
which might also hold true for TM itself (see chapter 4.2.2). 
 
Based on the above discussed findings, the characterisation of TMs was assessed in the 
presence of physiological Ca2+ concentrations (1.25 mM).  
An intrinsic resistance pattern of Gram-negative bacteria was observed, as none of the tested 
Gram-negative pathogens, including a membrane-permeabilized E. coli TolC-efflux 
deficient strain, was susceptible towards TMs (Table 4-3). These results indicate that 
susceptibility towards TMs relies on structural differences of the cell envelope of Gram-
negative compared to Gram-positive bacteria (Figure 4-22). The major difference is the 
presence of the outer membrane (OM) in Gram-negative bacteria which consists of a 
lipopolysaccharide (LPS) layer (outer leaflet) and phospholipids (inner leaflet) and is absent 
in Gram-positive bacteria.311 It serves to protect the cell against external stress (e.g. toxic 
molecules) and depicts a barrier to several antibacterial agents such as the hydrophobic 




membrane sensitizing agents such as polymyxins enable these compounds to act on Gram-
negative bacteria.235,236 Nevertheless, regarding the susceptibility of the membrane-
permeabilized E. coli TolC-efflux deficient strain towards TMs, structural changes of the 
cell envelope do not seem to be sufficient to cause inhibition of Gram-negative bacteria. 
Moreover, it was excluded that the resistance relies on efflux since the present E. coli strain 
depicts an TolC-efflux deficient mutant.312 Thus, it was concluded that TMs might target a 
structure within the Gram-positive cell envelope. This was consolidated since an overall 
broad activity spectrum against Gram-positive bacteria was observed. However, 
M. smegmatis and N. asteroids were not susceptible, but against slow growing mycobacteria 
(M. tuberculosis, M. bovis), inhibition was detected. In general, differences in susceptibility 
of TMs against mycobacteria compared to other Gram-positive bacteria may also rely on a 
different composition of the cell envelope (Figure 4-22). Even though mycobacteria are 
classified as Gram-positive bacteria, their outer envelope comprises structural features of 
Gram-negative bacteria such as an OM, and in total, their organisation is much more 
complex. The main component of the OM is mycolic acid, which is covalently linked to 
arabinogalactan. Additionally, within different mycobacterial species the arrangement of the 
mycolic acids structure differs, which may account for differences in sensitivity against 




Figure 4-22: Cellular envelope of Gram-negative bacteria, Gram-positive bacteria and mycobacteria. Adapted from Brown 
et al..52 
 
A comparison of activity spectra of all TMs revealed TM to be on average 2- to 8-fold less 
potent and by tendency, TM-N-Oct was slightly more active than TM-Dodec, in particular 
against Staphylococci. TM was virtually inactive against two resistant S. aureus strains 
(MDR, VISA/MRSA), but both derivatives were able to inhibit their growth. So far, this 
finding cannot be explained but it hints towards altered cell wall compositions of resistant 
strains, which hinder natural TM to enter the cell. Due to the emergence of hospital-acquired 
infections caused by pathogens such as Staphylococci, and a permanent increase of 
resistance mediated by these pathogens towards clinically used antibiotics, the effect of TMs 
against clinical S. aureus isolates was investigated. MIC50 and MIC90 values were 
determined and encouragingly, values were in the same range as observed with laboratory 
strains (low µg/mL range; Table 4-4). These results represent TMs and in particular both 
acyl-derivatives as promising source for the development of new drugs to target the 





TMs exert a bactericidal effect on Gram-positive bacteria including S. aureus and 
vancomycin-resistant Enterococci (VRE).146,148,160 Remarkably, despite a comparable 
activity pattern of TMs and DAP (Table 4-3), TM-Dodec exerts an even stronger bactericidal 
effect on S. aureus compared to the gold-standard antibiotic DAP.148 Overall, structural 
similarities, as well as an overlap in the antibacterial spectrum and the Ca2+-dependent 
mechanism of both, TM and DAP, hinted towards similar mechanisms of action. Thus, a 
general mechanistic comparison of TMs and DAP was performed. The potency of TM on 
the bacterial membrane potential was assessed by exposing S. carnosus DSM-20501 to 5-
fold MIC of TM in the presence of 0-10 mM CaCl2 over 2.5 h. A Ca
2+-dependent membrane 
depolarization was observed with an increase in depolarization proportional to the amount 
of present CaCl2 (Figure 4-3). At Ca
2+ concentrations ≥ 0.25 mM a 80 % reduction of the 
MP was observed, indicating a calcium-dependent effect on the cellular membrane, similar 
to the mechanism observed for DAP.314 Previous studies indicate that membrane 
depolarization by DAP occurs only as a consequence of cell membrane mechanisms which 
are mediated to trigger cell death.309,315 However, since the mechanism of action of DAP is 
still controversially discussed, several models exist. Besides a membrane disrupting action 
by the formation of pores316, studies described DAP to act as inhibitor of the biosynthesis of 
peptidoglycan (PG).317,318 Additionally, it was suggested that the main target depicts the cell 
wall and not the cell membrane.319 Recent studies confirmed that the inhibition of the cell 
wall synthesis counts to its action, a mechanism which is based on structural changes of the 
cell membrane by rearranging lipid domains309. This mechanism seems to impair several 
cellular processes and might account for the depolarization of the membrane, a process that 
could also be contemplated for TMs.  
 
Due to TM’s excellent activity on Gram-positive bacteria in broth, all derivatives were also 
assessed for their intracellular antibacterial activity. At concentrations as low as 4-fold MIC, 
TM, TM-Dodec and TM-N-Oct reduced the number of S. aureus cells by approximately 2-
log10 (Figure 4-2). Again, both modified derivatives were more potent compared to the 
natural product, as TM-Dodec and TM-N-Oct were still effective in this screen at lower 
antibiotic concentrations (1-fold MIC), whereas TM showed only a negligible activity at this 
concentration. The ability to kill intracellular pathogens is an important property of 
antibiotics that are used to treat severe infections caused by some bacteria. S. aureus depicts 
a major pathogen which is responsible for community- and hospital-acquired infections320–
322 and due to the severe problem of increasing numbers of MDR strains, only limited 
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treatment options are available. Moreover, S. aureus was shown to overcome host-defending 
mechanisms, which leads to increased levels of the bacteria within the host. For instance, S. 
aureus is able to survive within macrophages323–326 by overcoming phagocytosis, which is 
normally initiated as the host’s innate immune response327. With regard to the surviving 
abilities of S. aureus within macrophages and the results gained upon treatment of infected 
cells with TMs (Figure 4-2), the potential use of the compounds to treat infections caused by 
S. aureus, including MDR strains and potentially other Gram-positive pathogens, was 
consolidated. 
 
4.2.2 MECHANISM OF ACTION AND RESISTANCE MECHANISM 
4.2.2.1 GENETIC CHANGES IN RESISTANT MUTANTS 
To evaluate putative resistance mechanisms and targets of TMs, S. aureus mutants were 
generated by stepwise increasing the antibiotic concentration and mutants finally tolerated 
concentrations of 100 µg/mL TM and TM-Dodec. Initially, these mutants developed at 
frequencies of 4 x 10-6 for TM and 8.5 x 10-9 for TM-Dodec when treated at the respective 
4-fold MIC. Since the frequency of resistance for TM-Dodec was significantly lower than 
that for TM, the modified derivative might have additional bacterial targets or exhibit a 
different mechanism of action than TM. MIC testing confirmed the resistance phenotype of 
both sets of mutants against the respective telomycin derivative. Additionally, TM-Dodec-
resistant mutants revealed cross-resistance to TM and TM-N-Oct ( Table 4-8), but TM-
resistant mutants were still susceptible to both derivatives (Table 4-7). Against all other 
tested antibiotics, including DAP, no co-resistance was observed, which indicates that TMs 
might have a new target and exert novel mechanisms of action.  
The mechanism underlying resistance was further investigated by genome analysis of 
resistant mutants in comparison to the wildtype S. aureus Newman. Besides the presence of 
several inconsistent mutations (Table 4-7, Table 4-8), all TM- and TM-Dodec resistant 
mutants revealed mutations within cls2, a gene encoding cardiolipin synthase 2 (Cls2), 
which catalyses the reversible transphosphatidylation of two phosphatidylglycerol (PG) 
molecules into CL (Figure 4-23).292 In six mutants (Mt-T.4, Mt-T.7, Mt-T.8, Mt-T.9, Mt-
D.1, Mt-D.3) the point mutation led to a premature stop codon within cls2. Additional 
mutations within a gene encoding a diacylglycerol kinase (DagK, most probably DgkB from 
Pfam00781 superfamily of soluble proteins) were identified in four TM-resistant mutants 
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(Mt-T.1, Mt-T.4, Mt-T.7, Mt-T.8, Mt-T.9). DagKs are involved in the biosynthesis of 
phospholipids by catalysing the phosphorylation of diacylglycerol (DAG) into phosphatidic 
acid (PA).328,329 Furthermore, DAG is linked to the generation of lipoteichoic acid (LTA), 
since DAG is generated during the addition of glyercol-1-P groups from PG to the 
LTA.328,330 Moreover, in all TM-Dodec-resistant mutants, mutations of a gene encoding a 
GntR-type family repressor (PmtR) of an ABC transporter294 were present. Interestingly, in 
seven out of ten mutants the mutation occurred in the same amino acid (# 30), which led to 
a stop codon in all seven mutants. In summary, the resistance patterns of TM- and TM-
Dodec-resistant mutants hint towards effects of TMs, which are dependent on cell envelope 
components (CL, DAG, LTA) Moreover, the genomic characterisation indicated that 
resistance towards acylated TM-derivatives might involve additional cellular changes 
(additional, common mutation in PmtR encoding gene) compared to TM (only cls2 mutation 
common in all mutants).  
 
 
Figure 4-23: Transphosphatidylation of two phosphatidylglycerol (PG) molecules into cardiolipin (CL) Phospholipids are 
depicted as representatives with unsaturated 18-carbon acyl tails (typical length of synthetic phospholipids; natural 
occurring phospholipids can vary in the length/number of the acyl tail and the position/number of unsaturated bonds).331 
 
Since all mutants generated under the pressure of TM and TM-Dodec had mutations of cls2 
in common, and all other identified mutations were either only present in one set of mutants 
or did not appear commonly, CL seems to contribute to the antibacterial effect of TMs. Thus, 
for a further characterization of the resistance mechanism and the mechanism of action the 
role of CL including the function of cls2 was in the main focus. 
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4.2.2.2 ROLE OF CARDIOLIPIN 
The exact mechanism of action of TMs is not known and the compounds did not show an 
effect in RNA, DNA and protein synthesis reporter screens (data not shown; Dr. A. Müller, 
University Bonn). Instead, the induction of cell wall stress response was observed, which 
hints to a mechanism related to cell wall synthesis. Additionally, resistance studies (see 
previous chapter 4.2.2.1) hinted towards interaction of TMs with cell membrane 
components, especially with the phospholipid CL. CL is found in the bacterial and 
mitochondrial membrane and depicts an important phospholipid component of these 
domains332,333. In general, the relative amount of lipid types differs among different species 
(Table 4-18). This may account for differences in susceptibility of TMs against Gram-
positive compared to Gram-negative bacteria. For instance, the content of CL is usually 
much higher in Gram-positive bacteria compared to other species (approx. 3- to 10-fold 
higher), whereas Gram-negative bacteria mostly contain phosphatidylethanolamine (PE), a 
phospholipid which is completely absent in some Gram-positive species. Nevertheless, TMs 
are also active against Gram-positive bacteria with a low CL content (B. subtilis). Thus, an 
interaction with CL does not seem be the main trigger for their bactericidal effect and it is 
likely that an additional target (protein) which is only present in Gram-positive bacteria, and 
presumably associated with the cell envelope accounts for the mechanism of action of TMs. 
 
Table 4-18: Percentage of major phospholipids of total lipid content in Gram-positive, Gram-negative bacterial and 
mitochondrial membranes. Adapted from Epand and Epand334, Osman et al.335, and Schenkel and Bakovic336  
Species 
% Total lipid 
CL PG PE 
Gram-positive    
S. aureus 42 85 0 
S. pneumoniae 50 50 0 
B. subtilis 4 70 12 
Gram-negative    
E. coli 5 15 80 
K. pneumoniae 6 5 82 
P. aeruginosa 11 21 60 
Mitochondria 15 * 30 
*PG does not accumulate under normal conditions335; CL: cardiolipin; PG: phosphatidylglycerol; 
PE: phosphatidylethanolamine 
 
Certainly, the interaction of TM and CL was also described by Johnston et al., who described 
CL as the antibacterial target of TM.161 Within their study, a localization of TM in CL 
containing compartments (septa, poles) was provided. Due to CL’s structure (head groups 
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possess smaller cross section compared to cross section of lipid tails) it possess a high 
intrinsic curvature what leads to an enrichment of CL within these domains.331,337,338 An 
accumulation of TMs in CL-rich compartments could be also confirmed here, not only for 
TM but also for the acylated derivatives. B. subtilis and S. aureus were incubated with 
fluorophore-tagged telomycin analogues and an accumulation of TM, TM-Dodec and TM-
N-Oct tool compounds at septa and poles was observed (Figure 4-13). Furthermore, the 
fluorescence pattern of intracellular TM derivatives overlaps with fluorescence of NAO, a 
red fluorescent indicator for CL (Figure 4-14).296  
To investigate the interaction of TMs with potential other lipid binding partners of the cell 
membrane, binding of alkyne-coupled TM derivatives (TM-pentyne; TM-decyne, 
mimicking TM-Dodec) to membrane lipids and lipoteichoic acid (LTA) was determined. 
Direct binding of TMs was exclusively observed for CL in a CL concentration-dependent 
manner (max. binding in the presence of 64 pmol CL; Figure 4-12) and all other lipids as 
well as LTA did not show interaction at all (Figure 4-11). Furthermore, the binding capacity 
of TM (TM-pentyne) was shown be improved in the presence of high Ca2+ concentration 
(10 mM). Remarkably, the binding of CL to TM is in general dependent on calcium, since 
Ca2+ depletion by the addition of EDTA prevented binding at any tested CL concentration. 
Even though, binding of TMs to CL was proven this phospholipid is rather unlikely to be 
the antibacterial target of TMs. A disruption of cls and a thereof resulting CL-depletion was 
not lethal (Figure 4-6) and proved that CL is not directly involved in the bactericidal effect 
of TMs. Moreover, no direct correlation between the bacterial CL-content and the 
antibacterial activity of TMs was observed (e.g. B. subtilis vs. E. coli, Table 4-3, Table 4-18), 
what furthermore hints towards interaction of TMs with other – so far unknown – target 
molecules.  
Since CL is not only present in bacteria but also in the inner mitochondrial membrane297, 
effects of TMs compared to DAP on the mitochondrial membrane potential (MMP) were 
analysed. Due to CL binding there is a potential risk that TMs induce adverse effects in vivo, 
which are characterized by e.g. cardiotoxicity.339 To exclude such side effects TM’s toxicity 
was evaluated in a cell culture model. Human bone osteosarcoma cells (U-2 OS) were treated 
with TM, TM-Dodec, TM-N-Oct and DAP at 10 µg/mL and the MMP was determined after 
18 h. For all compounds, only a negligible reduction of the MMP (≤ 10 %) compared to 
untreated control cells was observed (Figure 4-19). Since TMs have no major effect on MMP 
of eukaryotic cells it is rather unlikely that their interaction with (bacterial) CL is problematic 
with regards to in vivo toxicity, particularly the induction of cardiotoxic effects due to 
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disrupted mitochondrial function339. Moreover, TMs in general do not show cytotoxic effects 
on eukaryotic cell lines148 (Table 4-17). However, these findings need to be confirmed in 
vivo, ideally in a well-monitored rodent model.  
As already mentioned, the reversible transphosphatidylation of PG molecules into CL is 
catalysed by a cardiolipin synthase (Cls)292. In S. aureus species, the synthesis of CL is 
mediated by two distinct Cls genes: cls1 and cls2.293 Both synthases are linked to CL 
accumulation, but under normal growth conditions, cls2 encodes the major synthase Cls2, 
whereas cls1 encodes the alternative enzyme Cls1, which can compensate for a loss of 
functional Cls2 under conditions of osmotic or pH stress.292,293 However, a loss of functional 
Cls2 is associated with a decrease of CL under normal growth conditions.293 Based on this, 
lipids from S. aureus Newman wildtype and from cls1 and cls2 disrupted S. aureus mutants 
were extracted and analysed by thin-layer chromatography (TLC). Spots detected by TLC 
indicated that a disruption of cls2 led to a decline in the appearance of CL, in comparison to 
CL accumulation in S. aureus Newman wildtype and cls1 disrupted mutant (Figure 4-7). 
Moreover, the accumulation of PG in cls2 disrupted mutant appeared to be slightly higher, 
in comparison to wildtype and cls1 disrupted mutant. This further underlines that the 
generation of CL is hampered in mutants bearing disrupted cls2, indicated by no conversion 
of PG into CL. This confirms that mutations of cls2 lead to a changed phospholipid 
composition what in turn contributes to antibiotic resistance and hints towards a CL-related 
mechanism of TMs. Moreover, the characterization of both cls disrupted S. aureus Newman 
mutants confirmed that only the inactivation of cls2 is involved in decreased susceptibility 
to TMs (Table 4-11). MIC determination revealed that a disruption of cls2 affected the 
activity of TM significantly more (MIC: > 64 µg/mL) than of both semi-synthetic derivatives 
(only 4- to 8-fold less active). This indicates that the activity of natural TM indirectly or 
directly highly relies on the presence of CL but does not prove CL to be the antibacterial 
target. Even more, a depletion of CL is not sufficient to cause a complete resistance towards 
both acylated derivatives, hinting towards a CL-independent effect of both derivatives, again 
supporting the assumption of an interaction with other target(s). Interestingly, inactivation 
of neither cls1 nor cls2 did affect the activity of DAP, even though mutations of cls in 
Staphylococcus or clinical Enterococcus (VRE) isolates were previously associated with 
resistance to DAP.64,65,340 Certainly, not only cls but also other genes were simultaneously 
affected within DAP-resistant mutants. Those genes were identified to be responsible for 
structural changes of the cell envelope. Interestingly, genes responsible for those changes 
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differed within different bacterial species (VRE vs. Staphylococci). Within VRE, liaF and 
gdpD were mainly associated with resistance to DAP65, whereas mprF was mostly affected 
within S. aureus isolates.64 Those genes have in common, that they are activated as a 
response to antibacterial agents, which results in changes in the composition of the cellular 
membrane. This is probably mediated based on a simultaneous mutations of other genes 
involved in phospholipid synthesis, such as cls2 or pgsA (encoding PG synthase PgsA).341 
Mutations of mprF (encoding lysyl-PG synthase) were associated with a decreased 
generation of PG and an increased conversion of this phospholipid into lysyl-PG (LPG). 
This leads to changes of the membrane charge and hinders cationic antimicrobial peptides 
(CAMPs) to enter the cell.64,342–344 In this context, one TM-resistant mutant (Mt-T.3) yielded 
a mutation within the lysyltransferase flippase domain of MprF. However no decreased 
sensitivity towards DAP was observed, indicating that this mutation did not lead to structural 
changes of the membrane as observed within DAP-resistant mutants, and does not seem to 
contribute to a resistance mechanism against TM. Regarding structural changes based on 
mutations of liaF or gdpD, none of the mutants yielded additional mutations within those 
genes. In general, mechanisms that led to resistance towards TMs seem to differ from 
mechanisms observed in DAP-resistant bacteria, since no cross-resistance to DAP was 
observed. However, with regard to the affected genes (Table 4-9, Table 4-10) in TM- and 
TM-Dodec-resistant mutants, it seems that the so far unknown mechanism is likewise 
associated to the cell membrane, in particular to CL, and that there are some genes mutated 
which are also found to be affected in DAP-resistant mutants.  
Under normal growth conditions, S. aureus undergoes a change in the phospholipid 
composition from logarithmic- to stationary-growth phase. During logarithmic growth, the 
major cell membrane component is PG, which is converted into CL during cellular growth. 
This in turn leads to a decrease of PG with a concurrent increase of CL as phospholipid in 
stationary-phase (30-40% of cell membrane constitutes of CL in stationary-phase).345 
Considering CL as an important cellular component during bacterial growth leads to the 
assumption that inactivated cls genes might interrupt cell growth. Certainly, as already 
mentioned, Cls1 is able to compensate the loss of functional Cls2 under conditions of 
osmotic or pH stress.292,293,346 To investigate whether a cls2 disrupted mutant is able to 
compensate the loss of Cls2 by Cls1 activation under stress conditions, expressed by a regain 
in susceptibility towards TMs, S. aureus Newman wildtype and the cls2 disrupted mutant 
were incubated under different stress conditions, followed by lipid extraction and MIC 
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determination. Against wildtype S. aureus Newman, no changes on susceptibility towards 
all TMs were observed (Table 4-12) at any test condition. Regarding cls2 disrupted mutant, 
only low pH conditions (pH 2) led to a slight improvement of activity to TM. However, 
against DAP, wildtype as well as cls2 disrupted mutant showed 16- and 8-fold increased 
susceptibility, respectively, under growth conditions at pH 2. Other stress-inducing 
conditions (4 M NaCl and pH 4) did not or only marginally influence the susceptibility 
towards DAP. Since DAP not only showed increased activity under low pH conditions 
(pH 2) against cls2 mutant but also against the wildtype, it can be excluded, that the observed 
effect relies on cls mutations. It rather seems that pH 2 led in general to changes that might 
rely on a changed phospholipid composition, which increased susceptibility to DAP but not 
to TMs. Acidic pH conditions can lead to an increase of LPG production in S. aureus.347,348 
However, as already mentioned, the increase of LPG leads to resistance towards DAP and 
not to increased sensitivity.64,342 Based on this, it is likely that pH 2 conditions induced a 
different change in cell membrane composition. To prove this assumption the amount of all 
lipid species present under stress conditions needs to be determined in comparison to normal 
growth conditions. In the course of this study, phospholipids of S. aureus Newman and cls2 
disrupted mutant incubated under stress conditions were extracted but analysis of LC-MS 
data could not be analysed properly since only trace amounts of lipids (partly below limit of 
detection) were detected. The HPLC method was validated using a CL-standard, however 
the amount of extracted was not sufficient to be detected. For a concise evaluation of 
phospholipids and to quantify CL methods (TLC, LC-MS) need to be optimized, a careful 
repeat of the experiments is needed, and extractions efficiency must be improved. 
 
In conclusion, the presence of CL is a major factor for natural TM to be active against 
bacteria. As shown by susceptibility studies performed with the CL-depleted S. aureus 
mutant (cls2 disrupted mutant; Table 4-11), the absence of CL is already sufficient to cause 
high-level resistance towards natural TM (≥ 64-fold decreased sensitivity compared to 
wildtype) and it does not seem that further cellular changes are needed. Nevertheless, in five 
out of seven TM-resistant mutants SNPs were identified in the same gene encoding a 
diacylglycerol kinase, an enzyme that is involved in the synthesis of phospholipids. As 
already mentioned, DagKs catalyse the phosphorylation of DAG into PA328,329, which yields 
in further steps the generation of PG. DAG in turn is generated by the addition of glyercol-
1-P groups from PG to LTA, a mechanism that functions in a circulating way, since DAG is 
re-introduced into the biosynthetic pathway that yields PG (Figure 4-24).328,330 A 
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dysfunction of DagK leads to a lethal accumulation of DAG within bacteria.328,330 However, 
it seems that the mutations found in TM-resistant mutants did not lead an increased 
accumulation of DAG, or at least was not lethal, since mutants did not display a fitness cost 
compared to the wildtype (Figure 4-8 A). However, to get further insights into the 
mechanism underlying mutations of DagK, the presence of all phospholipids included in the 
biosynthetic pathway of PG/LTA production needs to be analysed. Nonetheless, this 
indicates that malfunctioning DagK, does not seem to contribute significantly to resistance 
against TM, and that CL is the major key for natural TM to perform its action in the first 
place.  
 
Figure 4-24: Role of diacylglycerol kinases in the biosynthetic pathway of PG and LTA. An unknown enzyme (?) catalyses 
the transfer of glycerol-1-P groups from PG to the LTA glycolipid anchor diglucosyldiacylglycerol (Glc2DAG) yielding 
LTA and DAG, whereas DAG is re-introduced into the PG biosynthesis cycle. DgkB catalyses the phosphorylation of DAG 
into PA leading in further steps to the generation of PG. LTA: lipoteichoic acid, DAG: diacylglycerol, PA: phosphatidic 
acid, CDP-DAG: cytidine diphosphate diacylglycerol, PGP: phosphatidylglycerol phosphate, PG: phosphatidylglycerol, 
DgkB: DAG kinase, Cds: CDP-DAG synthase, PgsA: PGP synthase, PgpP: PGP phosphatase. Adapted from Jerga et al.330  
 
In contrast, the depletion of CL (cls2 disrupted mutant; Table 4-11) did not lead to complete 
resistance towards both acylated derivatives (TM-Dodec: 8-fold decreased activity, TM-N-
Oct: 4-fold decreased activity). In all TM-Dodec-resistant mutants, a second gene besides 
cls2 was mutated. This additional mutation within all TM-Dodec-resistant mutants thus 
contributes to high-level resistance towards TMs. The affected gene was recently identified 















(belonging to the family ABC transporter).294 PSMs depict a family of staphylococcal toxins 
that are involved in the pathogenesis of S. aureus349–351 and moreover, they are involved in 
regulating their own efflux. To avoid self-mediated lethality by PSMs, Staphylococci have 
established a self-regulating efflux system whose expression is induced by specific PSM 
subtypes (mainly low-level cytolytic PSMs, e.g. PSMα4).294 The system underlying PSM 
secretion (Pmt; an ATP-binding cassette transporter) is encoded by four genes (pmtA, pmtB, 
pmtC, pmtD) arranged on a single operon (pmt).295,350 The presence of Pmt was described to 
be essential for bacterial survival, as a deletion led to a lethal accumulation of PSMs within 
S. aureus.350 The regulator PmtR is encoded by pmtR which is located upstream the pmt gene 
cluster 294 and was characterized as a member of YtrA subfamily of helix-turn-helix GntR-
type transcriptional regulators.352,353 YtrA acts as repressor of the ytrABCDEF operon of B. 
subtilis, which is required for induction in bacterial responses to cell wall (lipid II) targeting 
antibiotics.354 Since PmtR depicts a homologue of YtrA, the lipid II targeting antibiotic 
vancomycin355 was included in co-resistance studies of TM-Dodec-resistant mutants. 
However, no decrease in sensitivity was observed when tested against TM-Dodec-resistant 
mutants compared to wildtype S. aureus (Table 4-8). Those results support the assumption 
that TM-Dodec seems to exhibit a novel mechanism of action by targeting a molecule 
different to that of known cell wall targeting antibacterial agents such as DAP and 
vancomycin. Regarding its regulatory function, Otto and co-workers described that no other 
genes but the pmt cluster is regulated by PmtR and no other substrate than PSMs were 
described in the context of this export system.294 In the absence of intracellular PSMs, PmtR 
prevents a permanent expression of the efflux system by binding to the pmt promoter (PmtR-
pmt complex) upstream pmtR. The production of PSMs, controlled by the accessory gene 
regulator (arg) quorum-sensing system356, leads to the transcription of the efflux system by 
the binding of PSM to PmtR, what leads to the disruption of the PmtR-pmt complex and 
expression of the efflux system. The observed mutations of pmtR in TM-Dodec-resistant 
mutants are inactivating (deletions) and thus, lead to the absence of PmtR and a permanently 
expressed efflux pump could be present. Fitness studies of TM-Dodec-resistant mutants 
revealed a retarded growth compared to the wildtype S. aureus Newman (Figure 4-8 B), 
indicating a PmtR-related growth defect. Additionally, a comparison to the fitness of TM-
resistant (Figure 4-8 A) and cls disrupted mutants (Figure 4-6) confirmed that the additional 
mutations within pmtR are responsible for the retarded growth as cls2 mutations are fitness 
neutral. In this context, Joo et al. described that a permanent and wasteful production of Pmt 
(pmtR-knockout mutant) is reflected in slight but significant bacterial growth deficiencies294 
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This consolidates the assumption of a permanent expressed export system within TM-
Dodec-resistant mutants. Moreover, PSMs are related to biofilm formation in S. aureus. On 
the one hand, PSMs are involved in structuring the 3-dimensionality of biofilms and on the 
other hand they facilitate a controlled detachment of the biofilm which is crucial for the 
dissemination of cells during infection.295,357–359 The characterisation of TM-Dodec-resistant 
mutants revealed, that the observed growth defects were accompanied by an impaired 
biofilm formation after 24 h incubation in all mutants in comparison to S. aureus Newman 
wildtype (Figure 4-9). After additional 24 h of incubation (48 h time-point), a further growth 
of the biofilm of the wildtype was observed, but for all mutants no changes or a degradation 
of their biofilm was observed. Assuming an increased expression of the efflux pump it might 
be possible that the unusual increased export of PSM leads to an uncontrolled and early 
detachment of the biofilms.  
Taking together the facts that mutations of pmtR were only present in TM-Dodec-resistant 
mutants and that those mutants showed an overall retarded fitness (growth and biofilm) 
compared to TM-resistant mutants (only cls2 mutations), lead to the conclusion, that the 
observed growth defects rely on mechanisms mediated by dysfunctional PmtR. Even though 
at the current stage there is no prove, it seems that the activity on the mutant strains of 
acylated TMs is hampered due to an upregulation of the efflux pump Pmt. Additionally, 
although so far only PSMs are described as substrates of Pmt, it might be possible that 
resistance towards TMs is mediated by efflux of the compounds. However, to get further 
insight into the proposed mechanism it needs to be assessed whether the mutations in pmtR 
indeed lead to increased expression of Pmt and whether TMs are substrates of this specific 
transporter. A PmtR knockout mutant is currently generated and studies in comparison to 
the wildtype strain are planned. Those include qPCR to investigate the expression levels of 
PmtR/Pmt and activity studies (including cross-resistance towards TM). Moreover, it needs 
to be investigated if merely the loss of function of PmtR is sufficient to cause resistance 
against TM-Dodec or if it only contributes to growth defects and if a concurrent CL 
deficiency is needed in any case for high-level resistance. The impact of the described 
mutations in cls2 and pmtR on transcriptome level is currently analysed by means of RNA 
sequencing experiments (performed in cooperation with Dr. A. Westermann/Prof Dr. J. 




In summary, TM and both derivatives seem to act by interfering with the bacterial cell 
envelope. However, even though binding of acylated TM to CL was proven, and an 
accumulation of both TM-derivatives within CL containing compartments was shown, the 
overall data set (Ca2+-independency, susceptibility of cls2 mutants, in vitro resistance 
development) still hints towards a mechanism in which CL only plays an indirect role. So 
far, the binding site of TMs on CL is not known but it seems likely that TMs bind via the 
cyclic peptide core structure, which is identical in natural TM and acylated derivatives. The 
binding of TM to CL is presumably needed to enable the compound to interact with the cell 
(most probably with the cell membrane; CL as “anchor” for TM), whereas acylated 
derivatives are able to interfere with the cells independent of the presence of CL. They 
presumably interact with the membrane by inserting their exposed lipophilic side chain 
(comparable to DAP), which is slightly less effective in the absence of CL. Natural TM first 
needs to undergo a conformational change (Ca2+-dependent) to resemble the 3D structure of 
acylated TMs and its membrane interaction fully relies on the presence of CL. In any case, 
the interaction with cell membrane seems to be only the first step of the mechanism of action 
and it is likely that the bactericidal effect of TMs relies on the interaction with a common 
additional target, which might be found in the cell wall.  
 
4.2.3 TARGET IDENTIFICATION 
Given that the interaction of CL with TMs mainly affects the activity of natural TM, and that 
no complete resistance against TM-Dodec was observed when CL was depleted, it is likely, 
that an additional (protein) target(s) account for the bactericidal mechanisms mediated by 
TMs. Moreover, the depletion of CL is not lethal (Figure 4-6), further indicating CL not 
representing the main antibacterial target for TMs. 
Since in vitro resistance development only hinted towards mechanisms mediated in 
association with the cell membrane, but no specific target molecule was identified, a protein 
pull down was performed. B. subtilis served as BSL1 model organism and semi-synthetic 
TM- and TM-N-Oct-biotin-tagged derivatives served as tool compounds to perform protein 
pull-down experiments. To identify proteins that interacted with TMs, proteins were 
separated by SDS-PAGE, followed by mass-spectrometry analysis. Since the success rate of 
identifying trypsin digested proteins by mass-spectrometry is dependent on the intensity of 
proteins, only proteins that appeared in the presence of 200 µg TM-N-Oct were chosen for 
further analysis (Figure 4-15 A) by MADLI-TOF/MS and LC-MS/MS. Four different 
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proteins were successfully identified as binding partners in the pull-down experiment: αβ-
subunit of ATP synthase, a putative lipoprotein YcdA, subunit II (QoxA) of the quinol 
oxidase, and flagellin (Figure 4-15 B). Flagellin depicts the protein component of the 
bacterial flagellum which is highly abundant in flagellated bacteria.360 The flagellum is 
needed for the bacterial movement and is found in Gram-positive as well as Gram-negative 
bacteria, such as E. coli or Pseudomonas spp., but is absent in Staphyloccoci.361,362 Binding 
of an antibiotic to flagellin might probably hinder bacterial movement but not cause bacterial 
killing. Furthermore, TMs depict an intrinsic resistance pattern to Gram-negative bacteria 
(flagellin containing bacteria) but strong inhibitory activities against Staphylococci (flagellin 
missing bacteria), what led to the exclusion of this protein to be involved in TMs mechanism 
of action. Moreover, the protein mass detected by protein separation on SDS-PAGE (33 
kDa) differs slightly from the actual mass of the intact protein (38 kDa), whereas masses for 
all other identified protein are in accordance to theoretical masses. However, the fishing of 
flagellin (or part of it) might have happened in association with YcdA, a putative lipoprotein 
that was previously characterized to be involved in the movement of B. subtilis but it is not 
essential for cellular growth.363 Besides a correlation to the swarming motility, the protein is 
uncharacterized and was only found in B. subtilis with no homologues in S. aureus. 
Nevertheless, direct binding of TMs to YcdA, which was heterologously expressed in 
E. coli, was analysed by SPR. Binding to TM, TM-Dodec, TM-N-Oct compared to DAP was 
monitored in the presence of increasing compound concentrations. Additionally, the effect 
of Ca2+ on the binding affinities was analysed. In accordance to protein fishing, binding to 
YcdA was only observed for TM-N-Oct, which bound in a concentration-dependent manner 
with moderate affinity in the micro-molar range (Table 4-16; Figure 4-16). Addition of 
5 mM CaCl2 only led to a minor increase of binding affinity (approx. 1.5-fold) in comparison 
to binding in the absence of Ca2+. For both cases (± Ca2+) a slow dissociation (4.3x10-3 s) 
was observed. Since the involvement of YcdA in TM’s mechanism of action is so far 
unknown, the generation of an ycdA knockout mutant (wildtype B. subtilis DSM-10) is 
planned to further characterize its involvement in the mechanism of action of TMs. Besides 
YcdA, binding of TMs and DAP to QoxA was also analysed. So far, solely binding of TM 
to QoxA was measured with a rather low binding affinity (50 µM; Table 4-16; Figure 4-16). 
However, binding affinity was increased approximately 9-fold (6 µM) when Ca2+ was 
present. Even though the potential mechanism underlying the binding of TM to QoxA still 
needs to be analysed, a Ca2+-dependent mechanism of TM was again determined. QoxA 
depicts subunit II of the terminal oxidase cytochrome aa3 and is involved in transferring 
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electrons to subunit I of the oxidase. Cytochrome aa3 was characterized to be most probably 
the major oxidase of the branched respiratory chain of B. subtilis.364 The aerobic growth of 
B. subtilis is branched into a cytochrome c oxidase and a quinol oxidase branch, whereas 
cytochrome aa3 is found in the latter one. Cytochrome aa3 belongs to the family of proton 
pumping heme-copper oxidases and consists of subunit I (QoxB), II (QoxA), III (QoxC) and 
IV (QoxD) which are encoded by qoxB, qoxA, qoxC and qoxD, respectively.365–368 
Additionally, two other bd-type cytochrome terminal oxidases are found within the quinol 
branch, cytochrome bd (encoded by cydAB) and cytochrome bb’ oxidase (encoded by 
ythAB), both of which are not associated with a proton pumping function.364,369,370 The 
cytochrome c branch differs in the type of terminal enzyme as it terminates in a cytochrome 
caa3 oxidase, which also belongs to the family of proton-pumping heme-copper oxidases 
and consists of subunits I-IV (CtaD, CtaC, CtaE, CtaF), encoded by ctaDCEF.364,368,371 
Oxidases belonging to the heme-copper family share the presence of a subunit that is 
homologue to subunit I of the mitochondrial cytochrome c oxidase (QoxB and CtaD for 
B. subtilis). Those subunits depict the active sites and contain a heme-copper centre 
consisting of two hemes (O, A or B) and copper (CuB).
372,373 Besides E. coli373,B. subtilis 
depicts a species whose respiratory system is well characterized, in contrast to Staphylococci 
among which only little is known.374 Studies in S. aureus alternated between the presence of 
two and three respiratory branches375,376, but recent studies hinted more towards the two 
branched system by a bd-type oxidase (encoded by cydAB)377–379 and a heme-copper oxidase 
(encoded by qoxABCD operon).380,381 Certainly, the qoxABCD operon found in S. aureus 
encodes four subunits that are related to caa3-type oxidases found in B. subtilis and refers 
rather to a cytochrome c related oxidase, than to a quinol one. In general, the aerobic 
respiration in different bacteria relies on a common feature, the presence of terminal 
oxidases, which all consists of homologues of subunit I-IV. They are involved in the electron 
transport during the last step of the respiratory chain (Figure 4-25) by transferring electrons 
to molecular oxygen what leads to a reduction of oxygen to water371,382. This process 
includes the oxidation of quinol, either directly by quinol oxidases (quinol branch) or via the 
bc1 complex in interaction with membrane bound cytochromes (cytochrome branch, Figure 
4-25). Quinols (menaquinol or ubiquinol) needed to proceed those steps, are generated 
through the oxidation of quinones by three different reductases, succinate (SDH), type-2 
NADH or glycerol-3-phosphate reductase.383–385 
The essentiality of the QoxA within the respiratory chain is not known, since previous 
studies focused either on the function of the whole qoxABCD operon (complete loss of the 
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qox operon) or on subunits other than subunit II.364,366 Based on this, it is not clear if QoxA 
represents an antibacterial target and if an interaction of TM with QoxA is able to trigger a 




Figure 4-25: Branched aerobic respiratory chain (quinol and cytochrome branch) terminating in one of four terminal 
oxidases. Electrons are donated by the oxidation of menaquinones (mostly distributed among Gram-positive and anaerobic 
Gram-negative bacteria383–385) or ubiquinones (predominantly found among aerobic Gram-negative bacteria384,386). n: 1-12 
(isoprene subunits). Adapted from Winstedt et al.364 
 
The electron transfer within the respiratory chain is coupled to a proton transport across the 
cell membrane what mediates the generation of a proton gradient that provides energy which 
is further processed by the F0F1-ATPase to synthesize ATP
387,388. Among all organisms that 
involve ATP in their metabolisms, structural related F0F1-ATP synthases are found
388,389. 
They consist of two domains: the extrinsic membrane part F1 and the membrane embedded 
part F0 (Figure 4-26). Both domains contain several subunits of which highly identical 
(≥ 80%) homologues in ATP-consuming species exists (Figure 4-27). Domain F1 is 
composed of subunit α, β, γ, δ and ε and involved in the synthesis of ATP. F0 consists of 
subunit a, b and c and depicts a transmembrane proton channel. Mitochondrial ATP 
synthases harbour additional subunits within both domains (F1: d, F6; F0: e, f, g, A6L, 

























generation of ATP.389 The common stoichiometry among all enzymes is α3β3δγεab2c8-15 with 
the main difference in the number of c-subunits. The typical ATP synthase found within 
bacteria is encoded on a single operon atpIBEFHAGDC. Subunits of domain F1 are encoded 
by atpA (α), atpD (β), atpG (γ), atpH (δ) and atpC (ε) and subunits of F0 by atpB (a), atpE 
(b) and atpF (c). The protein encoded by atpI depicts a protein with unknown function.390 
 
 
Figure 4-26: Schematic representation of the F0F1-ATP synthase. Membrane bound domain F0 consists of subunit a, b and 














Figure 4-27: Exemplary alignment of amino acid sequences of subunit β (AtpD) from B. subtilis and S. aureus. Both share 
87 % identity.  
 
With regard to bacterial species, the ATP synthase depicts a potent antibacterial drug target. 
Serval natural and synthetic compounds are known to act antibacterial by inhibiting the ATP 
synthase (e.g. bedaquiline).391,392 In this context, subunit αβ of the ATP synthase of B. 
subtilis was identified as potential target of TMs by protein fishing. Studies to analyse the 
binding of TMs to ATP synthase were restricted due to experimental limitations in the 
heterologous expression of ATP synthases. Thus, a functional assay on cell viability and a 
concurrent influence on the amount of ATP was performed. S. aureus Newman and cls2 
disrupted mutant were treated with TM, TM-Dodec, TM-N-Oct and DAP at 2-fold MIC and 
cell viability was assessed based on the amount of ATP within the cells. The treatment with 
any of the compounds did not decrease the amount of ATP (Figure 4-18) what leads to the 
conclusion that TMs do not directly interfere with the ATP synthase by interrupting its 
function. Previous studies performed with S. aureus transposon mutants revealed that atpA, 
atpD and atpG are not essential in S. aureus and that the transcript of atpE (subunit b of F0 
domain) plays an important role in the function of the ATP synthase.391,393 This leads to the 
assumption, that a direct inference of TMs with subunits αβ might not be involved in the 
mechanism of action. However, to analyse sensitivity of bacteria with disrupted ATP 
synthase to TMs, an activity-based screen of S. aureus transposon mutants [obtained from 
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Nebraska Transposon Mutant Library] yielding transposon mutations in genes encoding 
several subunits of the ATP synthase (atpA, atpB, atpD, atpG, atpH) will be performed. 
Moreover, to analyse if disrupted subunits of cytochrome caa3 oxidase contribute to a 
decrease in susceptibility of S. aureus towards TMs, mutants yielding transposon mutations 
in subunit I, II and III (qoxB, qoxA, qoxC) will additionally be tested.  
So far, with regard to the results gained from the characterization of the proteins identified 
as potential target proteins, no direct impact on the mechanism of TMs could be revealed. 
Since YcdA is only present in B. subtilis and binding was solely observed for TM-N-Oct, a 
function as global target molecule can be excluded. Regarding QoxA, it is not clear if 
interactions with subunit II may induce lethality, especially since subunit I represents the 
active side of the oxidase. Regarding the ATP synthase as potential target of TMs, it was 
already mentioned, that subunit αβ might not be involved in the mechanism of action since 
they are not essential for the function of the synthase. Nevertheless, a reason why those 
proteins have been fished might be a connection between respiratory chain complexes and 
cardiolipin. The individual parts of the respiratory chain of bacteria and mitochondria are 
able to associate into supercomplexes371,394, whose maintenance is associated with CL.395–
399 The formation of supercomplexes contributes to the stability of individual respiratory 
complexes and their function, e.g. the electron transport through the respiratory chain.371,400–
404 Previous studies in yeast as well as bacteria (B. subtilis and E. coli) revealed the presence 
of several supercomplexes, such as bc1-caa3
394,405–407 or bc1-caa3 with the ATP synthase, 
SDH-aa3 and a putative association of aa3 with the ATP synthase.
371 Moreover, the absence 
of CL was shown to lead to the dissociation of supercomplexes (e.g. bc1-caa3) and a thereof 
dependent decrease in the activity of the complexes.394,402,408,409 Taking together the facts 
that CL is needed to maintain the respiratory chain and that TMs were shown to bind to CL, 
leads to the assumption, that proteins identified by target fishing rather interacted with CL 
than with TM. It seems as if TMs primarily bound to CL, which was still associated with 
proteins involved in respiration and energy metabolism.  
So far, no direct prove is available that the above drawn hypothesis depicts an explanation 
why those proteins have been fished, but the present analysis strongly hints towards a CL-
mediated binding.  
In summary, the general comparison of TM to TM-Dodec and TM-N-Oct strongly indicated 
that both derivatives act calcium-independent and that their antibacterial effects do not 
Discussion 
157 
exclusively rely on the binding to CL. This furthermore indicates an interaction with an 
additional target, which might be common for all TMs to mediate a mechanism of action 
beyond membrane activity (presumably cell wall-associated). However, so far no distinct 
proteins targets could be assigned and alternative experiments to identify additional targets 
need to be performed. Moreover, since preliminary data revealed induction of cell wall stress 
by TMs, more specific screens could be performed to characterize the impact on the cell wall 
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4.3 SUMMARY AND OUTLOOK 
The cyclic depsipeptide TM was already described in 1950 by Bristol-Myers Company (New 
York, USA) and revealed promising antibacterial activities against Gram-positive bacteria 
including multidrug-resistant (MDR) pathogens. However, over the last 60 years no further 
investigation was described until the characterisation of the biosynthesis of the natural 
product. Based on the knowledge gained from those studies, semi-synthetic derivatives were 
generated, aiming to provide SAR-improved compounds. In the course of the present study, 
the two acylated derivatives TM-Dodec and TM-N-Oct were described to show promising 
antibacterial activities, including inhibition of MDR pathogens and clinical isolates, with 
overall improved activities compared to natural TM. However, the activities of TM and both 
derivatives are restricted to Gram-positive bacteria and Gram-negative pathogens revealed 
intrinsic resistance. Moreover, a calcium-dependent activity of TM could be revealed, 
whereas both derivatives were shown to act calcium-independent. Studies on the interaction 
of Ca2+ with TM indicated that the molecule presumably needs to undergo conformational 
changes mediated by the binding to Ca2+ to perform its action. In contrast, both derivatives 
seem to act without undergoing conformational changes.  
Regarding the mechanism of action, similarities in activity to the cell membrane targeting 
calcium-dependent antibiotic DAP were observed. TMs exert a bactericidal effect, which 
was in previous studies shown to be even stronger for TM-Dodec compared to DAP. 
Moreover, a calcium-dependent membrane depolarization for TM was observed, which hints 
towards a membrane-related mechanism of action, similar to that of DAP. Studies on the 
resistance mechanism consolidated this assumption, since the depletion of cardiolipin, a 
major component of the cellular membrane, was found to be involved in the generation of 
resistance towards TM and TM-Dodec. Mutations or the absence of the gene (cls2) encoding 
for the synthase (cardiolipin synthase 2), which catalyses the generation of CL were shown 
to lead to decreased sensitivity of S. aureus Newman towards TMs. However, this effect was 
more pronounced towards TM, compared to TM-Dodec and TM-N-Oct. Moreover, studies 
on the binding of TMs to membrane lipids revealed an exclusively binding of TMs to CL, 
but not to other lipids or membrane components. The intracellular localization of TMs was 
additionally shown to happen in CL-rich domains. Nevertheless, all together this study 
revealed that CL is solely needed for TM but not required for both derivatives to act on the 
bacteria. It is possible, that the absence of the lipid side chain within the structure of natural 
TM hinders its interaction with the bacterial cell and that the binding to Ca2+ and CL enables 
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the molecule to interact with the cell membrane. In contrast, both derivatives seem to be able 
to interfere with the cells by inserting their acyl chain into the membrane, similar as observed 
for DAP.  
 
Some proteins (YcdA, QoxA, αβ-subunit of ATP synthase) were identified as potential 
binding partners in a protein pull-down experiments and binding could be confirmed to the 
lipoprotein YcdA (TM-N-Oct) and to subunit II (QoxA) of the terminal oxidase aa3 (TM). 
However, at the current stage, it cannot be excluded that interaction with these proteins is 
associated with the presence of CL in the protein preparations. Previous studies showed that 
subunits of the respiratory chain (e.g. terminal oxidases, ATP synthase) are able to form 
respiratory chain supercomplexes whose stability and thereof based activity relies on the 
presence of CL. It might be possible that the binding of TMs to CL leads to a disruption of 
the respiratory chain complexes and a collapse of the cellular metabolism. To further 
investigate this assumption, a repeat of the target fishing experiment needs to be done to 
show if the same protein pattern will be detected from lysates of CL depleted S. aureus 
mutants. Although studies on the cell viability already showed no effect of TMs on the ATP 
amount, further studies to exclude a potential concentration- and time-dependent effect 
should be done. Additionally, a comparative binding study in the presence and absence of 
CL, with the proteins which showed interaction to TMs, could be performed.  
 
Nevertheless, it is not clear if binding to CL depicts the starting point of TMs mechanisms 
of action and which cellular processes are affected by this mechanism. So far, studies 
strongly point towards a target protein exclusively present in Gram-positive bacteria, which 
might be found associated with the cell wall. In a primary step, TMs seem to interact with 
the membrane, whereas the presence of CL is crucial for natural TM but both semi-synthetic 
TM derivatives are able to interfere CL-independent. After insertion or binding to the cell 
membrane, TMs seems to interact with the so far unknown target enzyme, which in further 
steps causes a collapse of the bacterial metabolism (presumably linked to a hampered cell 
wall synthesis) and finally cell death (comparable to DAP). In addition, if CL would depict 
the main target of TMs, it is not clear why those compounds do not exert cytotoxic effects 
and inhibition of Gram-negative bacteria even though CL is also present within those types 
of cells, what further indicates the interaction with an additional common target for TMs. 
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In summary, studies performed to characterize the mechanism of action of TMs revealed an 
interference with the cellular membrane, but the exact mechanism of action still needs to be 
further investigated. Moreover, two derivatives bearing lipid side chains revealed improved 
activities compared to the parent molecule TM and a mechanism of action beyond CL-
binding. However, further semi-synthetic optimisations (antimicrobial activity; 
physicochemical properties) with regard to further steps in the direction of preclinical 
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 CONCLUSION AND RELEVANCE 
The introduction of new antibiotic drugs in the clinics is accompanied by a fast development 
of resistance – a severe problem that exists almost since the beginning of the antibiotic era 
in the early 1900s.1 In addition, over the last decades, resistance to antibiotics exacerbated 
due to the emergence of multidrug-resistant (MDR) bacterial species and a decline in the 
development of novel antibiotics. To avoid the advent and progression of the so-called “pre-
antibiotic” era, the development of new antibiotics showing resistance-breaking properties 
by acting on new target molecules and exhibiting novel mechanisms of action is urgently 
needed.5,21  
Up to day, the main and most promising sources for the development of new effective lead 
structures are still natural products (NPs) derived from microorganisms (e.g. bacteria, 
fungi).72 During the ”Golden Era” of antibiotic discovery (1930s-1960s) a wide variety of 
compound classes have been characterized (e.g. penicillins, tetracyclines), but only 
antibiotics with favourable pharmacological properties were further pursued and developed 
into drugs. Thus, a number of neglected NP scaffolds exist, which are already known for 
decades and which exhibit pronounced antibacterial activity, but viable drug development 
procedures were not available at the time of their discovery. Due to today’s advanced 
knowledge in terms of e.g. chemical derivatization and synthesis and genetic engineering, at 
least some of those scaffolds are promising starting materials to develop new antibacterial 
drugs. However, to overcome hurdles in the drug development pipeline, such as 
unfavourable pharmaceutical and pharmacokinetic properties, it is of utmost importance to 
perform a detailed in vitro and in vivo profiling of such scaffolds and to further improve 
them. Crucial steps during preclinical development are the identification of the target 
molecule and the elucidation of the molecule’s mechanism of action. These data can help to 
inform the modification of a scaffold to improve on-target activity, to overcome resistance, 
and to widen the antibacterial spectrum. Further, derivatization programs aim at optimizing 
pharmaceutical properties to eventually achieve optimal in vivo efficacy.  
In the course of this study, NPs and respective derivatives of two different compound classes 
– chelocardins107,108,139 and telomycins145,148 – were characterized to elucidate their 
mechanism of action/resistance and to identify their target molecule(s). Both represent 
potent examples of underexploited compound classes derived from actinobacteria, an 
important source of NPs, with inhibitory activity against clinically relevant bacteria. 
Chelocardins are active against Gram-negative and Gram-positive pathogens and the 
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compounds possess resistance-breaking properties. This holds also true for telomycins as 
they act against MDR bacteria and display no cross-resistance to standard antibiotics; 
however, telomycins solely inhibit Gram-positive bacteria. Chelocardin and its more potent 
analogue amidochelocardin displayed in vitro inhibition of the ribosome without displaying 
cross-resistance with related tetracyclines. Their main target appeared to be related to 
bacterial membranes and efflux-mediated resistance in Gram-negative bacteria occurred 
only at very low frequency. Two new telomycin derivatives that act, in contrast to the 
original NP, independent of the presence of cardiolipin and calcium were in-depth 
characterized and it could be revealed that telomycins presumably act through a new 
mechanism targeting an enzyme involved in cell wall synthesis. Even though the main target 
molecule for both antibiotic families was not identified, the overall characterization revealed 
important insights into chelocardin’s and telomycin’s mechanisms of action and resistance 
mechanisms. These results contribute to a further optimisation of both compound classes 
and to the development of new potent lead structures, which can be forwarded into the 
development pipeline to provide new effective antibacterial drugs that can overcome 
resistance. 
In summary, this work highlights that the re-assessment of neglected compound classes is a 
promising, alternative pathway to provide new effective compounds and that NPs still play 
an important role in drug development. The two compound classes that were characterised 
within this study are now in preclinical development with the overall goals to introduce new 
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